Patent Publication Number: US-2007124175-A1

Title: Computational and/or control systems and methods related to nutraceutical agent selection and dosing

Description:
CROSS-REFERENCE TO RELATED APPLICATIONS  
      The present application is related to and claims the benefit of the earliest available effective filing date(s) from the following listed application(s) (the “Related Applications”) (e.g., claims earliest available priority dates for other than provisional patent applications or claims benefits under 35 USC § 119(e) for provisional patent applications, for any and all parent, grandparent, great-grandparent, etc. applications of the Related Application(s)).  
     RELATED APPLICATIONS  
      For purposes of the USPTO extra-statutory requirements, the present application constitutes a continuation-in-part of U.S. patent application Ser. No. 11/453,571, entitled INDIVIDUALIZED PHARMACEUTICAL SELECTION AND PACKAGING, naming Edward K. Y. Jung, Royce A. Levien, Robert W. Lord, Mark A. Malamud, John D. Rinaldo, Jr., and Lowell L. Wood, Jr. as inventors, filed 14 Jun. 2006, which is currently co-pending, or is an application of which a currently co-pending application is entitled to the benefit of the filing date.  
      For purposes of the USPTO extra-statutory requirements, the present application constitutes a continuation-in-part of U.S. patent application Ser. No. 11/478,341, entitled COMPUTATIONAL AND/OR CONTROL SYSTEMS RELATED TO INDIVIDUALIZED NUTRACEUTICAL SELECTION AND PACKAGING, naming Edward K. Y. Jung, Royce A. Levien, Robert W. Lord, Mark A. Malamud, John D. Rinaldo, Jr., and Lowell L. Wood Jr. as inventors, filed 28 Jun. 2006, which is currently co-pending, or is an application of which a currently co-pending application is entitled to the benefit of the filing date.  
      For purposes of the USPTO extra-statutory requirements, the present application constitutes a continuation-in-part of U.S. patent application Ser. No. 11/478,296, entitled COMPUTATIONAL AND/OR CONTROL SYSTEMS RELATED TO INDIVIDUALIZED NUTRACEUTICAL SELECTION AND PACKAGING, naming Edward K. Y. Jung, Royce A. Levien, Robert W. Lord, Mark A. Malamud, John D. Rinaldo, Jr., and Lowell L. Wood Jr. as inventors, filed 28 Jun. 2006, which is currently co-pending, or is an application of which a currently co-pending application is entitled to the benefit of the filing date.  
      For purposes of the USPTO extra-statutory requirements, the present application constitutes a continuation-in-part of U.S. patent application Ser. No. 11/486,998, entitled COMPUTATIONAL AND/OR CONTROL SYSTEMS RELATED TO INDIVIDUALIZED PHARMACEUTICAL AND NUTRACEUTICAL SELECTION AND PACKAGING, naming Edward K. Y. Jung, Royce A. Levien, Robert W. Lord, Mark A. Malamud, John D. Rinaldo, Jr., and Lowell L. Wood Jr. as inventors, filed 14 Jul. 2006, which is currently co-pending, or is an application of which a currently co-pending application is entitled to the benefit of the filing date.  
      For purposes of the USPTO extra-statutory requirements, the present application constitutes a continuation-in-part of U.S. patent application Ser. No. 11/486,973, entitled COMPUTATIONAL AND/OR CONTROL SYSTEMS RELATED TO INDIVIDUALIZED PHARMACEUTICAL AND NUTRACEUTICAL SELECTION AND PACKAGING, naming Edward K. Y. Jung, Royce A. Levien, Robert W. Lord, Mark A. Malamud, John D. Rinaldo, Jr., and Lowell L. Wood Jr. as inventors, filed 14 Jul. 2006, which is currently co-pending, or is an application of which a currently co-pending application is entitled to the benefit of the filing date.  
      For purposes of the USPTO extra-statutory requirements, the present application constitutes a continuation-in-part of U.S. patent application Ser. No. 11/474,109, entitled CUSTOMIZED VISUAL MARKING FOR MEDICATION LABELING, naming Edward K. Y. Jung, Royce A. Levien, Robert W. Lord, Mark A. Malamud, John D. Rinaldo, Jr., and Lowell L. Wood Jr. as inventors, filed 23 Jun. 2006, which is currently co-pending, or is an application of which a currently co-pending application is entitled to the benefit of the filing date.  
      For purposes of the USPTO extra-statutory requirements, the present application constitutes a continuation-in-part of U.S. patent application Ser. No. 11/314,945, entitled GENERATING A REQUEST-FROM A NUTRACEUTICAL INVENTORY, naming Edward K. Y. Jung, Royce A. Levien, Robert W. Lord, Mark A. Malamud, John D. Rinaldo, Jr., Clarence T. Tegreene, and Lowell L. Wood Jr. as inventors, filed 20 Dec. 2005, which is currently co-pending, or is an application of which a currently co-pending application is entitled to the benefit of the filing date.  
      For purposes of the USPTO extra-statutory requirements, the present application constitutes a continuation-in-part of U.S. patent application Ser. No. 11/291,482, entitled GENERATRNG A NUTRACEUTICAL REQUEST FROM AN INVENTORY, naming Edward K. Y. Jung, Royce A. Levien, Robert W. Lord, Mark A. Malamud, John D. Rinaldo, Jr., Clarence T. Tegreene, and Lowell L. Wood Jr. as inventors, filed 30 Nov. 2005, which is currently co-pending, or is an application of which a currently co-pending application is entitled to the benefit of the filing date. 
    
    
      The United States Patent Office (USPTO) has published a notice to the effect that the USPTO&#39;s computer programs require that patent applicants reference both a serial number and indicate whether an application is a continuation or continuation-in-part. Stephen G. Kunin,  Benefit of Prior - Filed Application,  USPTO Official Gazette Mar. 18, 2003, available at http://www.uspto.gov/web/offices/com/sol/og/2003/week 11/patbene.htm. The present applicant entity has provided above a specific reference to the application(s)from which priority is being claimed as recited by statute. Applicant entity understands that the statute is unambiguous in its specific reference language and does not require either a serial number or any characterization, such as “continuation” or “continuation-in-part,” for claiming priority to U.S. patent applications. Notwithstanding the foregoing, applicant entity understands that the USPTO&#39;s computer programs have certain data entry requirements, and hence applicant entity is designating the present application as a continuation-in-part of its parent applications as set forth above, but expressly points out that such designations are not to be construed in any way as any type of commentary and/or admission as to whether or not the present application contains any new-matter in addition to the matter of its parent application(s).  
      All subject matter of the Related Applications and of any and all parent, grandparent, great-grandparent, etc. applications of the Related Applications is incorporated herein by reference to the extent such subject matter is not inconsistent herewith.  
     Technical Field  
      The present disclosure relates to computational and/or control systems and methods related to nutraceutical agent selection and dosing.  
     SUMMARY  
      In some embodiments a method is provided that includes accepting data related to one or more specified goals of an individual; intaking information linked to one or more parameters associated with the one or more specified goals of the individual; selecting one or more nutraceutical agents in response to the intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual; and indicating one or more dosages of the one or more nutraceutical agents in response to the selecting the one or more nutraceutical agents in response to the intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual. In addition to the foregoing, other method aspects are described in the claims, drawings, and/or text forming a part of the present disclosure.  
      In some embodiments a method is provided that includes accepting data related to one or more specified goals of an individual; intaking information linked to one or more parameters associated with the one or more specified goals of the individual; and transmitting one or more signals in response to the intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual. In addition to the foregoing, other method aspects are described in the claims, drawings, and/or text forming a part of the present disclosure.  
      In some embodiments a method is provided that includes receiving one or more signals transmitted in response to intaking information linked to one or more parameters associated with one or more specified goals of an individual; selecting one or more nutraceutical agents in response to the receiving the one or more signals transmitted in response to the intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual; and indicating one or more dosages of the one or more nutraceutical agents in response to the selecting the one or more nutraceutical agents in response to the receiving the one or more signals transmitted in response to the intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual. In addition to the foregoing, other method aspects are described in the claims, drawings, and/or text forming a part of the present disclosure.  
      In some embodiments a system is provided that includes circuitry for accepting data related to one or more specified goals of an individual; circuitry for intaking information linked to one or more parameters associated with the one or more specified goals of the individual; circuitry for selecting one or more nutraceutical agents responsive to the circuitry for intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual; and circuitry for indicating one or more dosages of the one or more nutraceutical agents responsive to the circuitry for selecting the one or more nutraceutical agents responsive to the circuitry for intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual. In addition to the foregoing, other system aspects are described in the claims, drawings, and/or text forming a part of the present disclosure.  
      In some embodiments a system is provided that includes circuitry for accepting data related to one or more specified goals of an individual; circuitry for intaking information linked to one or more parameters associated with the one or more specified goals of the individual; and circuitry for transmitting one or more signals responsive to the circuitry for intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual. In addition to the foregoing, other system aspects are described in the claims, drawings, and/or text forming a part of the present disclosure.  
      In some embodiments a system is provided that includes circuitry for receiving one or more signals transmitted in response to-intaking information linked to one or more parameters associated with one or more specified goals of an individual; circuitry for selecting one or more nutraceutical agents responsive to the circuitry for receiving the one or more signals transmitted in response to intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual; and circuitry for indicating one or more dosages of the one or more nutraceutical agents responsive to the circuitry for selecting the one or more nutraceutical agents responsive to the circuitry for receiving the one or more signals transmitted in response to intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual. In addition to the foregoing, other system aspects are described in the claims, drawings, and/or text forming a part of the present disclosure.  
      In some embodiments a system is provided that includes means for accepting data related to one or more specified goals of an individual; means for intaking information linked to one or more parameters associated with the one or more specified goals of the individual; means for selecting one or more nutraceutical agents responsive to the means for intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual; and means for indicating one or more dosages of the one or more nutraceutical agents responsive to the means for selecting the one or more nutraceutical agents responsive to the means for intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual. In addition to the foregoing, other system aspects are described in the claims, drawings, and/or text forming a part of the present disclosure.  
      In some embodiments a system is provided that includes means for accepting data related to one or more specified goals of an individual; means for intaking information linked to one or more parameters associated with the one or more specified goals of the individual; and means for transmitting one or more signals responsive to the means for intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual. In addition to the foregoing, other system aspects are described in the claims, drawings, and/or text forming a part of the present disclosure.  
      In some embodiments a system is provided that includes means for receiving one or more signals transmitted in response to intaking information linked to one or more parameters associated with one or more specified goals of an individual; means for selecting one or more nutraceutical agents responsive to the means for receiving the one or more signals transmitted in response to intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual; and means for indicating one or more dosages of the one or more nutraceutical agents responsive to the means for selecting the one or more nutraceutical agents responsive to the means for receiving the one or more signals transmitted in response to intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual. In addition to the foregoing, other system aspects are described in the claims, drawings, and/or text forming a part of the present disclosure.  
      In some embodiments a system is provided that includes a signal-bearing medium bearing: one or more instructions for accepting data related to one or more specified goals of an individual; one or more instructions for intaking information linked to one or more parameters associated with the one or more specified goals of the individual; one or more instructions for selecting one or more nutraceutical agents in response to the intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual; and one or more instructions for indicating one or more dosages of the one or more nutraceutical agents in response to the selecting the one or more nutraceutical agents in response to the intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual. In addition to the foregoing, other system aspects are described in the claims, drawings, and/or text forming a part of the present disclosure.  
      In some embodiments a system is provided that includes a signal-bearing medium bearing: one or more instructions for accepting data related to one or more specified goals of an individual; one or more instructions for intaking information linked to one or more parameters associated with the one or more specified goals of the individual; and one or more instructions for transmitting one or more signals in response to the intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual. In addition to the foregoing, other system aspects are described in the claims, drawings, and/or text forming a part of the present disclosure.  
      In some embodiments a system is provided that includes a signal-bearing medium bearing: one or more instructions for receiving one or more signals transmitted in response to intaking information linked to one or more parameters associated with one or more specified goals of an individual; one or more instructions for selecting one or more nutraceutical agents in response to the receiving the one or more signals transmitted in response to the intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual; and one or more instructions for indicating one or more dosages of the one or more nutraceutical agents in response to the selecting the one or more nutraceutical agents in response to the receiving the one or more signals transmitted in response to the intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual. In addition to the foregoing, other system aspects are described in the claims, drawings, and/or text forming a part of the present disclosure.  
      In some embodiments, means include but are not limited to circuitry and/or programming for effecting the herein-referenced functional aspects; the circuitry and/or programming can be virtually any combination of hardware, software, and/or firmware configured to effect the herein-referenced functional aspects depending upon the design choices of the system designer. In addition to the foregoing, other system aspects means are described in the claims, drawings, and/or text forming a part of the present disclosure.  
      In some embodiments, related systems include but are not limited to circuitry and/or programming for effecting the herein-referenced method aspects; the circuitry and/or programming can be virtually any combination of hardware, software, and/or firmware configured to effect the herein-referenced method aspects depending upon the design choices of the system designer. In addition to the foregoing, other system aspects are described in the claims, drawings, and/or text forming a part of the present application.  
      The foregoing summary is illustrative only and is not intended to be in any way limiting. In addition to the illustrative aspects, embodiments, and features described above, further aspects, embodiments, and features will become apparent by reference to the drawings, claims, and the following detailed description. 
    
    
     BRIEF DESCRIPTION OF THE FIGURES  
       FIG. 1  illustrates an example system  100  in which embodiments may be implemented.  
       FIG. 2  illustrates an operational flow  200  representing example operations related to methods for nutraceutical agent selection and dosing.  
       FIG. 3  illustrates alternative embodiments of the example operation flow of  FIG. 2 .  
       FIG. 4  illustrates alternative embodiments of the example operation flow of  FIG. 2 .  
       FIG. 5  illustrates alternative embodiments of the example operation flow of  FIG. 2 .  
       FIG. 6  illustrates alternative embodiments of the example operation flow of  FIG. 2 .  
       FIG. 7  illustrates alternative embodiments of the example operation flow of  FIG. 2 .  
       FIG. 8  illustrates alternative embodiments of the example operation flow of  FIG. 2 .  
       FIG. 9  illustrates an operational flow  900  representing example operations related to methods for nutraceutical agent selection and dosing.  
       FIG. 10  illustrates an operational flow  1000  representing example operations related to methods for nutraceutical agent selection and dosing.  
       FIG. 11  illustrates alternative embodiments of the example operation flow of  FIG. 10 .  
       FIG. 12  illustrates alternative embodiments of the example operation flow of  FIG. 10 .  
       FIG. 13  illustrates alternative embodiments of the example operation flow of  FIG. 10 .  
       FIG. 14  illustrates alternative embodiments of the example operation flow of  FIG. 10 .  
       FIG. 15  illustrates alternative embodiments of the example operation flow of  FIG. 10 .  
       FIG. 16  illustrates alternative embodiments of the example operation flow of  FIG. 10 .  
       FIG. 17  illustrates an operational flow  1700  representing example operations related to methods for nutraceutical agent selection and dosing.  
       FIG. 18  illustrates an operational flow  1800  representing example operations related to methods for nutraceutical agent selection and dosing.  
       FIG. 19  illustrates alternative embodiments of the example operation flow of  FIG. 18 .  
       FIG. 20  illustrates alternative embodiments of the example operation flow of  FIG. 18 .  
       FIG. 21  illustrates alternative embodiments of the example operation flow of  FIG. 18 .  
       FIG. 22  illustrates alternative embodiments of the example operation flow of  FIG. 18 .  
       FIG. 23  illustrates alternative embodiments of the example operation flow of  FIG. 18 .  
       FIG. 24  illustrates an operational flow  2400  representing example operations related to methods for nutraceutical agent selection and dosing.  
       FIG. 25  illustrates an example system  2500  in which embodiments may be implemented.  
       FIG. 26  illustrates an example system  2600  in which embodiments may be implemented.  
       FIG. 27  illustrates an example system  2700  in which embodiments may be implemented.  
       FIG. 28  illustrates an example system  2800  in which embodiments may be implemented.  
       FIG. 29  illustrates an example system  2900  in which embodiments may be implemented.  
       FIG. 30  illustrates an example system  3000  in which embodiments may be implemented.  
       FIG. 31  illustrates an example system  3100  in which embodiments may be implemented.  
       FIG. 32  illustrates an example system  3200  in which embodiments may be implemented.  
       FIG. 33  illustrates an example system  3300  in which embodiments may be implemented.  
       FIG. 34  illustrates an example system  3400  in which embodiments may be implemented.  
       FIG. 35  illustrates an example system  3500  in which embodiments may be implemented.  
       FIG. 36  illustrates an example system  3600  in which embodiments may be implemented. 
    
    
     DETAILED DESCRIPTION  
      In the following detailed description, reference is made to the accompanying drawings, which form a part hereof. In the drawings, similar symbols typically identify similar components, unless context dictates otherwise. The illustrative embodiments described in the detailed description, drawings, and claims are not meant to be limiting. Other embodiments may be utilized, and other changes may be made, without departing from the spirit or scope of the subject matter presented here.  
      While various aspects and embodiments have been disclosed herein, other aspects and embodiments will be apparent to those skilled in the art. The various aspects and embodiments disclosed herein are for purposes of illustration and are not intended to be limiting, with the true scope and spirit being indicated by the following claims.  
       FIG. 1  illustrates an example system  100  in which embodiments may be implemented. In some embodiments, the system  100  is operable to provide a method and system for nutraceutical agent  118  selection and dosing. In some embodiments, the system  100  may be used by one or more individuals  108  to achieve one or more specified goals  106 . In some embodiments, one or more accepting units  102  accept data  104  related to one or more specified goals  106  of one or more individuals  108 . In some embodiments, one or more intaking units  110  intake information  112  linked to one or more parameters  114  associated with one or more specified goals  106  of an individual  108 . In some embodiments, one or more selecting units  116  select one or more nutraceutical agents  118  in response to intaking information  112  linked to one or more parameters  114  associated with one or more specified goals  106  of an individual  108 . In some embodiments, one or more indicating units  120  indicate one or more dosages  122  of one or more nutraceutical agents  118  in response to selecting the one or more nutraceutical agents  118  in response to intaking information  112  linked to one or more parameters  114  associated with the one or more specified goals  106  of the individual  108 . In some embodiments, one or more recording units  124  record the results of: accepting data  104  related to one or more specified goals  106  of an individual  108 , intaking information  112  linked to one or more parameters  114  associated with the one or more specified goals  106  of the individual  108 , selecting one or more nutraceutical agents  118  in response to intaking information  112  linked to one or more parameters  114  associated with the one or more specified goals  106  of the individual  108 , indicating one or more dosages  122  of the one or more nutraceutical agents  118  in response to selecting one or more nutraceutical agents  118  in response to intaking information  112  linked to one or more parameters  114  associated with the one or more specified goals  106  of the individual  108 , or substantially any combination thereof, on a recordable-medium  126 . In some embodiments, one or more transmitting units  128  transmit one or more signals  130  in response to intaking information  112  linked to one or more parameters  114  associated with one or more specified goals  106  of an individual  108 . In some embodiments, one or more receiving units  132  receive one or more signals  130  transmitted in response to intaking information  112  linked to one or more parameters  114  associated with one or more specified goals  106  of the individual  108 . In some embodiments, system  100  provides for user interaction  134  with one or more users  136 . In some embodiments, such user interaction  134  can occur with one or more recording units  124 , one or more indicating units  120 , one or more selecting units  116 , one or more receiving units  132 , one or more transmitting units  128 , one or more intaking units  110 , one or more accepting units  102 , and substantially any combination thereof. In some embodiments of system  100 , one or more recording units  124 , one or more indicating units  120 , one or more selecting units  116 , one or more receiving units  132 , one or more transmitting units  128 , one or more intaking units  110 , and one or more accepting units  102 , are hardwired together in substantially any combination. In some embodiments of system  100 , one or more recording units  124 , one or more indicating units  120 , one or more selecting units  116 , one or more receiving units  132 , one or more transmitting units  128 , one or more intaking units  110 , and one or more accepting units  102 , may communicate through wireless connection. Numerous technologies may be used to establish and maintain wireless connections. In some embodiments of system  100 , one or more recording units  124 , one or more indicating units  120 , one or more selecting units  116 , one or more receiving units  132 , one or more transmitting units  128 , one or more intaking units  110 , and one or more accepting units  102 , may communicate through wireless connection and hardwired connections in substantially any combination. In some embodiments, user interaction  134  is provided through hardwired connections. In some embodiments, user interaction  134  is provided through wireless connections. In some embodiments, user interaction  134  is provided through hardwired and wireless connections.  
     Accepting Unit  102   
      The system  100  can include one or more accepting units  102 . In some embodiments, one or more accepting units  102  can be used to accept data  104  related to one or more specified goals  106  of one or more individuals  108 . In some embodiments, one or more accepting units  102  can include a physical device with allows data  104  entry, such as a touchpad, keypad, hardwired telephone, and the like. In some embodiments, one or more accepting units  102  can include a wireless connection that allows the one or more accepting units  102  to accept data  104  from one or more individuals  108  through a wireless connection. For example, in some embodiments, one or more accepting units  102  may accept data  104  from one or more individuals  108  through use of a cellular telephone, a personal digital assistant, a wireless computer, and the like.  
     Data  104 /Specified Goals  106   
      The system  100  can include data  104  related to one or more specified goals  106  of an individual  108 . In some embodiments, the data  104  can be related to one or more physical characteristics of an individual  108 . In some embodiments, the data  104  can be related to one or more mental characteristics of an individual  108 . In some embodiments, the data  104  can be related to one or more physiological characteristics of an individual  108 . In some embodiments, the data  104  can be related to one or more performance characteristics of an individual  108 . In some embodiments, the data  104  can be related to one or more psychological characteristics of an individual  108 . Data  104  can be related to numerous types of specified goals  106 . For example, in some embodiments, the data  104  can be related to attentiveness, alertness, test performance, relaxation, pain, fever, attractiveness, anxiety, fall, injury, accident, bite, bleeding, inflammation, infection, drowsiness, insomnia, discomfort, stress, grooming, appearance, capability, performance, improvement, enhancement, curtailment, wellbeing, vitality, vigor, disability, phobia, malady, psychosis, environmental extremes, environmental exposure, dysfunction, disease symptom, chronic condition, mental acuity, emotional behavior, physical prowess, addiction, obsession, therapy, remedy, behavior, nutrition, diet (includes weight-loss), exercise, immunization, prevention, diagnosis, subscription, regimen, social performance, social interaction, endurance, sexual attribute, sexual performance, age-related attribute, age-related condition, prophylaxis, treatment, and substantially any combination thereof.  
     Individual  108   
      The system  100  can include one or more individuals  108 . In some embodiments, an individual  108  may be afflicted with a diagnosed condition. For example, in some embodiments, an individual  108  may be afflicted with depression, anemia, obesity, insomnia, lower hormone levels, and the like. In some embodiments, an individual  108  may be afflicted with an undiagnosed condition. In some embodiments, such an undiagnosed condition may be an actual condition or a perceived condition.  
     Intaking Unit  110   
      The system  100  can include one or more intaking units  110 . In some embodiments, one or more intaking units  110  can be used to intake information  112  linked to one or more parameters  114  associated with one or more specified goals  106  of an individual  108 . In some embodiments, one or more intaking units  110  include instrumentation that can be used to assay one or more samples linked to an individual  108 . In some embodiments, one or more intaking units  110  can be used to determine one or more levels of one or more metabolic indicators linked to an individual  108 . In some embodiments, one or more intaking units  110  can be used to determine one or more levels of one or more metabolic activities linked to the individual  108 . In some embodiments, one or more intaking units  110  can be used to determine one or more levels of one or more nutraceutical agents  118  linked to the individual  108 . In some embodiments, one or more intaking units  110  can be used to determine one or more levels of one or more pharmaceutical agents linked to the individual  108 . In some embodiments, one or more intaking units  110  can intake information  112  from another device. For example, in some embodiments, one or more intaking units  110  can intake information  112  provided by a diagnostic device. Such diagnostic devices include, but are not limited to, devices used to analyze bodily samples obtained from an individual  108  (i.e., blood, urine, saliva, synovial fluid, pleural fluid, peritoneal fluid, breath, skin, tissue, tears, mucus, genital products, hair, fecal material, and the like), devices used to analyze the appearance of an individual  108  (i.e., eye color, skin color, hair color, the presence or absence of bags under the eyes, presence or absence of hair, and the like), devices used to analyze a characteristic of the individual  108  (i.e., speech, reaction time, reflexes, temperature, eye dilation, retinal profile, height, weight, waistline, and the like), and other devices used to diagnose and/or analyze an individual  108 . In some embodiments, one or more intaking units  110  can be included within system  100  through use of a hardwired connection. In some embodiments, one or more intaking units  110  can be included within system  100  through use of a wireless connection. In some embodiments, one or more intaking units  110  can be included within system  100  through use of a hardwired and a wireless connection. For example, in some embodiments, one or more intaking units  110  may intake, information  112  from a diagnostic or analytical device that is hardwired to the intaking unit  110 . In other embodiments, one or more intaking units  110  may intake information  112  from a diagnostic or analytical device through use of a wireless connection.  
     Selecting Unit  116   
      The system  100  can include one or more selecting units  116 . In some embodiments, one or more selecting units  116  can be used to select one or more nutraceutical agents  118  in response to intaking information  112  linked to one or more parameters  114  associated with one or more specified goals  106  of an individual  108 . In some embodiments, one or more selecting units  116  can be used to select one or more nutraceutical agents  118  to increase one or more levels of one or more components associated with the one or more specified goals  106  of the individual  108 . In some embodiments, one or more selecting units  116  can be used to select one or more nutraceutical agents  118  to decrease one or more levels of one or more components associated with the one or more specified goals  106  of the individual  108 . In some embodiments, one or more selecting units  116  can be used to select one or more nutraceutical agents  118  that stimulate one or more metabolic pathways linked to the individual  108 . In some embodiments, one or more selecting units  116  can be used to select one or more nutraceutical agents  118  that inhibit one or more metabolic pathways linked to the individual  108 . In some embodiments, one or more selecting units  116  can be used to select at least one vitamin, mineral, enzyme, amino acid, homeopathic supplement, toxin, homeopathic substance, traditional remedy, herbal supplement, glandular supplement, or substantially any combination thereof. In some embodiments, one or more selecting units  116  may access one or more databases that include information  112  with regard to nutraceutical agents  118 , pharmaceutical agents, interaction of nutraceutical agents  118  with pharmaceutical agents, interaction of nutraceutical agents  118  and/or pharmaceutical agents with other substances, such as foods, beverages, over the counter drugs, and the like. In some embodiments, such databases may be included within one or more selecting units  116 . In some embodiments, such databases may be remote from the one or more selecting units  116 . Numerous criteria may be used to select nutraceutical agents  118 . Examples of such criteria include, but are not limited to, price, availability, dosage form, interactions with other substances, method of administration (i.e., oral, nasal, pulmonary, and the like), time of administration, time of effect, duration of effect, single or multiple administration, and the like. In some embodiments, one or more selecting units  116  can be included within system  100  through use of a hardwired connection. In some embodiments, one or more selecting units  116  can be included within system  100  through use of a wireless connection. In some embodiments, one or more selecting units  116  can be included within system  100  through use of a hardwired and a wireless connection.  
     Nutraceutical Agent  118   
      Nutraceutical agents  118  typically include natural, bioactive chemical compounds or any substance that is a plant, food, an extracted part of a food, that provides medical or health benefits but which generally fall outside regulations controlling pharmaceuticals. Included in this category of substances may be foods, isolated nutrients, supplements and herbs. Nutraceuticals are often referred to as phytochemicals or functional foods and include dietary supplements. Numerous nutraceuticals have been described (i.e., Roberts et al., Nutraceuticals: The Complete Encyclopedia of Supplements, Herbs, Vitamins, and Healing Foods, 1 st  Edition, Perigee Trade (2001) and Susan G. Wynn, Emerging Therapies: Using Herbs and Nutraceuticals for Small Animals, American Animal Hospital Assn Press (1999); and Handbook of Nutraceuticals and Functional Foods., edited by Robert E. C. Wildman, CRC Press (2001)). Examples of nutraceutical agents  118  include, but are not limited to, Amino Acids, Terpenoids, Carotenoid Terpenoids (Lycopene, Beta-Carotene, Alpha-Carotene, Lutein, Zeaxanthin, Astaxanthin), Herbal Supplements, Homeopathic Supplements, Glandular Supplements, Non-Carotenoid Terpeniods (Perillyl Alcohol, Saponins, Terpeneol, Terpene Limonoids), Polyphenolics, Flavonoid Polyphenolics (Anthocyanins, Catechins, Isoflavones, Hesperetin, Naringin, Rutin, Quercetin, Silymarin, Tangeretin, Tannins), Phenolic Acids (Ellagic Acid, Chlorogenic Acid, Para-Coumaric Acid, Phytic Acid, Cinnamic Acid), Other Non-Flavonoid Polyphenolics (Curcumin, Resveratrol, Lignans), Glucosinolates, Isothiocyanates (Phenethyl Isothiocyanate, Benzyl Isothiocyanate, Sulforaphane), Indoles (Indole-3-Carbinol (I3C), Thiosulfonates, Phytosterols (Beta-Sitosterol), Anthraquinones (Senna, Barbaloin, Hypericin), Capsaicin, Piperine, Chlorophyll, Betaine, Pectin, Oxalic Acid, Acetyl-L-Carnitine, Allantoin, Androsterondiol, Androsterondione, Betaine (Trimethylglycine), Caffeine, Calcium pyvurate (Pyruvic Acid), Carnitine, Carnosine, Carotene (alpha &amp; beta), Carotenoid (Total for beadlets), Choline, Chlorogenic Acid, Cholic Acid (Ox Bile), Chondroitin Sulfate, Chondroitin Sulfate (Total Mucopolysaccharides), Cholestin, Chrysin, Coenzyme Q10 (Co-Q10), Conjugated Linoleic Acid (CLA), Corosolic Acid, Creatine, Dehydroepiandrosterone (DHEA), Dichlorophen, Diindolymethane (DIM), Dimethyglycine (DMG), Dimercapto Succinic Acid (DMSA), Ebselen, Ellagic Acid, Enzymes, Fisetin, Formonetin, Glucaric Acid (Glucarate), Glucosamine (HCl or Sulfate), Glucosamine (N-Acetyl), Glutathione (Reduced), Hesperidine, Hydroxy-3-Methylbutyric Acid (HMB), 5-Hydroxytryptophan (L-5-HTP), Indole-3-Carbinol, Inositol, Isothiocyanates, Linolenic Acid-Gamma (GLA), Lipoic Acid (alpha), Melatonin, Methylsulfonylmethane (MSM), Minerals, Naringin, Pancreatin, Para-aminobenzoic Acid (PABA), Paraben (methyl or propyl), Phenolics, Phosphatidylcholine (Lecithin), Phosphatidylserine, Phospholipids, Phytosterols, Pregersterone, Pregnenolone, Quercetin, Resveratrol, D-Ribose, Rutin, S-adenosylmethionine (SAM-e), Salicylic Acid, Sulforaphane, Tartaric Acid, Taxifolin, Tetrahydropalmatine, Thephyline, Theobromine, Tigogenin, Troxerutin, Tryptophan, Tocotrienol (alph, beta &amp; gamma), Vitamins, Zeaxanthin, Gingo Biloba, Ginger, Cat&#39;s Claw, Hypericum, Aloe Vera, Evening Primrose, Garlic, Capsicum, Dong Quai, Ginseng, Feverview, Fenugreek, Echinacea, Green Tea, Marshmallow, Saw Palmetto, Tea Tree Oil, Payllium, Kava-Kava, Licorice Root, Manonia Aquifolium, Hawthorne, Hohimbr, Tumeric, Witch Hazel, Valerian, Mistletoe, Bilberry, Bee Pollen, Peppermint Oil, Beta-Carotene, Genistein, Lutein, Lycopene, the Polyphenols (bioflavonoids), and the like.  
      In some embodiments, nutraceutical agents  118  may include microbes (i.e., probiotics). Examples of such microbes include, but are not limited to, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Bifidobacterium bifidum, Bifidobacterium longum, Saccharomyces boulardii, Saccharomyces cerevisiae, and the like (i.e., Samuel and Gordon, A humanized gnotobiotic mouse model of host-archaeal-bacterial mutualism, PNAS, 103(26):10011-10016 (2006)). In some embodiments, nutraceutical agents  118  may include non-living microbes. For example, non-living Saccharomyces cerevisiae may be used as a source of vitamin B12. In some embodiments, recombinant microbes may be utilized as nutraceutical agents  118 . For example, in some embodiments, microbes may be genetically modified to produce, or overexpress, one or more nutraceutical agents  118 .  
     Indicating Unit  120   
      The system  100  can include one or more indicating units  120 . In some embodiments, one or more indicating units  120  can be used to indicate one or more dosages  122  of one or more nutraceutical agents  118  in response to selecting one or more nutraceutical agents  118  in response to intaking information  112  linked to one or more parameters  114  associated with one or more specified goals  106  of an individual  108 . In some embodiments, one or more indicating units  120  indicate one or more dosages  122  of one or more nutraceutical agents  118  in human-readable format. In some embodiments, one or more indicating units  120  indicate one or more dosages  122  of one or more nutraceutical agents  118  in machine-readable format. In some embodiments, one or more indicating units  120  deposit one or more dosages  122  of one or more nutraceutical agents  118  on one or more labels. In some embodiments, one or more indicating units  120  dispense one or more nutraceutical agents  118 . In some embodiments, one or more indicating units  120  dispense one or more nutraceutical agents  118  in unit dosage form. In some embodiments, one or more indicating units  120  dispense two or more nutraceutical agents  118  in a single administration form. In some embodiments, one or more indicating units  120  can be included within system  100  through use of a hardwired connection. In some embodiments, one or more indicating units  120  can be included within system  100  through use of a wireless connection. In some embodiments, one or more indicating units  120  can be included within system  100  through use of a hardwired and a wireless connection.  
     Dosage  122   
      Dosages  122  may be expressed in numerous ways. In some embodiments, a dosage  122  may be expressed as an absolute quantity (i.e., 500 milligrams of a nutraceutical agent  118 ). In other embodiments, a dosage  122  may be expressed in accordance with the body weight of an individual  108  (i.e., 10 milligram nutraceutical agent  118  per kilogram body weight). In some embodiments, a dosage  122  may be expressed as a range of quantities (i.e., 10 milligrams to 100 milligrams of a nutraceutical agent  118 ). In some embodiments, a dosage  122  may be an amount of a nutraceutical agent  118  that produces a desired response when administered to a specific individual  108 . For example, a dosage  122  of melatonin may be the amount of melatonin that induces sleep in a specific individual  108 . The dosage  122  of a nutraceutical agent  118  may vary according to numerous considerations that include, but are not limited to, the route of administration, the age of the individual  108 , the size of the individual  108 , the metabolic characteristics of the individual  108 , the condition of the individual  108 , and the like. In some embodiments, the dosage  122  of a nutraceutical agent  118  may be determined that produces a measurable effect, such as a physical effect, a psychological effect, a physiological effect, and the like. Accordingly, in some embodiments, a dosage  122  may be expressed as an amount of a nutraceutical agent  118  that produces a mental response in an individual  108 . For example, in some embodiments, a dosage  122  may be the amount of a nutraceutical agent  118  that produces a sensation of well-being when administered to an individual  108 . In other embodiments, a dosage  122  may be the amount of a nutraceutical agent  118  that elevates the mood of an individual  108  to whom the nutraceutical is to be administered. Numerous additional criteria may be used to determine the dosage  122  of a nutraceutical for administration to an individual  108 .  
      In some embodiments, one or more indicating units  120  can indicate one or more dosages  122  of one or more nutraceutical agents  118  and one or more formulations of the one or more nutraceutical agents  118 . For example, in some embodiments, one or more indicating units  120  may indicate a formulation and dosage  122  of chromium. Presently, the most widely available chromium supplements are chromium salts such as chromium polynicotinate, chromium picolinate, and various chromium/amino acid chelates. Such formulations help increase the absorption and availability of chromium when compared to isolated chromium salts such as chromium chloride. The estimated safe and adequate daily dietary intake of chromium is 50-200 micrograms. Natural forms of supplemental chromium, such as chromium-rich yeast, may be absorbed somewhat more efficiently than inorganic forms of chromium, such as chromium chloride, found in some supplements. One ounce of brewer&#39;s yeast provides approximately 100-200 micrograms of chromium. Accordingly, in some embodiments, one or more indicating units  120  may indicate a dosage  122  of chromium and a corresponding formulation of the chromium. In another embodiment, one or more indicating units  120  may indicate a dosage  122  of vitamin A. For vitamin A deficiency syndromes, vitamin A may be orally supplemented at a dosage  122  of 600 micrograms for children aged 3 years or younger, 900 micrograms for children aged 4-8 years, 1700 micrograms for children aged 9-13 years, 2800 micrograms for persons aged 14-18 years, and 3000 micrograms for all adults. Therapeutic doses for severe disease include 60,000 micrograms, which has been shown to reduce child mortality rates by 35-70%. One or more indicating units  120  may indicate dosages  122  for numerous types of nutraceutical agents  118  that are formulated in numerous ways.  
     Transmitting Unit  128   
      The system  100  can include one or more transmitting units  128 . In some embodiments, one or more transmitting units  128  can be used to transmit one or more signals  130  in response to intaking information  112  linked to one or more parameters  114  associated with one or more specified goals  106  of an individual  108 . In some embodiments, one or more transmitting units  128  can be used to transmit one or more levels of one or more metabolic indicators linked to an individual  108 . In some embodiments, one or more transmitting units  128  can be used to transmit one or more levels of one or more metabolic activities linked to an individual  108 . In some embodiments, one or more transmitting units  128  can be used to transmit one or more levels of one or more nutraceutical agents  118  linked to an individual  108 . In some embodiments, one or more transmitting units  128  can be used to transmit one or more levels of one or more pharmaceutical agents linked to an individual  108 . In some embodiments, one or more transmitting units  128  can be used to transmit one or more parameters  114  associated with one or more specified goals  106  of an individual  108 . In some embodiments, one or more transmitting units  128  can be used to transmit one or more instructions to select one or more nutraceutical agents  118  in response to intaking information  112  linked to one or more parameters  114  associated with one or more specified goals  106  of an individual  108 . In some embodiments, one or more transmitting units  128  can be used to transmit one or more signals  130  to select one or more nutraceutical agents  118  to increase one or more levels of one or more components associated with one or more specified goals  106  of an individual  108 . In some embodiments, one or more transmitting units  128  can be used to transmit one or more signals  130  to select one or more nutraceutical agents  118  to decrease one or more levels of one or more components associated with one or more specified goals  106  of an individual  108 . In some embodiments, one or more transmitting units  128  can be used to transmit one or more signals  130  to select one or more nutraceutical agents  118  that stimulate one or more metabolic pathways linked to an individual  108 . In some embodiments, one or more transmitting units  128  can be used to transmit one or more signals  130  to select one or more nutraceutical agents  118  that inhibit one or more metabolic pathways linked to an individual  108 . In some embodiments, one or more transmitting units  128  can be used to transmit one or more signals  130  to select at least one vitamin, mineral, enzyme, amino acid, homeopathic supplement, toxin, homeopathic substance, traditional remedy, herbal supplement, glandular supplement, or substantially any combination thereof. In some embodiments, one or more transmitting units  128  can be included within system  100  through use of a hardwired connection. In some embodiments, one or more transmitting units  128  can be included within system  100  through use of a wireless connection. In some embodiments, one or more transmitting units  128  can be included within system  100  through use of a hardwired and a wireless connection.  
     Signal  130   
      The system  100  may include one or more signals  130 . Numerous types of signals  130  may be transmitted. Examples of such signals  130  include, but are not limited to, hardwired signals  130 , wireless signals  130 , infrared signals  130 , optical signals  130 , radiofrequency (RF) signals  130 , audible signals  130 , digital signals  130 , analog signals  130 , or substantially any combination thereof.  
     Receiving Unit  132   
      The system  100  may include one or more receiving units  132 . In some embodiments, one or more receiving units  132  receive one or more signals  130  transmitted in response to intaking information  112  linked to one or more parameters  114  associated with one or more specified goals  106  of an individual  108 . In some embodiments, one or more receiving units  132  receive one or more signals  130  indicating one or more levels of one or more metabolic indicators linked to an individual  108 . In some embodiments, one or more receiving units  132  receive one or more signals  130  indicating one or more metabolic activities linked to an individual  108 . In some embodiments, one or more receiving units  132  receive one or more signals  130  indicating one or more levels of one or more nutraceutical agents  118  linked to an individual  108 . In some embodiments, one or more receiving units  132  receive one or more signals  130  indicating one or more levels of one or more pharmaceutical agents linked to an individual  108 . In some embodiments, one or more receiving units  132  receive one or more parameters  114  associated with one or more specified goals  106  of an individual  108 . In some embodiments, one or more receiving units  132  receive one or more instructions to select one or more nutraceutical agents  118  in response to intaking information  112  linked to one or more parameters  114  associated with the one or more specified goals  106  of the individual  108 . In some embodiments, one or more receiving units  132  receive one or more signals  130  to select one or more nutraceutical agents  118  to increase one or more levels of one or more components associated with one or more specified goals  106  of an individual  108 . In some embodiments, one or more receiving units  132  receive one or more signals  130  to select one or more nutraceutical agents  118  to decrease one or more levels of one or more components associated with one or more specified goals  106  of an individual  108 . In some embodiments, one or more receiving units  132  receive one or more signals  130  to select one or more nutraceutical agents  118  that stimulate one or more metabolic pathways linked to an individual  108 . In some embodiments, one or more receiving units  132  receive one or more signals  130  to select one or more nutraceutical agents  118  that inhibit one or more metabolic pathways linked to an individual  108 . In some embodiments, one or more receiving units  132  receive one or more signals  130  to select at least one vitamin, mineral, enzyme, amino acid, homeopathic supplement, toxin, homeopathic substance, traditional remedy, herbal supplement, glandular supplement, or substantially any combination thereof.  
      Receiving units  132  may receive numerous types of signals  130 . Examples of such signals  130  include, but are not limited to, hardwired signals  130 , wireless signals  130 , infrared signals  130 , optical signals  130 , radiofrequency (RF) signals  130 , auditory signals  130 , digital signals  130 , analog signals  130 , or substantially any combination thereof.  
     Recording Unit  124   
      The system  100  may include one or more recording units  124 . In some embodiments, one or more recording units  124  can communicate with one or more accepting units  102 , one or more intaking units  110 , one or more transmitting units  128 , one or more receiving units  132 , one or more selecting units  116 , one or more indicating units  120 , one or more users  136 , and/or substantially any combination thereof. Many types of recording units  124  may be used within system  100 . Examples of such recording devices include those that utilize a recordable medium  126  that includes, but is not limited to, many types of memory, optical disks, magnetic disks, magnetic tape, and the like.  
     User Interaction  134 /User  136   
      The system  100  may provide for user interaction  134 . In some embodiments, a user  136  may interact with one or more accepting units  102 , one or more intaking units  110 , one or more transmitting units  128 , one or more receiving units  132 , one or more selecting units  116 , one or more indicating units  120 , one or more recording units  124 , and/or substantially any combination thereof. The user  136  can interact through use of numerous technologies. For example, user interaction  134  can occur through use of hardwired methods, such as through use of a keyboard, use of wireless methods, use of the internet, and the like. In some embodiments, a user  136  is a health-care worker. Examples of such health-care workers include, but are not limited to, physicians, nurses, dieticians, pharmacists, and the like. In some embodiments, users  136  may include those persons who work in health-related fields, such as coaches, personal trainers, clerks at food supplement stores, clerks at grocery stores, and the like. In some embodiments, a user  136  is not human.  
       FIG. 2  illustrates an operational flow  200  representing examples of operations that are related to the performance of a method for nutraceutical agent  118  and dosing. In  FIG. 2  and in following figures that include various examples of operations used during performance of the method, discussion and explanation may be provided with respect to the above-described example of  FIG. 1 , and/or with respect to other examples and contexts. However, it should be understood that the operations may be executed in a number of other environments and contexts, and/or modified versions of  FIG. 1 . Also, although the various operations are presented in the sequence(s) illustrated, it should be understood that the various operations may be performed in other orders than those which are illustrated, or may be performed concurrently.  
      After a start operation, the operational flow  200  includes an accepting operation  210  involving accepting data related to one or more specified goals of an individual. In some embodiments, one or more accepting units  102  may accept data  104  related to one or more specified goals  106  of an individual  108 . The one or more specified goals  106  may be virtually any goal to be achieved, or attempted by, an individual  108  that may be affected by administration of one or more nutraceutical agents  118  to the individual  108 . In some embodiments, administration of one or more nutraceutical agents  118  to an individual  108  may assist the individual  108  to achieve one or more specified goals  106 . In some embodiments, administration of one or more nutraceutical agents  118  to an individual  108  may stimulate the individual  108  to achieve one or more specified goals  106 . In some embodiments, administration of one or more nutraceutical agents  118  to an individual  108  may reduce an inhibition coupled to the individual  108  to promote achieving one or more specified goals  106  by the individual  108 . Numerous examples of specified goals  106  of an individual  108  exist. In some embodiments, specified goals  106  of an individual  108  may be related to attentiveness, alertness, test performance, relaxation, pain, fever, attractiveness, anxiety, fall, injury, accident, bite, bleeding, inflammation, infection, drowsiness, insomnia, discomfort, stress, grooming, appearance, capability, performance, improvement, enhancement, curtailment, wellbeing, vitality, vigor, disability, phobia, malady, psychosis, environmental extremes, environmental exposure, dysfunction, disease symptom, chronic condition, mental acuity, emotional behavior, physical prowess, addiction, obsession, therapy, remedy, behavior, nutrition, diet, exercise, immunization, prevention, diagnosis, subscription, regimen, social performance, social interaction, endurance, sexual attribute, sexual performance, age-related attribute, age-related condition, prophylaxis, treatment, and substantially any combination thereof. In some embodiments, data  104  may include identification of one or more of the specified goals  106  of an individual  108 . In some embodiments, data  104  may include characteristics of an individual  108 . Examples of such data  104  may include, but are not limited to, physical characteristics, metabolic characteristics, financial characteristics, and the like. In some embodiments, data  104  may include, an individual&#39;s  108  height, weight, gender, kidney function, liver function, level of physical fitness, age, allergic response, metabolic level (i.e., resting metabolic rate and/or activity-related metabolic rate), disease state, body fat percentage, body mass index, personal health habits (i.e., smoking, alcohol consumption, diet, illegal drug use, and the like), family health history, insurance coverage, food supplement usage, nutraceutical agent  118  usage, non-prescription drug use, prescription drug use, pregnancy status, and the like. In some embodiments, the one or more characteristics may be specifically associated with an individual.  108 . As such, in some embodiments, the one or more characteristics may be unique to the individual  108  as opposed to being common to a group. For example, in some embodiments, an individual  108  may be a member of a group of persons who are diabetic while exhibiting one or more characteristics, such as metabolic characteristics, that are unique to the individual  108 . Accordingly, in some embodiments, data  104  may be input that provides for selection of nutraceutical agents  118  in accordance with one or more characteristics and specified goals  106  of an individual  108 .  
      The operational flow  200  includes an intaking operation  220  involving intaking information linked to one or more parameters associated with the one or more specified goals of the individual. In some embodiments, one or more intaking units  110  may intake information  112  linked to one or more parameters  114  associated with the one or more specified goals  106  of the individual  108 . Numerous parameters  114  may be associated with one or more specified goals  106  of an individual  108 . Examples of such parameters  114  include, but are not limited to, blood sugar levels, blood insulin levels, blood iron levels, hormone levels (amine-derived hormones: such as catecholamines (adrenaline, dopamine, noradrenaline); tryptophan derivatives (melatonin, serotonin); tyrosine derivatives (thyroxine and triiodothyronine); peptide hormones such as antimullerian hormone, adiponectin, adrenocorticotropic hormone, angiotensinogen and angiotensin, antidiuretic hormone, atrial-natriuretic peptide, calcitonin, cholecystokinin, corticotropin-releasing hormone, erythropoietin, follicle-stimulating hormone, gastrin, ghrelin, glucagons, gonadotropin-releasing hormone, growth hormone-releasing hormone, human chorionic gonadotropin, growth hormone, inhibin, insulin, insulin-like growth factor, luteinizing hormone, melanocyte stimulating hormone, neuropeptide Y, oxytocin, parathyroid hormone, prolactin, relaxin, secretin, somatostatin, thrombopoietin, thyroid-stimulating hormone, thyrotropin-releasing hormone; steroid hormones: Glucocorticoids (cortisol); Mineralocorticoids (aldosterone); sex steroids: androgens (testosterone, dehydroepiandrosterone, dehydroepiandrosterone sulfate, androstenedione, dihydrotestosterone); estrogens (estradiol); progestagens (progesterone and progestins); sterol hormones: vitamin D derivatives (calcitriol); lipid hormones (prostaglandins, leukotrienes, prostacyclin, and thromboxane)), nutraceutical agent  118  levels, pharmaceutical agent levels, cytokine levels, and the like (i.e., Fitzgerald et al., The Cytokine Facts Book, Academic Press, San Francisco, Second Edition, (2001)). Methods to gain information  112  with regard to components of biological systems are known (i.e., Clinical Laboratory Medicine, Lippincott Williams and Wilkins, Philadelphia, Second Edition, 2002). In some embodiments, one or more intaking units  110  may include instrumentation that provides for analysis of a sample obtained from an individual  108 . For example, in some embodiments, an intaking unit  110  may be configured to intake a blood sample obtained from an individual  108  and analyze the blood sample to determine one or more parameters  114  associated with one or more specified goals  106  of an individual  108  (i.e., determine the level of free testosterone or the level of melatonin in a blood sample obtained from an individual  108 ). Numerous analytical technologies are known and may be included within one or more intaking units  110 . Examples of such technologies include, but are not limited to, gas chromatography, mass spectrometry, atomic absorption, immunoassay based methods, microfluidic based methods, spectrophotometry (i.e., infrared, ultraviolet, fluorescence, and the like), surface plasmon resonance, fluorescence resonance energy transfer, and the like. In some embodiments, one or more intaking units  110  may intake information  112  linked to one or more parameters  114  associated with the one or more specified goals  106  of an individual  108  from a source that is independent of the one or more intaking units  110 . In some embodiments, one or more intaking units  110  may intake information  112  linked to one or more parameters  114  associated with the one or more specified goals  106  of an individual  108  from a source that is coupled to the one or more intaking units  110 .  
      The operational flow  200  includes a selecting operation  230  involving selecting one or more nutraceutical agents in response to the intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual. In some embodiments, one or more selecting units  116  may select one or more nutraceutical agents  118  in response to the intaking information  112  linked to one or more parameters  114  associated with the one or more specified goals  106  of the individual  108 . In some embodiments, one or more selecting units  116  may select one or more nutraceutical agents  118  in response to one or more intaking units  110 . In some embodiments, one or more selecting units  116  may select one or more nutraceutical agents  118  in response to one or more accepting units  102 . In some embodiments, one or more selecting units  116  may select one or more nutraceutical agents  118  in response to one or more intaking units  110  and one or more accepting units  102 . Accordingly, in some embodiments, one or more selecting units  116  may select one or more nutraceutical agents  118  with regard to one or more characteristics of the individual  108  and one or more parameters  114  associated with one or more specified goals  106  of the individual  108 . For example, in some embodiments, one or more selecting units  116  may select one or more nutraceutical agents  118  based on the age of the individual  108  and the level of testosterone in the individual&#39;s  108  blood. In other embodiments, one or more selecting units  116  may select one or more nutraceutical agents  118  based on insurance coverage held by an individual  108  and a specified goal  106  of the individual  108 . Accordingly, numerous combinations of information  112  and data  104  may be used by one or more selecting units  116  to select one or more nutraceutical agents  118 .  
      The operational flow  200  includes an indicating operation  240  involving indicating one or more dosages of the one or more nutraceutical agents in response to the selecting the one or more nutraceutical agents in response to the intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual. In some embodiments, one or more indicating units  120  may indicate one or more dosages  122  of the one or more nutraceutical agents  118  in response to the intaking information  112  linked to one or more parameters  114  associated with the one or more specified goals  106  of the individual  108 . In some embodiments, one or more indicating units  120  may indicate one or more dosages  122  of one or more nutraceutical agents  118  in human-readable format. In some embodiments, one or more indicating units  120  may indicate one or more dosages  122  of one or more nutraceutical agents  118  in machine-readable format. In some embodiments, one or more indicating units  120  may deposit one or more dosages  122  of one or more nutraceutical agents  118  on one or more labels. In some embodiments, one or more indicating units  120  may dispense one or more nutraceutical agents  118 . In some embodiments, one or more indicating units  120  may dispense one or more nutraceutical agents  118  in unit dosage form. In some embodiments, one or more indicating units  120  may dispense two or more of one or more nutraceutical agents  118  in a single administration form.  
       FIG. 3  illustrates alternative embodiments of the example operational flow  200  of  FIG. 2 .  FIG. 3  illustrates example embodiments where the accepting operation  210  may include at least one additional operation. Additional operations may include an operation  302 , an operation  304 , an operation  306 , an operation  308 , and/or an operation  310 .  
      At operation  302 , the accepting operation  210  may include accepting the data related to one or more physical characteristics of the individual. In some embodiments, one or more accepting units  102  accept data  104  related to one or more physical characteristics of the individual  108 .  
      One or more accepting units  102  may accept data  104  related to numerous physical characteristics of an individual  108 . Examples of such physical characteristics include, but are not limited to, height, weight, gender, kidney function, liver function, level of physical fitness, age, allergic response, metabolic level (i.e., resting metabolic rate and/or activity-related metabolic rate), disease state, body fat percentage, body mass index, personal health habits (i.e., smoking, alcohol consumption, diet, illegal drug use, and the like), family health history, food supplement usage, nutraceutical agent  118  usage, non-prescription drug use, prescription drug use, pregnancy status, and the like. In some embodiments, such data  104  may be used to identify one or more nutraceutical agents  118  that are compatible with an individual  108 . For example, if an individual  108  is taking a selective serotonin reuptake inhibitor (SSRI), one or more nutraceutical agents  118  should not be selected that would interfere with the serotonin reuptake inhibitor.  
      At operation  304 , the accepting operation  210  may include accepting the data related to one or more mental characteristics of the individual. In some embodiments, one or more accepting units  102  accept data  104  related to one or more mental characteristics of the individual  108 .  
      One or more accepting units  102  may accept data  104  related to numerous mental characteristics of an individual  108 . Examples of such mental characteristics include, but are not limited to, daily time periods when the mental processes of an individual  108  are most acute or least acute (i.e., morning, afternoon, evening, night), an individual&#39;s  108  sleep schedule, an individual&#39;s  108  daily schedule of activities (i.e., meetings, presentations, travel, athletic activity), and the like.  
      At operation  306 , the accepting operation  210  may include accepting the data related to one or more physiological characteristics of the individual. In some embodiments, one or more accepting units  102  accept data  104  related to one or more physiological characteristics of the individual  108 .  
      One or more accepting units  102  may accept data  104  related to numerous physiological characteristics of an individual  108 . Examples of such physiological characteristics include, but are not limited to, the ability of an individual  108  to metabolize one or more nutraceutical agents  118 , the ability of an individual  108  to metabolize one or more pharmaceutical agents, the response of an individual  108  to one or more pharmaceutical agents, the response of an individual  108  to one or more nutraceutical agents  118 , the concentration or level of one or more metabolites in one or more samples obtained from an individual  108 , the concentration or level of one or more components of a sample obtained from an individual  108  that include, but are not limited to, concentrations or levels of: vitamins, minerals, metals, proteins, one or more hormones, hemoglobin, one or more neurotransmitters, metabolites, proteolytic products, antibodies, white blood cells, red blood cells, enzyme activities, lipids, lipoproteins, carbohydrates, phosphates, tumor markers, bacteria, fungi, viruses, parasites, and the like.  
      At operation  308 , the accepting operation  210  may include accepting the data related to one or more performance characteristics of the individual. In some embodiments, one or more accepting units  102  accept data  104  related to one or more performance characteristics of the individual  108 .  
      One or more accepting units  102  may accept data  104  related to numerous performance characteristics of an individual  108 . Generally, performance characteristics relate to physical or mental activities in which an individual  108  engages. Examples of such performance characteristics include, but are not limited to, athletic ability, mental ability, sexual ability, ability to interact socially, and the like. For example, in some embodiments, data  104  related to giving a presentation may be accepted.  
      At operation  310 , the accepting operation  210  may include accepting the data related to one or more psychological characteristics of the individual. In some embodiments, one or more accepting units  102  accept data  104  related to one or more psychological characteristics of the individual  108 .  
      One or more accepting units  102  may accept data  104  related to numerous psychological characteristics of an individual  108 . Examples of such psychological characteristics include, but are not limited to, the presence or absence of a psychological malady. Examples of psychological maladies include, but are not limited to, antisocial personal disorder, anxiety disorder, avoidant personality disorder, bipolar disorder, conduct disorder, depression, depressive disorder, drug addiction, insomnia, primary sleep disorders, schizophrenia, seasonal affective disorder, sexual disorder, sexual dysfunctions, social anxiety disorder, specific phobia, and the like.  
       FIG. 4  illustrates alternative embodiments of the example operational flow  200  of  FIG. 2 .  FIG. 4  illustrates example embodiments where the accepting operation  210  may include at least one additional operation  402 .  
      At operation  402 , the accepting operation  210  may include accepting the data related to attentiveness, alertness, test performance, relaxation, pain, fever, attractiveness, anxiety, fall, injury, accident, bite, bleeding, inflammation, infection, drowsiness, insomnia, discomfort, stress, grooming, appearance, capability, performance, improvement, enhancement, curtailment, wellbeing, vitality, vigor, disability, phobia, malady, psychosis, environmental extremes, environmental exposure, dysfunction, disease symptom, chronic condition, mental acuity, emotional behavior, physical prowess, addiction, obsession, therapy, remedy, behavior, nutrition, diet, exercise, immunization, prevention, diagnosis, subscription, regimen, social performance, social interaction, endurance, sexual attribute, sexual performance, age-related attribute, age-related condition, prophylaxis, or treatment. In some embodiments, one or more accepting units  102  accept data  104  related to attentiveness, alertness, test performance, relaxation, pain, fever, attractiveness, anxiety, fall, injury, accident, bite, bleeding, inflammation, infection, drowsiness, insomnia, discomfort, stress, grooming, appearance, capability, performance, improvement, enhancement, curtailment, wellbeing, vitality, vigor, disability, phobia, malady, psychosis, environmental extremes, environmental exposure, dysfunction, disease symptom, chronic condition, mental acuity, emotional behavior, physical prowess, addiction, obsession, therapy, remedy, behavior, nutrition, diet, exercise, immunization, prevention, diagnosis, subscription, regimen, social performance, social interaction, endurance, sexual attribute, sexual performance, age-related attribute, age-related condition, prophylaxis, or treatment.  
       FIG. 5  illustrates alternative embodiments of the example operational flow  200  of  FIG. 2 .  FIG. 5  illustrates example embodiments where the intaking operation  220  may include at least one additional operation. Additional operations may include an operation  502 , an operation  504 , an operation  506 , an operation  508 , and/or an operation  510 .  
      At operation  502 , the intaking operation  220  may include assaying one or more samples linked to the individual that include one or more bodily fluids, bodily tissues, or bodily products. In some embodiments, one or more intaking units  110  can assay one or more samples linked to the individual  108  that include one or more bodily fluids, bodily tissues, or bodily products. Examples of such samples include, but are not limited to, blood, urine, saliva, synovial fluid, pleural fluid, peritoneal fluid, tears, mucus, ejaculate, skin, muscle, bone, hair, teeth, nails, urine, breath, fecal material, genital products, and the like.  
      At operation  504 , the intaking operation  220  may include determining one or more levels of one or more metabolic indicators linked to the individual. In some embodiments, one or more intaking units  110  can determine one or more levels of one or more metabolic indicators linked to the individual  108 .  
      For example, vitamin B 12  and folate are two vitamins that have interdependent roles in nucleic acid synthesis. Deficiencies of either vitamin can cause megaloblastic anemia. Accordingly, in some embodiments, the levels of homocysteine and methylmalonic acid may be determined and used as metabolic indicators to indicate levels of vitamin B 12  and folate within an individual  108 . In some embodiments, vitamin A deficiency may be assessed by determining albumin levels which are an indirect measure of vitamin A levels. In some embodiments, magnesium levels may be assessed directly. In some embodiments, magnesium levels may be assessed indirectly through analysis of insulin because magnesium deficiency results in impaired insulin secretion. Accordingly, in some embodiments, magnesium replacement may be used to restore insulin secretion. In some embodiments, fluorescent indicators may be used to determine chloride, zinc, and calcium levels as well as pH. Accordingly, numerous metabolic indicators that are linked to an individual  108  may be determined through use of known methods.  
      At operation  506 , the intaking operation  220  may include determining one or more levels of one or more metabolic activities linked to the individual. In some embodiments, one or more intaking units  110  can determine one or more levels of one or more metabolic activities linked to the individual  108   
      In some embodiments, one or more intaking units  110  can be used to determine one or more enzyme activities of an individual  108 . For example, when digested properly, protein supplies acidity to the blood. If an individual  108  is not able to adequately digest protein, the individual&#39;s  108  blood acquires excess alkaline reserves which must be continuously dumped via the kidneys into the urine. Accordingly, in some embodiments, blood alkalinity may be tested to assist in determining if an individual  108  is deficient in protease activity. In instances of protease deficiency, an individual  108  may wish to ingest a protease supplement to assist with digestion of protein. In some embodiments, enzyme activity may be determined directly. For example, protease activity can be measured directly through use of peptide substrates having an amino acid sequence that is recognized by a protease to be assayed. Such peptide substrates may be readily prepared or be obtained from commercial sources (i.e., Biotium, Inc., Hayward, Calif.; Biomol International Inc., Plymouth Meeting, Pa.; JPT Peptide Technologies, Inc., Springfield, Va.). In some embodiments, vitamin K deficiency exhibited by an individual  108  may be determined through measurement of Protein Induced by Vitamin K Absence (PIVKA-II) using several known methods (Widdershoven, Clin. Chem., 33(11):2074-2078 (1987)). Examples of such methods include, but are not limited to, electrophoresis-immunofixation and enzyme immunoassay. Numerous metabolic activities of an individual  108  may be determined through use of methods that are known and that have been described (i.e., Clinical Laboratory Medicine, Lippincott Williams and Wilkins, Philadelphia, Second Edition, 2002).  
      At operation  508 , the intaking operation  220  may include determining one or more levels of one or more nutraceutical agents linked to the individual. In some embodiments, one or more intaking units  110  can determine one or more levels of one or more nutraceutical agents  118  linked to the individual  108 .  
      Numerous methods may be used to determine one or more nutraceutical agents  118  that are linked to an individual  108 . Examples of such methods include, but are not limited to, chromatographic assay, mass spectrometry, spectrophotometry, immunological assay, and the like. These methods may be performed on numerous types of samples obtained from an individual  108  that are exemplified by bodily fluids, bodily tissues, bodily products and the like.  
      In some embodiments, one or more intaking units  110  may determine one or more levels of one or more nutraceutical agents  118  that administered to an individual  108  at one or more times. For example, in some embodiments, the level of a nutraceutical agent  118  at the time when administered to an individual  108 , at time two hours post-administration, at time four hours post-administration, and at time six hours post-administration may be determined. Accordingly, in some embodiments, the rate at which one or more nutraceutical agents  118  are metabolized by an individual  108  may be determined. In some embodiments, the rate at which a level of a nutraceutical agent  118  is reached within an individual  108  may be determined. Numerous times and concentrations of nutraceutical agents  118  may be transmitted.  
      At operation  510 , the intaking operation  220  may include determining one or more levels of one or more pharmaceutical agents linked to the individual. In some embodiments, one or more intaking units  110  can determine one or more levels of one or more pharmaceutical agents linked to the individual  108 .  
      Numerous methods may be used to determine one or more pharmaceutical agents that are linked to an individual  108 . Examples of such methods include, but are not limited to, chromatographic assay, mass spectrometry, spectrophotometry, immunological assay, and the like. These methods may be performed on numerous types of samples obtained from an individual  108  that are exemplified by bodily fluids, bodily tissues, bodily products and the like.  
      In some embodiments, one or more intaking units  110  may determine one or more levels of one or more pharmaceutical agents that administered to an individual  108  at one or more times. For example, in some embodiments, the level of a pharmaceutical agent at the time when administered to an individual  108 , at time two hours post-administration, at time four hours post-administration, and at time six hours post-administration may be determined. Accordingly, in some embodiments, the rate at which one or more pharmaceutical agents are metabolized by an individual  108  may be determined. In some embodiments, the rate at which a level of a pharmaceutical agent is reached within an individual  108  may be determined. Numerous times and concentrations of pharmaceutical agents may be determined.  
       FIG. 6  illustrates alternative embodiments of the example operational flow  200  of  FIG. 2 .  FIG. 6  illustrates example embodiments where the selecting operation  230  may include at least one additional operation. Additional operations may include an operation  602 , an operation  604 , and/or an operation  606 .  
      At operation  602 , the selecting operation  230  may include selecting the one or more nutraceutical agents to increase one or more levels of one or more components associated with the one or more specified goals of the individual. In some embodiments, one or more selecting units  116  can select one or more nutraceutical agents  118  to increase one or more levels of one or more components associated with the one or more specified goals  106  of the individual  108 .  
      In some embodiments, one or more nutraceutical agents  118  may be selected that may directly complement one or more levels of one or more components associated with one or more specified goals  106  of the individual  108 . For example, calcium in various forms (i.e., calcium citrate, calcium aspartate, calcium carbonate) may be selected by an individual  108  who wants to avoid or reduce the effects of osteoporosis. In another embodiment, chromium may be selected to lower blood sugar, increase insulin sensitivity, reduce body fat, control hunger, suppress appetite, increase lean body/muscle mass, or substantially any combination thereof. In some embodiments, one or more nutraceutical agents  118  associated with one or more specified goals  106  of an individual  108  may be selected that may be administered to an individual  108  to indirectly supplement a component associated with the one or more specified goals  106 . For example, 5-hydroxy-tryptophan may be selected for administration to an individual  108  if the individual  108  suffers from depression and is found to exhibit low levels of serotonin. The 5-hydroxy-tryptophan will be converted to serotonin following administration to the individual  108 . Numerous nutraceutical agents  118  may be selected to increase one or more levels of one or more components associated with one or more specified goals  106  of an individual  108 .  
      At operation  604 , the selecting operation  230  may include selecting the one or more nutraceutical agents to decrease one or more levels of one or more components associated with the one or more specified goals of the individual. In some embodiments, one or more selecting units  116  can select one or more nutraceutical agents  118  to decrease one or more levels of one or more components associated with the one or more specified goals  106  of the individual  108 .  
      In some embodiments, one or more components may be associated with one or more specified goals  106  of an individual  108 . Low density lipoproteins are examples of components that are linked to vascular disease. Accordingly, in some embodiments, one or more nutraceutical agents  118  may be selected that will act to lower the low density lipoprotein concentration of an individual  108 . Examples of such nutraceutical agents  118  include, but are not limited to, plant stanols, dietary fiber, stanol esters, isoflavones, diallyl sulfides, niacin, soy protein, and substantially any combination thereof. Glucose is an example of a component that is linked to hyperglycemia. Accordingly, in some embodiments, buckwheat is an example of a nutraceutical agent  118  that may be selected to lower blood glucose levels of an individual  108 . Free radical oxygen species that include singlet oxygen, hydroxyl radicals, peroxides, and superoxide radicals are components that act to damage lipids and other cellular structures. Accordingly, one or more nutraceutical agents  118  may be selected to reduce levels of free radicals within an individual  108 . Examples of such nutraceutical agents  118  include, but are not limited to, terpenes, carotenoids, limonoids, phenols, flavonoids, isoprenoids, and the like. Numerous other nutraceutical agents  118  may be selected to decrease one or more levels of one or more components associated with the one or more specified goals  106  of the individual  108 .  
      At operation  606 , the selecting operation  230  may include selecting the one or more nutraceutical agents that stimulate one or more metabolic pathways linked to the individual. In some embodiments, one or more selecting units  116  can select one or more nutraceutical agents  118  that stimulate one or more metabolic pathways linked to the individual  108 .  
      In some embodiments, stimulation of one or more metabolic pathways may be associated with one or more specified goals  106  of an individual  108 . For example, in some embodiments, decline in L-carnitine synthesis is thought to be linked to senile reduction in bone synthesis (Colucci et al., Calcified Tissue International, 76:458-465 (2005)). Dihydroepiandrosterone (DHEA) is thought to affect levels of L-carnitine through promoting the expression of carnitine-synthesizing enzymes (Chiu et al., Calcified Tissue International, 64:527-533 (1999)). Accordingly, DHEA may be selected to stimulate the L-carnitine synthetic pathway to reduce senile reduction in bone synthesis. In other embodiments, buckwheat extract may be selected to lower blood glucose due to the ability of buckwheat extract to activate mitogen activated protein kinase via phospholipase D (Appleton and Lockwood, The Pharmaceutical Journal, 277:78-83 (2006)). In another embodiment, resveratrol has been shown to stimulate endothelial nitric oxide synthase activity (Klinge et al., J. Biol. Chem., 280(9):7460-7468 (2005); Wallerath et al., Circulation, 106(13):1652-1658 (2002)). Endothelial nitric oxide synthase is an enzyme that catalyzes the formation of nitric oxide by vascular endothelial cells. Nitric oxide is needed to maintain arterial relaxation (vasodilation), and impaired nitric oxide-dependent vasodilation is associated with increased risk of cardiovascular disease (Duffy and Vita, Curr. Opin. Lipidol., 14(1):21-27 (2003)). Accordingly, in some embodiments, resveratrol may be selected to reduce cardiovascular disease. Numerous nutraceutical agents  118  may be selected to one or more metabolic pathways linked to the individual  108 .  
       FIG. 7  illustrates alternative embodiments of the example operational flow  200  of  FIG. 2 .  FIG. 7  illustrates example embodiments where the selecting operation  230  may include at least one additional operation. Additional operations may include an operation  702 , and/or an operation  704 .  
      At operation  702 , the selecting operation  230  may include selecting the one or more nutraceutical agents that inhibit one or more metabolic pathways linked to the individual. In some embodiments, one or more selecting units  116  can select one or more nutraceutical agents  118  that inhibit one or more metabolic pathways linked to the individual  108 .  
      In some embodiments, one or more metabolic pathways may be inhibited through inhibition of one or more enzymes that participate within the metabolic pathway. Such metabolic pathways may be involved with a specified goal  106  of an individual  108 . For example, angiotensin-converting enzyme has been linked to high blood pressure. Flavonoids have been shown to inhibit angiotensin-converting enzyme (Actis-Goretta et al., J. Agric. Food Chem., 54(1):229-234 (2006)). Accordingly, flavonoids may be selected to assist in the reduction of blood pressure (Li et al., Chin. J. Physiol., 48(2):101-106 (2005); Machha and Mustafa, J. Cardiovasc. Pharmacol., 46(1):36-40 (2005)). Genistein, one of the predominant soy isoflavones, has been shown to compete with 17beta-estradiol for estrogen receptor binding because of its structural similarity, resulting in agonistic or antagonistic activity. This has been shown to cause inhibition of cell growth in breast and prostate cancers in vivo and in vitro. Accordingly, soy isoflavones containing genistein may be selected as a nutraceutical agent  118  for cancer chemoprevention (Sarkar et al., Mini Rev. Med. Chem., 6(4):401-407 (2006)). The isoflavonoids, daidzin, daidzein, and puerarin have been shown to reduce alcohol consumption (Lin RC, Alcohol Clin. Exp. Res., 20(4):659-663 (1996)). A link between daidzin&#39;s capacity to reduce alcohol consumption and its ability to increase the liver mitochondrial monoamine oxidase: aldehyde dehydrogenase activity ratio has been established (Keung, Med. Res. Rev., 23(6):669-696 (2003)). This increase in ratio is thought to occur through inhibition of aldehyde dehydrogenase activity. Accordingly, isoflavonoid mixtures that include daidzin, daidzein, and/or puerarin may be selected to lower alcohol consumption. Numerous other nutraceutical agents  118  may be selected that inhibit one or more metabolic pathways linked to the individual  108 .  
      At operation  704 , the selecting operation  230  may include selecting at least one vitamin, mineral, enzyme, amino acid, homeopathic supplement, toxin, homeopathic substance, traditional remedy, herbal supplement, or glandular supplement. In some embodiments, one or more selecting units  116  can select at least one vitamin, mineral, enzyme, amino acid, homeopathic supplement, toxin, homeopathic substance, traditional remedy, herbal supplement, or glandular supplement.  
       FIG. 8  illustrates alternative embodiments of the example operational flow  200  of  FIG. 2 .  FIG. 8  illustrates example embodiments where the indicating operation  240  may include at least one additional operation. Additional operations may include an operation  802 , an operation  804 , an operation  806 , an operation  808 , an operation  810 , and/or an operation  812 .  
      At operation  802 , the indicating operation  240  may include indicating the one or more dosages of the one or more nutraceutical agents in human-readable format. In some embodiments, one or more indicating units  120  can indicate the one or more dosages  122  of the one or more nutraceutical agents  118  in human-readable format.  
      In some embodiments, one or more indicating units  120  may indicate one or more dosages  122  of one or more nutraceutical agents  118  on a visual display, a touch display, an audible display, and the like. For example, in some embodiments, one or more indicating units  120  may display one or more dosages  122  on a light emitting diode display, a liquid crystal display, various monitors, and the like. Such visual displays may indicate one or more dosages  122  through display of colors, pictures, printed language, and the like. In some embodiments, one or more indicating units  120  may display one or more dosages  122  on a touch display (i.e., a touch pad display in Braille for use by blind or visually impaired persons). In some embodiments, one or more indicating units  120  may display one or more dosages  122  through use of an audible display that verbally speaks to an individual  108 .  
      In some embodiments, one or more indicating units  120  may display one or more dosages  122  of one or more nutraceutical agents  118  in typographical symbols in numerous languages that are in human-readable format. In some embodiments, one or more indicating units  120  may display one or more dosages  122  of one or more nutraceutical agents  118  and the formulation type of the one or more nutraceutical agents  118  in typographical symbols in numerous languages that are in human-readable format. In some embodiments, one or more indicating units  120  may display one or more dosages  122  of one or more nutraceutical agents  118  in pictographic form that is in human-readable format. In some embodiments, one or more indicating units  120  may display one or more dosages  122  of one or more nutraceutical agents  118  and the formulation type of the one or more nutraceutical agents  118  in pictographic form that is in human-readable format. In some embodiments, one or more indicating units  120  may display one or more dosages  122  of one or more nutraceutical agents  118  according to a color scheme that is in human-readable format. In some embodiments, one or more indicating units  120  may display one or more dosages  122  of one or more nutraceutical agents  118  and the formulation type of the one or more nutraceutical agents  118  according to a color scheme that is in human-readable format. In some embodiments, one or more indicating units  120  may display one or more dosages  122  of one or more nutraceutical agents  118 , one or more routes of administration for the one or more nutraceutical agents  118 , one or more times and/or periodicities for administration of the one or more nutraceutical agents  118 , one or more formulation types for the one or more nutraceutical agents  118 , whether to administer the one or more nutraceutical agents  118  with or without food, whether to administer the one or more nutraceutical agents  118  with or without other nutraceutical agents  118  and/or pharmaceutical agents, and substantially any combination thereof. Dosages  122  may be displayed according to numerous methods that are known and have been described (i.e., U.S. patent application Ser. No. 11/474,109, entitled CUSTOMIZED VISUAL MARKING FOR MEDICATION LABELING, filed 23 Jun. 2006, herein incorporated by reference to the extent such subject matter is not inconsistent herewith). In some embodiments, one or more indicating units  120  may indicate one or more dosages  122  in human-readable format and machine-readable format.  
      At operation  804 , the indicating operation  240  may include indicating the one or more dosages of the one or more nutraceutical agents in machine-readable format. In some embodiments, one or more indicating units  120  can indicate the one or more dosages  122  of the one or more nutraceutical agents  118  in machine-readable format.  
      In some embodiments, one or more indicating units  120  may indicate one or more dosages  122  of one or more nutraceutical agents  118  in machine-readable format. Numerous methods may be used to indicate one or more dosages  122 . Examples of such methods include, but are not limited to, radio frequency identification, bar coding, typographical methods, symbol based methods (i.e., use of symbols that represent dosages  122  and nutraceutical agents  118 ), optical methods (i.e., pulsed light), and the like.  
      In some embodiments, one or more indicating units  120  may indicate one or more dosages  122  of one or more nutraceutical agents  118  and the formulation type of the one or more nutraceutical agents  118  in machine-readable form. In some embodiments, one or more indicating units  120  may indicate one or more dosages  122  of one or more nutraceutical agents  118  in a pictographic form that is in machine-readable format. In some embodiments, one or more indicating units  120  may indicate one or more dosages  122  of one or more nutraceutical agents  118  and the formulation type of the one or more nutraceutical agents  118  in a pictographic form that is in machine-readable format. In some embodiments, one or more indicating units  120  may indicate one or more dosages  122  of one or more nutraceutical agents  118  according to a color scheme that is in machine-readable format. In some embodiments, one or more indicating units  120  may indicate one or more dosages  122  of one or more nutraceutical agents  118  and the formulation type of the one or more nutraceutical agents  118  according to a color scheme that is in machine-readable format. In some embodiments, one or more indicating units  120  may indicate one or more dosages  122  of one or more nutraceutical agents  118 , one or more routes of administration for the one or more nutraceutical agents  118 , one or more times and/or periodicities for administration of the one or more nutraceutical agents  118 , one or more formulation types for the one or more nutraceutical agents  118 , whether to administer the one or more nutraceutical agents  118  with or without food, whether to administer the one or more nutraceutical agents  118  with or without other nutraceutical agents  118  and/or pharmaceutical agents, and substantially any combination thereof. Numerous labeling methods are known and have been described that may be adapted into a machine-readable format (i.e., U.S. patent application Ser. No. 11/474,109, entitled CUSTOMIZED VISUAL MARKING FOR MEDICATION LABELING, filed 23 Jun. 2006, herein incorporated by reference to the extent such subject matter is not inconsistent herewith). In some embodiments, one or more indicating units  120  may indicate one or more dosages  122  in human-readable and in a machine-readable format.  
      At operation  806 , the indicating operation  240  may include depositing the one or more dosages of the one or more nutraceutical agents on one or more labels. In some embodiments, one or more indicating units  120  can deposit the one or more dosages  122  of the one or more nutraceutical agents  118  on one or more labels.  
      In some embodiments, one or more indicating units  120  may print one or more labels that include one or more dosages  122  of one or more nutraceutical agents  118  and the formulation type of the one or more nutraceutical agents  118 . In some embodiments, one or more indicating units  120  may print one or more labels that include one or more dosages  122  of one or more nutraceutical agents  118  in pictographic form. In some embodiments, one or more indicating units  120  may print one or more labels that include one or more dosages  122  of one or more nutraceutical agents  118  and the formulation type of the one or more nutraceutical agents  118  in pictographic form. In some embodiments, one or more indicating units  120  may print one or more labels that include one or more dosages  122  of one or more nutraceutical agents  118  according to a color scheme. In some embodiments, one or more indicating units  120  may print one or more labels that include one or more dosages  122  of one or more nutraceutical agents  118  and the formulation type of the one or more nutraceutical agents  118  according to a color scheme. In some embodiments, one or more indicating units  120  may indicate one or more dosages  122  of one or more nutraceutical agents  118 , one or more routes of administration for the one or more nutraceutical agents  118 , one or more times and/or periodicities for administration of the one or more nutraceutical agents  118 , one or more formulation types for the one or more nutraceutical agents  118 , whether to administer the one or more nutraceutical agents  118  with or without food, whether to administer the one or more nutraceutical agents  118  with or without other nutraceutical agents  118  and/or pharmaceutical agents, and substantially any combination thereof. Numerous labeling methods are known and have been described which may be adapted into machine-readable form (i.e., U.S. patent application Ser. No. 11/474,109, entitled CUSTOMIZED VISUAL MARKING FOR MEDICATION LABELING, filed 23 Jun. 2006, herein incorporated by reference to the extent such subject matter is not inconsistent herewith).  
      In some embodiments, one or more indicating units  120  may indicate one or more dosages  122  in human-readable and machine-readable form. Numerous types of depositing methods may be used by one or more indicating units  120 . Examples of such methods include, but are not limited to, printing methods (i.e., stamping, ink-jet printing, laser printing, and the like). In some embodiments, ink containing magnetic particles may be used.  
      At operation  808 , the indicating operation  240  may include dispensing the one or more nutraceutical agents. In some embodiments, one or more indicating units  120  can dispense the one or more nutraceutical agents  118 .  
      One or more indicating units  120  may dispense one or more nutraceutical agents  118  in numerous dosage forms. In some embodiments, one or more indicating units  120  may dispense one or more nutraceutical agents  118  in powder form. In some embodiments, one or more indicating units  120  may dispense one or more nutraceutical agents  118  in liquid form. In some embodiments, one or more indicating units  120  may dispense one or more nutraceutical agents  118  in tablet form. In some embodiments, one or more indicating units  120  may dispense one or more nutraceutical agents  118  in capsule form.  
      At operation  810 , the indicating operation  240  may include dispensing the one or more nutraceutical agents in unit dosage form. In some embodiments, one or more indicating units  120  can dispense the one or more nutraceutical agents  118  in unit dosage form.  
      In some embodiments, one or more indicating units  120  may dispense one or more nutraceutical agents  118  in a unit dosage form in which the entire dosage  122  is to be administered to an individual  108  as a single dosage  122 . In some embodiments, one or more indicating units  120  may dispense one or more nutraceutical agents  118  in a unit dosage form that may be administered such that the individual  108  will maintain a level of the one or more nutraceuticals for a given time period. For example, in some embodiments, a unit dosage form may be an amount of one or more nutraceutical agents  118  that will allow the one or more nutraceutical agents  118  to be maintained within an individual  108  for four hours. Numerous criteria may be used to determine a unit dosage form. Examples of such criteria include, but are not limited to, physical characteristics of the individual  108 , physiological characteristics of the individual  108 , activity of the individual  108 , and the like.  
      At operation  812 , the indicating operation  240  may include dispensing two or more of the one or more nutraceutical agents in a single administration form. In some embodiments, one or more indicating units  120  can dispense two or more of the one or more nutraceutical agents  118  in a single administration form.  
      In some embodiments, one or more indicating units  120  may dispense two or more nutraceutical agents  118  in a single administration form to provide for administration of the two or more nutraceutical agents  118  to an individual  108 . Such methods have been described (i.e., U.S. patent application Ser. No. 11/453,571, filed 14 Jun. 2006; U.S. patent application Ser. No. 11/478,341, filed 28 Jun. 2006; U.S. patent application Ser. No. 11/478,296, filed 28 Jun. 2006; and U.S. patent application No. 11/486,998, filed 14 Jul. 2006, herein incorporated by reference to the extent such subject matter is not inconsistent herewith).  
       FIG. 9  illustrates an operational flow  900  that includes an accepting operation  910 , an intaking operation  920 , a selecting operation  930 , and an indicating operation  940  (which correspond to the accepting operation  210 , the intaking operation  220 , the selecting operation  230 , and the indicating operation  240  illustrated in  FIG. 2 ) with an additional recording operation  950 . In  FIG. 9 , discussion and explanation may be provided with respect to the above-described example of  FIG. 1 , and/or with respect to other examples and contexts. However, it should be understood that the operations may be executed in a number of other environments and contexts, and/or modified versions of  FIG. 1 . Also, although the various operations are presented in the sequence(s) illustrated, it should be understood that the various operations may be performed in other orders than those which are illustrated, or may be performed concurrently.  
      After a start operation, the operational flow  900  includes the operations  910 ,  920 ,  930 , and  940  (which correspond to operations  210 ,  220 ,  230 , and  240  as described with regard to  FIG. 2 ) and an additional recording operation  950  involving recording results of, the accepting data related to one or more specified goals of an individual, the intaking information linked to one or more parameters associated with the one or more specified goals of the individual, the selecting one or more nutraceutical agents in response to the intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual, or the indicating one or more dosages of the one or more nutraceutical agents in response to the selecting the one or more nutraceutical agents in response to the intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual on a recordable-medium. In some embodiments, one or more recording units  124  may record results of, the accepting data  104  related to one or more specified goals  106  of an individual  108 , the intaking information  112  linked to one or more parameters  114  associated with the one or more specified goals  106  of the individual  108 , the selecting one or more nutraceutical agents  118  in response to the intaking information  112  linked to one or more parameters  114  associated with the one or more specified goals  106  of the individual  108 , or the indicating one or more dosages  122  of the one or more nutraceutical agents  118  in response to the selecting one or more nutraceutical agents  118  in response to the intaking information  112  linked to one or more parameters  114  associated with the one or more specified goals  106  of the individual  108  on a recordable-medium  126 .  
       FIG. 10  illustrates an operational flow  1000  representing examples of operations that are related to the performance of a method for nutraceutical agent  118  and dosing. In  FIG. 10  and in following figures that include various examples of operations used during performance of the method, discussion and explanation may be provided with respect to the above-described example of  FIG. 1 , and/or with respect to other examples and contexts. However, it should be understood that the operations may be executed in a number of other environments and contexts, and/or modified versions of  FIG. 1 . Also, although the various operations are presented in the sequence(s) illustrated, it should be understood that the various operations may be performed in other orders than those which are illustrated, or may be performed concurrently.  
      After a start operation, the operational flow  1000  includes an accepting operation  1010  involving accepting data related to one or more specified goals of an individual. In some embodiments, one or more accepting units  102  may accept data  104  related to one or more specified goals  106  of an individual  108 .  
      In some embodiments, one or more accepting units  102  may accept data  104  related to one or more specified goals  106  of an individual  108 . The one or more specified goals  106  may be virtually any goal to be achieved, or attempted by, an individual  108  that may be affected by administration of one or more nutraceutical agents  118  to the individual  108 . In some embodiments, administration of one or more nutraceutical agents  118  to an individual  108  may assist the individual  108  to achieve one or more specified goals  106 . In some embodiments, administration of one or more nutraceutical agents  118  to an individual  108  may stimulate the individual  108  to achieve one or more specified goals  106 . In some embodiments, administration of one or more nutraceutical agents  118  to an individual  108  may reduce an inhibition coupled to the individual  108  to promote achieving one or more specified goals  106  by the individual  108 . Numerous examples of specified goals  106  of an individual  108  exist. In some embodiments, specified goals  106  of an individual  108  may be related to attentiveness, alertness, test performance, relaxation, pain, fever, attractiveness, anxiety, fall, injury, accident, bite, bleeding, inflammation, infection, drowsiness, insomnia, discomfort, stress, grooming, appearance, capability, performance, improvement, enhancement, curtailment, wellbeing, vitality, vigor, disability, phobia, malady, psychosis, environmental extremes, environmental exposure, dysfunction, disease symptom, chronic condition, mental acuity, emotional behavior, physical prowess, addiction, obsession, therapy, remedy, behavior, nutrition, diet, exercise, immunization, prevention, diagnosis, subscription, regimen, social performance, social interaction, endurance, sexual attribute, sexual performance, age-related attribute, age-related condition, prophylaxis, treatment, and substantially any combination thereof. In some embodiments, data  104  may include identification of one or more of the specified goals  106  of an individual  108 . In some embodiments, data  104  may include characteristics of an individual  108 . Examples of such data  104  may include, but are not limited to, physical characteristics, metabolic characteristics, financial characteristics, and the like. In some embodiments, data  104  may include, an individual&#39;s  108  height, weight, gender, kidney function, liver function, level of physical fitness, age, allergic response, metabolic level (i.e., resting metabolic rate and/or activity-related metabolic rate), disease state, body fat percentage, body mass index, personal health habits (i.e., smoking, alcohol consumption, diet, illegal drug use, and the like), family health history, insurance coverage, food supplement usage, nutraceutical agent  118  usage, non-prescription drug use, prescription drug use, pregnancy status, and the like. In some embodiments, the one or more characteristics may be specifically associated with an individual  108 . As such, in some embodiments, the one or more characteristics may be unique to the individual  108  as opposed to being common to a group. For example, in some embodiments, an individual  108  may be a member of a group of persons who are diabetic while exhibiting one or more characteristics, such as metabolic characteristics, that are unique to the individual  108 . Accordingly, in some embodiments, data  104  may be input that provides for selection of nutraceutical agents  118  in accordance with one or more characteristics and specified goals  106  of an individual  108 .  
      After a start operation, the operational flow  1000  includes an intaking operation  1020  involving intaking information linked to one or more parameters associated with the one or more specified goals of the individual. In some embodiments, one or more intaking units  110  may intake information  112  linked to one or more parameters  114  associated with the one or more specified goals  106  of the individual  108 .  
      In some embodiments, one or more intaking units  110  may intake information  112  linked to one or more parameters  114  associated with the one or more specified goals  106  of the individual  108 . Numerous parameters  114  may be associated with one or more specified goals  106  of an individual  108 . Examples of such parameters  114  include, but are not limited to, blood sugar levels, blood insulin levels, blood iron levels, hormone levels (amine-derived hormones: such as catecholamines (adrenaline, dopamine, noradrenaline); tryptophan derivatives (melatonin, serotonin); tyrosine derivatives (thyroxine and triiodothyronine); peptide hormones such as antimullerian hormone, adiponectin, adrenocorticotropic hormone, angiotensinogen and angiotensin, antidiuretic hormone, atrial-natriuretic peptide, calcitonin, cholecystokinin, corticotropin-releasing hormone, erythropoietin, follicle-stimulating hormone, gastrin, ghrelin, glucagons, gonadotropin-releasing hormone, growth hormone-releasing hormone, human chorionic gonadotropin, growth hormone, inhibin, insulin, insulin-like growth factor, luteinizing hormone, melanocyte stimulating hormone, neuropeptide Y, oxytocin, parathyroid hormone, prolactin, relaxin, secretin, somatostatin, thrombopoietin, thyroid-stimulating hormone, thyrotropin-releasing hormone; steroid hormones: Glucocorticoids (cortisol); Mineralocorticoids (aldosterone); sex steroids: androgens (testosterone, dehydroepiandrosterone, dehydroepiandrosterone sulfate, androstenedione, dihydrotestosterone); estrogens (estradiol); progestagens (progesterone and progestins); sterol hormones: vitamin D derivatives (calcitriol); lipid hormones (prostaglandins, leukotrienes, prostacyclin, and thromboxane)), nutraceutical agent  118  levels, pharmaceutical agent levels, cytokine levels, and the like (i.e., Fitzgerald et al., The Cytokine Facts Book, Academic Press, San Francisco, Second Edition, (2001)). Methods to gain information  112  with regard to components of biological systems are known (i.e., Clinical Laboratory Medicine, Lippincott Williams and Wilkins, Philadelphia, Second Edition, 2002). In some embodiments, one or more intaking units  110  may include instrumentation that provides for analysis of a sample obtained from an individual  108 . For example, in some embodiments, an intaking unit  110  may be configured to intake a blood sample obtained from an individual  108  and analyze the blood sample to determine one or more parameters  114  associated with one or more specified goals  106  of an individual  108  (i.e., determine the level of free testosterone or the level of melatonin in a blood sample obtained from an individual  108 ). Numerous analytical technologies are known and may be included within one or more intaking units  110 . Examples of such technologies include, but are not limited to, gas chromatography, mass spectrometry, atomic absorption, immunoassay based methods, microfluidic based methods, spectrophotometry (i.e., infrared, ultraviolet, fluorescence, and the like), surface plasmon resonance, fluorescence resonance energy transfer, and the like. In some embodiments, one or more intaking units  110  may intake information  112  linked to one or more parameters  114  associated with the one or more specified goals  106  of an individual  108  from a source that is independent of the one or more intaking units  110 . In some embodiments, one or more intaking units  110  may intake information  112  linked to one or more parameters  114  associated with the one or more specified goals  106  of an individual  108  from a source that is coupled to the one or more intaking units  110 .  
      After a start operation, the operational flow  1000  includes a transmitting operation  1030  involving transmitting one or more signals in response to the intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual. In some embodiments, one or more transmitting units  128  may transmit one or more signals  130  in response to the intaking information  112  linked to one or more parameters  114  associated with the one or more specified goals  106  of the individual  108 .  
      In some embodiments, one or more transmitting units  128  transmit one or more levels of one or more metabolic indicators linked to the individual  108 . In some embodiments, one or more transmitting units  128  transmit one or more levels of one or more metabolic activities linked to the individual  108 . In some embodiments, one or more transmitting units  128  transmit one or more levels of one or more nutraceutical agents  118  linked to the individual  108 . In some embodiments, one or more transmitting units  128  transmit one or more levels of one or more pharmaceutical agents linked to the individual  108 . In some embodiments, one or more transmitting units  128  transmit one or more parameters  114  associated with the one or more specified goals  106  of the individual  108 . In some embodiments, one or more transmitting units  128  transmit one or more instructions to select one or more nutraceutical agents  118  in response to the intaking information  112  linked to one or more parameters  114  associated with the one or more specified goals  106  of the individual  108 . In some embodiments, one or more transmitting units  128  transmit one or more signals  130  to select one or more nutraceutical agents  118  to increase one or more levels of one or more components associated with the one or more specified goals  106  of the individual  108 . In some embodiments, one or more transmitting units  128  transmit one or more signals  130  to select one or more nutraceutical agents  118  to decrease one or more levels of one or more components associated with the one or more specified goals  106  of the individual  108 . In some embodiments, one or more transmitting units  128  transmit one or more signals  130  to select one or more nutraceutical agents  118  that stimulate one or more metabolic pathways linked to the individual  108 . In some embodiments, one or more transmitting units  128  transmit one or more signals  130  to select one or more nutraceutical agents  118  that inhibit one or more metabolic pathways linked to the individual  108 . In some embodiments, one or more transmitting units  128  transmit one or more signals  130  to select at least one vitamin, mineral, enzyme, amino acid, homeopathic supplement, toxin, homeopathic substance, traditional remedy, herbal supplement, glandular supplement, or substantially any combination thereof.  
      In some embodiments, one or more transmitting units  128  may transmit one or more signals  130  that include data  104  related to one or more specified goals  106  of an individual  108 . One or more transmitting units  128  may transmit one or more signals  130  through use of numerous technologies. Examples of such technologies include, but are not limited to, wireless transmission, telephone, internet transmission, digital transmission, analog transmission, optical transmission, and the like.  
       FIG. 11  illustrates alternative embodiments of the example operational flow  1000  of  FIG. 10 .  FIG. 11  illustrates example embodiments where the accepting operation  1010  may include at least one additional operation. Additional operations may include an operation  1102 , an operation  1104 , an operation  1106 , an operation  1108 , and/or an operation  1110 .  
      At operation  1102 , the accepting operation  1010  may include accepting the data related to one or more physical characteristics of the individual. In some embodiments, one or more accepting units  102  accept data  104  related to one or more physical characteristics of the individual  108 .  
      One or more accepting units  102  may accept data  104  related to numerous physical characteristics of an individual  108 . Examples of such physical characteristics include, but are not limited to, height, weight, gender, kidney function, liver function, level of physical fitness, age, allergic response, metabolic level (i.e., resting metabolic rate and/or activity-related metabolic rate), disease state, body fat percentage, body mass index, personal health habits (i.e., smoking, alcohol consumption, diet, illegal drug use, and the like), family health history, food supplement usage, nutraceutical agent  118  usage, non-prescription drug use, prescription drug use, pregnancy status, and the like. In some embodiments, such data  104  may be used to identify one or more nutraceutical agents  118  that are compatible with an individual  108 . For example, if an individual  108  is taking a selective serotonin reuptake inhibitor (SSRI), one or more nutraceutical agents  118  should not be selected that would interfere with the serotonin reuptake inhibitor.  
      At operation  1104 , the accepting operation  1010  may include accepting the data related to one or more mental characteristics of the individual. In some embodiments, one or more accepting units  102  accept data  104  related to one or more mental characteristics of the individual  108 .  
      One or more accepting units  102  may accept data  104  related to numerous mental characteristics of an individual  108 . Examples of such mental characteristics include, but are not limited to, daily time periods when the mental processes of an individual  108  are most acute or least acute (i.e., morning, afternoon, evening, night), an individual&#39;s  108  sleep schedule, an individual&#39;s  108  daily schedule of activities (i.e., meetings, presentations, travel, athletic activity), and the like.  
      At operation  1106 , the accepting operation  1010  may include accepting the data related to one or more physiological characteristics of the individual. In some embodiments, one or more accepting units  102  accept data  104  related to one or more physiological characteristics of the individual  108 .  
      One or more accepting units  102  may accept data  104  related to numerous physiological characteristics of an individual  108 . Examples of such physiological characteristics include, but are not limited to, the ability of an individual  108  to metabolize one or more nutraceutical agents  118 , the ability of an individual  108  to metabolize one or more pharmaceutical agents, the response of an individual  108  to one or more pharmaceutical agents, the response of an individual  108  to one or more nutraceutical agents  118 , the concentration or level of one or more metabolites in one or more samples obtained from an individual  108 , the concentration or level of one or more components of a sample obtained from an individual  108  that include, but are not limited to, concentrations or levels of: vitamins, minerals, metals, proteins, one or more hormones, hemoglobin, one or more neurotransmitters, metabolites, proteolytic products, antibodies, white blood cells, red blood cells, enzyme activities, lipids, lipoproteins, carbohydrates, phosphates, tumor markers, bacteria, fungi, viruses, parasites, and the like.  
      At operation  1108 , the accepting operation  1010  may include accepting the data related to one or more performance characteristics of the individual. In some embodiments, one or more accepting units  102  accept data  104  related to one or more performance characteristics of the individual  108 .  
      One or more accepting units  102  may accept data  104  related to numerous performance characteristics of an individual  108 . Generally, performance characteristics relate to physical or mental activities in which an individual  108  engages. Examples of such performance characteristics include, but are not limited to, athletic ability, mental ability, sexual ability, ability to interact socially, and the like. For example, in some embodiments, data  104  related to giving a presentation may be accepted.  
      At operation  1110 , the accepting operation  1010  may include accepting the data related to one or more psychological characteristics of the individual. In some embodiments, one or more accepting units  102  accept data  104  related to one or more psychological characteristics of the individual  108 .  
      One or more accepting units  102  may accept data  104  related to numerous psychological characteristics of an individual  108 . Examples of such psychological characteristics include, but are not limited to, the presence or absence of a psychological malady. Examples of psychological maladies include, but are not limited to, antisocial personal disorder, anxiety disorder, avoidant personality disorder, bipolar disorder, conduct disorder, depression, depressive disorder, drug addiction, insomnia, primary sleep disorders, schizophrenia, seasonal affective disorder, sexual disorder, sexual dysfunctions, social anxiety disorder, specific phobia, and the like.  
       FIG. 12  illustrates alternative embodiments of the example operational flow  1000  of  FIG. 10 .  FIG. 12  illustrates example embodiments where the accepting operation  1010  may include at least one additional operation  1202 .  
      At operation  1202 , the accepting operation  1010  may include accepting the data related to attentiveness, alertness, test performance, relaxation, pain, fever, attractiveness, anxiety, fall, injury, accident, bite, bleeding, inflammation, infection, drowsiness, insomnia, discomfort, stress, grooming, appearance, capability, performance, improvement, enhancement, curtailment, wellbeing, vitality, vigor, disability, phobia, malady, psychosis, environmental extremes, environmental exposure, dysfunction, disease symptom, chronic condition, mental acuity, emotional behavior, physical prowess, addiction, obsession, therapy, remedy, behavior, nutrition, diet, exercise, immunization, prevention, diagnosis, subscription, regimen, social performance, social interaction, endurance, sexual attribute, sexual performance, age-related attribute, age-related condition, prophylaxis, or treatment. In some embodiments, one or more accepting units  102  accept data  104  related to attentiveness, alertness, test performance, relaxation, pain, fever, attractiveness, anxiety, fall, injury, accident, bite, bleeding, inflammation, infection, drowsiness, insomnia, discomfort, stress, grooming, appearance, capability, performance, improvement, enhancement, curtailment, wellbeing, vitality, vigor, disability, phobia, malady, psychosis, environmental extremes, environmental exposure, dysfunction, disease symptom, chronic condition, mental acuity, emotional behavior, physical prowess, addiction, obsession, therapy, remedy, behavior, nutrition, diet, exercise, immunization, prevention, diagnosis, subscription, regimen, social performance, social interaction, endurance, sexual attribute, sexual performance, age-related attribute, age-related condition, prophylaxis, or treatment.  
       FIG. 13  illustrates alternative embodiments of the example operational flow  1000  of  FIG. 10 .  FIG. 13  illustrates example embodiments where the intaking operation  1020  may include at least one additional operation. Additional operations may include an operation  1302 , an operation  1304 , an operation  1306 , an operation  1308 , and/or an operation  1310 .  
      At operation  1302 , the intaking operation  1020  may include assaying one or more samples linked to the individual that include one or more bodily fluids, bodily tissues, or bodily products. In some embodiments, one or more intaking units  110  can assay one or more samples linked to the individual  108  that include one or more bodily fluids, bodily tissues, or bodily products. Examples of such samples include, but are not limited to, blood, urine, saliva, synovial fluid, pleural fluid, peritoneal fluid, tears, mucus, ejaculate, skin, muscle, bone, hair, teeth, nails, urine, breath, fecal material, genital products, and the like.  
      At operation  1304 , the intaking operation  1020  may include determining one or more levels of one or more metabolic indicators linked to the individual. In some embodiments, one or more intaking units  110  determine one or more levels of one or more metabolic indicators linked to the individual  108 .  
      For example, vitamin B 12  and folate are two vitamins that have interdependent roles in nucleic acid synthesis. Deficiencies of either vitamin can cause megaloblastic anemia. Accordingly, in some embodiments, the levels of homocysteine and methylmalonic acid may be determined and used as metabolic indicators to indicate levels of vitamin B 12  and folate within an individual  108 . In some embodiments, vitamin A deficiency may be assessed by determining albumin levels which are an indirect measure of vitamin A levels. In some embodiments, magnesium levels may be assessed directly. In some embodiments, magnesium levels may be assessed indirectly through analysis of insulin because magnesium deficiency results in impaired insulin secretion. Accordingly, in some embodiments, magnesium replacement may be used to restore insulin secretion. In some embodiments, fluorescent indicators may be used to determine chloride, zinc, and calcium levels as well as pH. Accordingly, numerous metabolic indicators that are linked to an individual  108  may be determined through use of known methods.  
      At operation  1306 , the intaking operation  1020  may include determining one or more levels of one or more metabolic activities linked to the individual. In some embodiments, one or more intaking units  110  determine one or more levels of one or more metabolic activities linked to the individual  108 .  
      In some embodiments, one or more intaking units  110  can be used to determine one or more enzyme activities of an individual  108 . For example, when digested properly, protein supplies acidity to the blood. If an individual  108  is not able to adequately digest protein, the individual&#39;s  108  blood acquires excess alkaline reserves which must be continuously dumped via the kidneys into the urine. Accordingly, in some embodiments, blood alkalinity may be tested to assist in determining if an individual  108  is deficient in protease activity. In instances of protease deficiency, an individual  108  may wish to ingest a protease supplement to assist with digestion of protein. In some embodiments, enzyme activity may be determined directly. For example, protease activity can be measured directly through use of peptide substrates having an amino acid sequence that is recognized by a protease to be assayed. Such peptide substrates may be readily prepared or be obtained from commercial sources (i.e., Biotium, Inc., Hayward, Calif.; Biomol International Inc., Plymouth Meeting, Pa.; JPT Peptide Technologies, Inc., Springfield, Va.). In some embodiments, vitamin K deficiency exhibited by an individual  108  may be determined through measurement of Protein Induced by Vitamin K Absence (PIVKA-II) using several known methods (Widdershoven J., Clin. Chem., 33(11):2074-2078 (1987)). Examples of such methods include, but are not limited to, electrophoresis-immunofixation and enzyme immunoassay. Numerous metabolic activities of an individual  108  may be determined through use of methods that are known and that have been described (i.e., Clinical Laboratory Medicine, Lippincott Williams and Wilkins, Philadelphia, Second Edition, 2002).  
      At operation  1308 , the intaking operation  1020  may include determining one or more levels of one or more nutraceutical agents linked to the individual. In some embodiments, one or more intaking units  110  determine one or more levels of one or more nutraceutical agents  118  linked to the individual  108 .  
      Numerous methods may be used to determine one or more nutraceutical agents  118  that are linked to an individual  108 . Examples of such methods include, but are not limited to, chromatographic assay, mass spectrometry, spectrophotometry, immunological assay, and the like. These methods may be performed on numerous types of samples obtained from an individual  108  that are exemplified by bodily fluids, bodily tissues, bodily products and the like.  
      At operation  1310 , the intaking operation  1020  may include determining one or more levels of one or more pharmaceutical agents linked to the individual. In some embodiments, one or more intaking units  110  determine one or more levels of one or more pharmaceutical agents linked to the individual  108 .  
      Numerous methods may be used to determine one or more pharmaceutical agents that are linked to an individual  108 . Examples of such methods include, but are not limited to, chromatographic assay, mass spectrometry, spectrophotometry, immunological assay, and the like. These methods may be performed on numerous types of samples obtained from an individual  108  that are exemplified by bodily fluids, bodily tissues, bodily products and the like.  
       FIG. 14  illustrates alternative embodiments of the example operational flow  1000  of  FIG. 10 .  FIG. 14  illustrates example embodiments where the transmitting operation  1030  may include at least one additional operation. Additional operations may include an operation  1402 , an operation  1404 , an operation  1406 , an operation  1408 , and/or an operation  1410 .  
      At operation  1402 , the transmitting operation  1030  may include transmitting one or more levels of one or more metabolic indicators linked to the individual. In some embodiments, one or more transmitting units  128  transmit one or more levels of one or more metabolic indicators linked to the individual  108 .  
      In some embodiments, one or more transmitting units  128  may transmit one or more signals  130  indicating the levels of homocysteine and methylmalonic acid to indicate levels of vitamin B 12  and folate within an individual  108 . In some embodiments, one or more transmitting units  128  may transmit one or more signals  130  indicating the level of albumin as an indirect measure of vitamin A levels. In some embodiments, one or more transmitting units  128  may transmit one or more signals  130  indicating the level of a metabolic indicator directly. For example, in some embodiments, one or more transmitting units  128  may transmit one or more signals  130  indicating vitamin A concentration, pH, magnesium concentration, calcium concentration, and the like. One or more transmitting units  128  may transmit one or more signals  130  indicating the level of numerous metabolic indicators.  
      At operation  1404 , the transmitting operation  1030  may include transmitting one or more levels of one or more metabolic activities linked to the individual. In some embodiments, one or more transmitting units  128  transmit one or more levels of one or more metabolic activities linked to the individual  108 .  
      In some embodiments, one or more transmitting units  128  can be used to transmit one or more signals  130  indicating the level of one or more enzyme activities of an individual  108 . For example, in some embodiments, one or more transmitting units  128  can transmit one or more signals  130  indicating the level of a protease activity of an individual  108 . In some embodiments, one or more transmitting units  128  can transmit one or more signals  130  indicating the level of Protein Induced by Vitamin K Absence (PIVKA-II) to indicate vitamin K deficiency or adequacy of an individual  108 . One or more transmitting units  128  may transmit one or more signals  130  indicating the level of numerous metabolic activities linked to an individual  108 .  
      At operation  1406 , the transmitting operation  1030  may include transmitting one or more levels of one or more nutraceutical agents linked to the individual. In some embodiments, one or more transmitting units  128  transmit one or more levels of one or more nutraceutical agents  118  linked to the individual  108 .  
      In some embodiments, one or more transmitting units  128  can transmit one or more signals  130  indicating one or more levels of one or more nutraceutical agents  118  that were determined at one or more times. For example, in some embodiments, one or more signals  130  indicating the level of a nutraceutical agent  118  at the time when administered to an individual  108 , at time two hours post-administration, at time four hours post-administration, and at time six hours post-administration may be transmitted. Accordingly, in some embodiments, the rate at which one or more nutraceutical agents  118  are metabolized by an individual  108  may be determined. In some embodiments, the rate at which a level of nutraceutical is reached within an individual  108  may be determined. One or more signals  130  indicating numerous times and concentrations of nutraceutical agents  118  may be transmitted.  
      At operation  1408 , the transmitting operation  1030  may include transmitting one or more levels of one or more pharmaceutical agents linked to the individual. In some embodiments, one or more transmitting units  128  transmit one or more levels of one or more pharmaceutical agents linked to the individual  108 .  
      In some embodiments, one or more transmitting units  128  can transmit one or more signals  130  indicating one or more levels of one or more pharmaceutical agents that were determined at one or more times. For example, in some embodiments, one or more signals  130  indicating the level of a pharmaceutical agent at the time when administered to an individual  108 , at time two hours post-administration, at time four hours post-administration, and at time six hours post-administration may be transmitted. Accordingly, in some embodiments, the rate at which one or more pharmaceutical agents are metabolized by an individual  108  may be determined. In some embodiments, the rate at which a level of a pharmaceutical agent is reached within an individual  108  may be determined. One or more signals  130  indicating numerous times and concentrations of pharmaceutical agents may be transmitted.  
      At operation  1410 , the transmitting operation  1030  may include transmitting the one or more parameters associated with the one or more specified goals of the individual. In some embodiments, one or more transmitting units  128  transmit one or more parameters  114  associated with the one or more specified goals  106  of the individual  108 .  
      One or more transmitting units  128  can transmit one or more signals  130  indicating numerous parameters  114  that are associated with one or more specified goals  106  of an individual  108 . Examples of such parameters  114  include, but are not limited to, blood sugar levels, blood insulin levels, blood iron levels, hormone levels, nutraceutical agent  118  levels, pharmaceutical agent levels, cytokine levels, and the like (i.e., Fitzgerald et al., The Cytokine Facts Book, Academic Press, San Francisco, Second Edition, (2001)).  
       FIG. 15  illustrates alternative embodiments of the example operational flow  1000  of  FIG. 10 .  FIG. 15  illustrates example embodiments where the transmitting operation  1030  may include at least one additional operation. Additional operations may include an operation  1502 , an operation  1504 , and/or an operation  1506 .  
      At operation  1502 , the transmitting operation  1030  may include transmitting one or more instructions to select one or more nutraceutical agents in response to the intaking information linked to one or more parameters associated with the one or more specified goals of the individual. In some embodiments, one or more transmitting units  128  transmit one or more instructions to select one or more nutraceutical agents  118  in response to the intaking information  112  linked to one or more parameters  114  associated with the one or more specified goals  106  of the individual  108 .  
      In some embodiments, one or more transmitting units  128  transmit one or more signals  130  that include one or more instructions to select one or more nutraceutical agents  118  in response to accepting data  104  related to one or more specified goals  106  of an individual  108 . One or more transmitting units  128  can transmit one or more signals  130  that include one or more instructions to select one or more nutraceutical agents  118  based on numerous parameters  114 . Examples of such parameters  114  include, but are not limited to, blood sugar levels, blood insulin levels, blood iron levels, hormone levels, nutraceutical agent  118  levels, pharmaceutical agent levels, cytokine levels, and the like.  
      At operation  1504 , the transmitting operation  1030  may include transmitting the one or more signals to select one or more nutraceutical agents to increase one or more levels of one or more components associated with the one or more specified goals of the individual. In some embodiments, one or more transmitting units  128  transmit one or more signals  130  to select one or more nutraceutical agents  118  to increase one or more levels of one or more components associated with the one or more specified goals  106  of the individual  108 .  
      In some embodiments, one or more transmitting units  128  transmit one or more signals  130  to select one or more nutraceutical agents  118  that may directly complement one or more levels of one or more components associated with one or more specified goals  106  of the individual  108 . For example, in some embodiments, one or more transmitting units  128  transmit one or more signals  130  to select calcium in various forms (i.e., calcium citrate, calcium aspartate, calcium carbonate) to avoid or reduce the effects of osteoporosis. In another embodiment, one or more transmitting units  128  transmit one or more signals  130  to select chromium to lower blood sugar, increase insulin sensitivity, reduce body fat, control hunger, suppress appetite, increase lean body/muscle mass, or substantially any combination thereof. In some embodiments, one or more transmitting units  128  transmit one or more signals  130  to select one or more nutraceutical agents  118  to indirectly supplement a component associated with one or more specified goals  106  of an individual  108 . For example, one or more transmitting units  128  may transmit one or more signals  130  to select 5-hydroxy-tryptophan for administration to an individual  108  if the individual  108  suffers from depression and is found to exhibit low levels of serotonin. Numerous signals  130  may be transmitted to select one or more nutraceutical agents  118  to increase one or more levels of one or more components associated with one or more specified goals  106  of an individual  108 .  
      At operation  1506 , the transmitting operation  1030  may include transmitting the one or more signals to select one or more nutraceutical agents to decrease one or more levels of one or more components associated with the one or more specified goals of the individual. In some embodiments, one or more transmitting units  128  transmit one or more signals  130  to select one or more nutraceutical agents  118  to decrease one or more levels of one or more components associated with the one or more specified goals  106  of the individual  108 .  
      Low density lipoproteins are examples of components that are linked to vascular disease. Accordingly, in some embodiments, one or more transmitting units  128  may transmit one or more signals  130  to select one or more nutraceutical agents  118  that will act to lower the low density lipoprotein concentration of an individual  108 . Examples of such nutraceutical agents  118  include, but are not limited to, plant stanols, dietary fiber, stanol esters, isoflavones, diallyl sulfides, niacin, soy protein, and substantially any combination thereof. Glucose is an example of a component that is linked to hyperglycemia. Accordingly, in some embodiments, one or more transmitting units  128  may transmit one or more signals  130  to select buckwheat to lower blood glucose levels of an individual  108 . Free radical oxygen species that include singlet oxygen, hydroxyl radicals, peroxides, and superoxide radicals are components that act to damage lipids and other cellular structures. Accordingly, in some embodiments, one or more transmitting units  128  may transmit one or more signals  130  to select one or more nutraceutical agents  118  to reduce levels of free radicals within an individual  108 . Examples of such nutraceutical agents  118  include, but are not limited to, terpenes, carotenoids, limonoids, phenols, flavonoids, isoprenoids, and the like. One or more transmitting units  128  can transmit one or more signals  130  to select numerous types of nutraceutical agents  118  to decrease one or more levels of one or more components associated with the one or more specified goals  106  of the individual  108 .  
       FIG. 16  illustrates alternative embodiments of the example operational flow  1000  of  FIG. 10 .  FIG. 16  illustrates example embodiments where the transmitting operation  1030  may include at least one additional operation. Additional operations may include an operation  1602 , an operation  1604 , and/or an operation  1606 .  
      At operation  1602 , the transmitting operation  1030  may include transmitting the one or more signals to select one or more nutraceutical agents that stimulate one or more metabolic pathways linked to the individual. In some embodiments, one or more transmitting units  128  transmit one or more signals  130  to select one or more nutraceutical agents  118  that stimulate one or more metabolic pathways linked to the individual  108 .  
      In some embodiments, one or more transmitting units  128  can transmit one or more signals  130  to select one or more nutraceutical agents  118  that stimulate one or more metabolic pathways associated with one or more specified goals  106  of an individual  108 . For example, in some embodiments, decline in L-carnitine synthesis is thought to be linked to senile reduction in bone synthesis (Colucci et al., Calcified Tissue International, 76:458-465 (2005)). Dihydroepiandrosterone (DHEA) is thought to affect levels of L-carnitine through promoting the expression of carnitine-synthesizing enzymes (Chiu et al., Calcified Tissue International, 64:527-533 (1999)). Accordingly, in some embodiments, one or more transmitting units  128  can transmit one or more signals  130  to select DHEA to stimulate the L-carnitine synthetic pathway to reduce senile reduction in bone synthesis. In other embodiments, one or more transmitting units  128  can transmit one or more signals  130  to select buckwheat extract to lower blood glucose through activation of mitogen activated protein kinase via phospholipase D (Appleton and Lockwood, The Pharmaceutical Journal, 277:78-83 (2006)). In another embodiment, resveratrol has been shown to stimulate endothelial nitric oxide synthase activity (Klinge et al., J. Biol. Chem., 280(9):7460-7468 (2005); Wallerath et al., Circulation, 106(13):1652-1658 (2002)). Endothelial nitric oxide synthase is an enzyme that catalyzes the formation of nitric oxide by vascular endothelial cells. Nitric oxide is needed to maintain arterial relaxation (vasodilation), and impaired nitric oxide-dependent vasodilation is associated with increased risk of cardiovascular disease (Duffy and Vita, Curr. Opin. Lipidol., 14(1):21-27 (2003)). Accordingly, in some embodiments, one or more transmitting units  128  transmit one or more signals  130  to select resveratrol to reduce cardiovascular disease. One or more transmitting units  128  can transmit one or more signals  130  to select numerous types of nutraceutical agents  118  to stimulate one or more metabolic pathways linked to the individual  108 .  
      At operation  1604 , the transmitting operation  1030  may include transmitting the one or more signals to select one or more nutraceutical agents that inhibit one or more metabolic pathways linked to the individual. In some embodiments, one or more transmitting units  128  transmit one or more signals  130  to select one or more nutraceutical agents  118  that inhibit one or more metabolic pathways linked to the individual  108 .  
      In some embodiments, one or more transmitting units  128  can transmit one or more signals  130  to select one or more nutraceutical agents  118  that inhibit one or more enzymes that participate within a metabolic pathway. Such metabolic pathways may be involved with a specified goal  106  of an individual  108 . For example, angiotensin-converting enzyme has been linked to high blood pressure. Flavonoids have been shown to inhibit angiotensin-converting enzyme (Actis-Goretta et al., J. Agric. Food Chem., 54(1):229-234 (2006)). Accordingly, in some embodiments, one or more transmitting units  128  can transmit one or more signals  130  to select flavonoids to assist in the reduction of blood pressure (Li et al., Chin. J. Physiol., 48(2):101-106 (2005); Machha and Mustafa, J. Cardiovasc. Pharmacol., 46(1):36-40 (2005)). Genistein, one of the predominant soy isoflavones, has been shown to compete with 17 beta-estradiol for estrogen receptor binding because of its structural similarity, resulting in agonistic or antagonistic activity. This has been shown to cause inhibition of cell growth in breast and prostate cancers in vivo and in vitro. Accordingly, in some embodiments, one or more transmitting units  128  can transmit one or more signals  130  to select soy isoflavones containing genistein as a nutraceutical agent  118  for cancer chemoprevention (Sarkar et al., Mini Rev. Med. Chem., 6(4):401-407 (2006)). The isoflavonoids, daidzin, daidzein, and puerarin have been shown to reduce alcohol consumption (Lin R C, Alcohol Clin. Exp. Res., 20(4):659-663 (1996)). A link between daidzin&#39;s capacity to reduce alcohol consumption and its ability to increase the liver mitochondrial monoamine oxidase: aldehyde dehydrogenase activity ratio has been established (Keung, Med. Res. Rev., 23(6):669-696 (2003)). This increase in ratio is thought to occur through inhibition of aldehyde dehydrogenase activity. Accordingly, in some embodiments, one or more transmitting units  128  can transmit one or more signals  130  to select isoflavonoid mixtures that include daidzin, daidzein, and/or puerarin to lower alcohol consumption. One or more transmitting units  128  can transmit one or more signals  130  to select numerous other types of nutraceutical agents  118  that inhibit one or more metabolic pathways linked to the individual  108 .  
      At operation  1606 , the transmitting operation  1030  may include transmitting the one or more signals to select at least one vitamin, mineral, enzyme, amino acid, homeopathic supplement, toxin, homeopathic substance, traditional remedy, herbal supplement, or glandular supplement. In some embodiments, one or more transmitting units  128  transmit one or more signals  130  to select at least one vitamin, mineral, enzyme, amino acid, homeopathic supplement, toxin, homeopathic substance, traditional remedy, herbal supplement, or glandular supplement.  
       FIG. 17  illustrates an operational flow  1700  that includes an accepting operation  1710 , an intaking operation  1720 , and a transmitting operation  1730  (which correspond to the accepting operation  1010 , the intaking operation  1020 , and the transmitting operation  1030  illustrated in  FIG. 10 ) with an additional recording operation  1740 . In  FIG. 17 , discussion and explanation may be provided with respect to the above-described example of  FIG. 1 , and/or with respect to other examples and contexts. However, it should be understood that the operations may be executed in a number of other environments and contexts, and/or modified versions of  FIG. 1 . Also, although the various operations are presented in the sequence(s) illustrated, it should be understood that the various operations may be performed in other orders than those which are illustrated, or may be performed concurrently.  
      After a start operation, the operational flow  1700  includes the operations  1710 ,  1720 , and  1730  (which correspond to operations  1010 ,  1020 , and  1030  as described with regard to  FIG. 10 ) and an additional recording operation  1740  involving recording results of, the accepting data related to one or more specified goals of an individual, the intaking information linked to one or more parameters associated with the one or more specified goals of the individual, or the transmitting one or more signals in response to the intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual, on a recordable-medium. In some embodiments, one or more recording units  124  may record results of, the accepting data  104  related to one or more specified goals  106  of an individual  108 , the intaking information  112  linked to one or more parameters  114  associated with the one or more specified goals  106  of the individual  108 , or the transmitting one or more signals  130  in response to the intaking information  112  linked to one or more parameters  114  associated with the one or more specified goals  106  of the individual  108 , on a recordable-medium  126 .  
       FIG. 18  illustrates an operational flow  1800  representing examples of operations that are related to the performance of a method for nutraceutical agent  118  and dosing. In  FIG. 18  and in following figures that include various examples of operations used during performance of the method, discussion and explanation may be provided with respect to the above-described example of  FIG. 1 , and/or with respect to other examples and contexts. However, it should be understood that the operations may be executed in a number of other environments and contexts, and/or modified versions of  FIG. 1 . Also, although the various operations are presented in the sequence(s) illustrated, it should be understood that the various operations may be performed in other orders than those which are illustrated, or may be performed concurrently.  
      After a start operation, the operational flow  1800  includes a receiving operation  1810  involving receiving one or more signals transmitted in response to intaking information linked to one or more parameters associated with one or more specified goals of an individual. In some embodiments, one or more receiving units  132  receive one or more signals  130  transmitted in response to intaking information  112  linked to one or more parameters  114  associated with one or more specified goals  106  of the individual  108 .  
      In some embodiments, one or more receiving units  132  may receive one or more signals  130  that include data  104  related to one or more specified goals  106  of an individual  108 . In some embodiments, one or more receiving units  132  receive one or more signals  130  indicating one or more levels of one or more metabolic indicators linked to the individual  108 . In some embodiments, one or more receiving units  132  receive one or more signals  130  indicating one or more metabolic activities linked to the individual  108 . In some embodiments, one or more receiving units  132  receive one or more signals  130  indicating one or more levels of one or more nutraceutical agents  118  linked to the individual  108 . In some embodiments, one or more receiving units  132  receive one or more signals  130  indicating one or more levels of one or more pharmaceutical agents linked to the individual  108 . In some embodiments, one or more receiving units  132  receive one or more parameters  114  associated with the one or more specified goals  106  of the individual  108 . In some embodiments, one or more receiving units  132  receive one or more instructions to select one or more nutraceutical agents  118  in response to the intaking information  112  linked to one or more parameters  114  associated with the one or more specified goals  106  of the individual  108 . In some embodiments, one or more receiving units  132  receive one or more signals  130  to select one or more nutraceutical agents  118  to increase one or more levels of one or more components associated with the one or more specified goals  106  of the individual  108 . In some embodiments, one or more receiving units  132  receive one or more signals  130  to select one or more nutraceutical agents  118  to decrease one or more levels of one or more components associated with the one or more specified goals  106  of the individual  108 . In some embodiments, one or more receiving units  132  receive one or more signals  130  to select one or more nutraceutical agents  118  that stimulate one or more metabolic pathways linked to the individual  108 . In some embodiments, one or more receiving units  132  receive one or more signals  130  to select one or more nutraceutical agents  118  that inhibit one or more metabolic pathways linked to the individual  108 . In some embodiments, one or more receiving units  132  receive one or more signals  130  to select at least one vitamin, mineral, enzyme, amino acid, homeopathic supplement, toxin, homeopathic substance, traditional remedy, herbal supplement, glandular supplement, or substantially any combination thereof.  
      In some embodiments, one or more receiving units  132  may receive one or more signals  130  that include data  104  related to one or more specified goals  106  of an individual  108 . One or more receiving units  132  may receive one or more signals  130  through use of numerous technologies. Examples of such technologies include, but are not limited to, wireless transmission, telephone, internet transmission, digital transmission, analog transmission, optical transmission, and the like.  
      After a start operation, the operational flow  1800  includes a selecting operation  1820  involving selecting one or more nutraceutical agents in response to the receiving the one or more signals transmitted in response to the intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual. In some embodiments, one or more selecting units  116  select one or more nutraceutical agents  118  in response to the receiving one or more signals  130  transmitted in response to intaking information  112  linked to one or more parameters  114  associated with one or more specified goals  106  of the individual  108 .  
      In some embodiments, one or more selecting units  116  may select one or more nutraceutical agents  118  in response to the intaking information  112  linked to one or more parameters  114  associated with the one or more specified goals  106  of the individual  108 . In some embodiments, one or more selecting units  116  may select one or more nutraceutical agents  118  in response to one or more intaking units  110 . In some embodiments, one or more selecting units  116  may select one or more nutraceutical agents  118  in response to one or more accepting units  102 . In some embodiments, one or more selecting units  116  may select one or more nutraceutical agents  118  in response to one or more intaking units  110  and one or more accepting units  102 . Accordingly, in some embodiments, one or more selecting units  116  may select one or more nutraceutical agents  118  with regard to one or more characteristics of the individual  108  and one or more parameters  114  associated with one or more specified goals  106  of the individual  108 . For example, in some embodiments, one or more selecting units  116  may select one or more nutraceutical agents  118  based on the age of the individual  108  and the level of testosterone in the individual&#39;s  108  blood. In other embodiments, one or more selecting units  116  may select one or more nutraceutical agents  118  based on insurance coverage held by an individual  108  and a specified goal  106  of the individual  108 . Accordingly, numerous combinations of information  112  and data  104  may be used by one or more selecting units  116  to select one or more nutraceutical agents  118 .  
      After a start operation, the operational flow  1800  includes an indicating operation  1830  involving indicating one or more dosages of the one or more nutraceutical agents in response to the selecting the one or more nutraceutical agents in response to the receiving the one or more signals transmitted in response to the intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual. In some embodiments, one or more indicating units  120  indicate one or more dosages  122  of the one or more nutraceutical agents  118  in response to the selecting one or more nutraceutical agents  118  in response to the receiving one or more signals  130  transmitted in response to intaking information  112  linked to one or more parameters  114  associated with one or more specified goals  106  of the individual  108 .  
      In some embodiments, one or more indicating units  120  may indicate one or more dosages  122  of the one or more nutraceutical agents  118  in response to the intaking information  112  linked to one or more parameters  114  associated with the one or more specified goals  106  of the individual  108 . In some embodiments, one or more indicating units  120  may indicate one or more dosages  122  of one or more nutraceutical agents  118  in human-readable format. In some embodiments, one or more indicating units  120  may indicate one or more dosages  122  of one or more nutraceutical agents  118  in machine-readable format. In some embodiments, one or more indicating units  120  may deposit one or more dosages  122  of one or more nutraceutical agents  118  on one or more labels. In some embodiments, one or more indicating units  120  may dispense one or more nutraceutical agents  118 . In some embodiments, one or more indicating units  120  may dispense one or more nutraceutical agents  118  in unit dosage form. In some embodiments, one or more indicating units  120  may dispense two or more of one or more nutraceutical agents  118  in a single administration form.  
       FIG. 19  illustrates alternative embodiments of the example operational flow  1800  of  FIG. 18 .  FIG. 19  illustrates example embodiments where the receiving operation  1810  may include at least one additional operation. Additional operations may include an operation  1902 , an operation  1904 , an operation  1906 , an operation  1908 , and/or an operation  1910 .  
      At operation  1902 , the receiving operation  1810  may include receiving the one or more signals indicating one or more levels of one or more metabolic indicators linked to the individual. In some embodiments, one or more receiving units  132  receive one or more signals  130  indicating one or more levels of one or more metabolic indicators linked to the individual  108 .  
      In some embodiments, one or more receiving units  132  may receive one or more signals  130  indicating the levels of homocysteine and methylmalonic acid to indicate levels of vitamin B 12  and folate within an individual  108 . In some embodiments, one or more receiving units  132  may receive one or more signals  130  indicating the level of albumin as an indirect measure of vitamin A levels. In some embodiments, one or more receiving units  132  may receive one or more signals  130  indicating the level of a metabolic indicator directly. For example, in some embodiments, one or more receiving units  132  may receive one or more signals  130  indicating vitamin A concentration, pH, magnesium concentration, calcium concentration, and the like. One or more receiving units  132  may receive one or more signals  130  indicating the level of numerous metabolic indicators.  
      At operation  1904 , the receiving operation  1810  may include receiving the one or more signals indicating one or more metabolic activities linked to the individual. In some embodiments, one or more receiving units  132  receive one or more signals  130  indicating one or more metabolic activities linked to the individual  108 .  
      In some embodiments, one or more receiving units  132  can be used to receive one or more signals  130  that indicate the level of one or more enzyme activities of an individual  108 . For example, in some embodiments, one or more receiving units  132  can receive one or more signals  130  that indicate the level of a protease activity of an individual  108 . In some embodiments, one or more receiving units  132  can receive one or more signals  130  that indicate the level of Protein Induced by Vitamin K Absence (PIVKA-II) to indicate vitamin K deficiency or adequacy of an individual  108 . One or more receiving units  132  may receive one or more signals  130  that indicate the level of numerous metabolic activities linked to an individual  108 .  
      At operation  1906 , the receiving operation  1810  may include receiving the one or more signals indicating one or more levels of one or more nutraceutical agents linked to the individual. In some embodiments, one or more receiving units  132  receive one or more signals  130  indicating one or more levels of one or more nutraceutical agents  118  linked to the individual  108 .  
      In some embodiments, one or more receiving units  132  can receive one or more signals  130  indicating one or more levels of one or more nutraceutical agents  118  that were determined at one or more times. For example, in some embodiments, one or more signals  130  indicating the level of a nutraceutical agent  118  at the time when administered to an individual  108 , at time two hours post-administration, at time four hours post-administration, and at time six hours post-administration may be received. Accordingly, in some embodiments, the rate at which one or more nutraceutical agents  118  are metabolized by an individual  108  may be determined. In some embodiments, the rate at which a level of nutraceutical is reached within an individual  108  may be determined. One or more signals  130  indicating numerous times and concentrations of nutraceutical agents  118  may be received.  
      At operation  1908 , the receiving operation  1810  may include receiving the one or more signals indicating one or more levels of one or more pharmaceutical agents linked to the individual. In some embodiments, one or more receiving units  132  receive one or more signals  130  indicating one or more levels of one or more pharmaceutical agents linked to the individual  108 .  
      In some embodiments, one or more receiving units  132  can receive one or more signals  130  indicating one or more levels of one or more pharmaceutical agents that were determined at one or more times. For example, in some embodiments, one or more signals  30  indicating the level of a pharmaceutical agent at the time when administered to an individual  108 , at time two hours post-administration, at time four hours post-administration, and at time six hours post-administration may be received. Accordingly, in some embodiments, the rate at which one or more pharmaceutical agents are metabolized by an individual  108  may be determined. In some embodiments, the rate at which a level of a pharmaceutical agent is reached within an individual  108  may be determined. One or more signals  130  indicating numerous times and concentrations of pharmaceutical agents may be received.  
      At operation  1910 , the receiving operation  1810  may include receiving the one or more parameters associated with the one or more specified goals of the individual. In some embodiments, one or more receiving units  132  receive one or more parameters  114  associated with the one or more specified goals  106  of the individual  108 .  
      One or more receiving units  132  can receive one or more signals  130  indicating numerous parameters  114  that are associated with one or more specified goals  106  of an individual  108 . Examples of such parameters  114  include, but are not limited to, blood sugar levels, blood insulin levels, blood iron levels, hormone levels, nutraceutical agent  118  levels, pharmaceutical agent levels, cytokine levels, and the like (i.e., Fitzgerald et al., The Cytokine Facts Book, Academic Press, San Francisco, Second Edition, (2001)).  
       FIG. 20  illustrates alternative embodiments of the example operational flow  1800  of  FIG. 18 .  FIG. 20  illustrates example embodiments where the receiving operation  1810  may include at least one additional operation. Additional operations may include an operation  2002 , an operation  2004 , and/or an operation  2006 .  
      At operation  2002 , the receiving operation  1810  may include receiving one or more instructions to select the one or more nutraceutical agents in response to the intaking information linked to one or more parameters associated with the one or more specified goals of the individual. In some embodiments, one or more receiving units  132  receive one or more instructions to select one or more nutraceutical agents  118  in response to the intaking information  112  linked to one or more parameters  114  associated with the one or more specified goals  106  of the individual  108 .  
      In some embodiments, one or more receiving units  132  receive one or more signals  130  that include one or more instructions to select one or more nutraceutical agents  118  in response to accepting data  104  related to one or more specified goals  106  of an individual  108 . One or more receiving units  132  can receive one or more signals  130  that include one or more instructions to select one or more nutraceutical agents  118  based on numerous parameters  114 . Examples of such parameters  114  include, but are not limited to, blood sugar levels, blood insulin levels, blood iron levels, hormone levels, nutraceutical agent  118  levels, pharmaceutical agent levels, cytokine levels, and the like.  
      At operation  2004 , the receiving operation  1810  may include receiving the one or more signals to select the one or more nutraceutical agents to increase one or more levels of one or more components associated with the one or more specified goals of the individual. In some embodiments, one or more receiving units  132  receive one or more signals  130  to select one or more nutraceutical agents  118  to increase one or more levels of one or more components associated with the one or more specified goals  106  of the individual  108 .  
      In some embodiments, one or more receiving units  132  receive one or more signals  130  to select one or more nutraceutical agents  118  that may directly complement one or more levels of one or more components associated with one or more specified goals  106  of the individual  108 . For example, in some embodiments, one or more receiving units  132  receive one or more signals  130  to select calcium in various forms (i.e., calcium citrate, calcium aspartate, calcium carbonate) to avoid or reduce the effects of osteoporosis. In another embodiment, one or more receiving units  132  receive one or more signals  130  to select chromium to lower blood sugar, increase insulin sensitivity, reduce body fat, control hunger, suppress appetite, increase lean body/muscle mass, or substantially any combination thereof. In some embodiments, one or more receiving units  132  receive one or more signals  130  to select one or more nutraceutical agents  118  to indirectly supplement a component associated with one or more specified goals  106  of an individual  108 . For example, one or more receiving units  132  may receive one or more signals  130  to select 5-hydroxy-tryptophan for administration to an individual  108  if the individual  108  suffers from depression and is found to exhibit low levels of serotonin. Numerous signals  130  may be received to select one or more nutraceutical agents  118  to increase one or more levels of one or more components associated with one or more specified goals  106  of an individual  108 .  
      At operation  2006 , the receiving operation  1810  may include receiving the one or more signals to select the one or more nutraceutical agents to decrease one or more levels of one or more components associated with the one or more specified goals of the individual. In some embodiments, one or more receiving units  132  receive one or more signals  130  to select one or more nutraceutical agents  118  to decrease one or more levels of one or more components associated with the one or more specified goals  106  of the individual  108 .  
      Low density lipoproteins are examples of components that are linked to vascular disease. Accordingly, in some embodiments, one or more receiving units  132  may receive one or more signals  130  to select one or more nutraceutical agents  118  that will act to lower the low density lipoprotein concentration of an individual  108 . Examples of such nutraceutical agents  118  include, but are not limited to, plant stanols, dietary fiber, stanol esters, isoflavones, diallyl sulfides, niacin, soy protein, and substantially any combination thereof. Glucose is an example of a component that is linked to hyperglycemia. Accordingly, in some embodiments, one or more receiving units  132  may receive one or more signals  130  to select buckwheat to lower blood glucose levels of an individual  108 . Free radical oxygen species that include singlet oxygen, hydroxyl radicals, peroxides, and superoxide radicals are components that act to damage lipids and other cellular structures. Accordingly, in some embodiments, one or more receiving units  132  may receive one or more signals  130  to select one or more nutraceutical agents  118  to reduce levels of free radicals within an individual  108 . Examples of such nutraceutical agents  118  include, but are not limited to, terpenes, carotenoids, limonoids, phenols, flavonoids, isoprenoids, and the like. One or more receiving units  132  can receive one or more signals  130  to select numerous types of nutraceutical agents  118  to decrease one or more levels of one or more components associated with the one or more specified goals  106  of the individual  108 .  
       FIG. 21  illustrates alternative embodiments of the example operational flow  1800  of  FIG. 18 .  FIG. 21  illustrates example embodiments where the receiving operation  1810  may include at least one additional operation. Additional operations may include an operation  2102 , an operation  2104 , and/or an operation  2106 .  
      At operation  2102 , the receiving operation  1810  may include receiving the one or more signals to select the one or more nutraceutical agents that stimulate one or more metabolic pathways linked to the individual. In some embodiments, one or more receiving units  132  receive one or more signals  130  to select one or more nutraceutical agents  118  that stimulate one or more metabolic pathways linked to the individual  108 .  
      In some embodiments, one or more receiving units  132  can receive one or more signals  130  to select one or more nutraceutical agents  118  that stimulate one or more metabolic pathways associated with one or more specified goals  106  of an individual  108 . For example, in some embodiments, decline in L-carnitine synthesis is thought to be linked to senile reduction in bone synthesis (Colucci et al.; Calcified Tissue International, 76:458-465 (2005)). Dihydroepiandrosterone (DHEA) is thought to affect levels of L-carnitine through promoting the expression of carnitine-synthesizing enzymes (Chiu et al., Calcified Tissue International, 64:527-533 (1999)). Accordingly, in some embodiments, one or more receiving units  132  can receive one or more signals  130  to select DHEA to stimulate the L-carnitine synthetic pathway to reduce senile reduction in bone synthesis. In other embodiments, one or more receiving units  132  can receive one or more signals  130  to select buckwheat extract to lower blood glucose through activation of mitogen activated protein kinase via phospholipase D (Appleton and Lockwood, The Pharmaceutical Journal, 277:78-83 (2006)). In another embodiment, resveratrol has been shown to stimulate endothelial nitric oxide synthase activity (Klinge et al., J. Biol. Chem., 280(9):7460-7468 (2005); Wallerath et al., Circulation, 106(13):1652-1658 (2002)). Endothelial nitric oxide synthase is an enzyme that catalyzes the formation of nitric oxide by vascular endothelial cells. Nitric oxide is needed to maintain arterial relaxation (vasodilation), and impaired nitric oxide-dependent vasodilation is associated with increased risk of cardiovascular disease (Duffy and Vita, Curr. Opin. Lipidol., 14(1):21-27 (2003)). Accordingly, in some embodiments, one or more receiving units  132  receive one or more signals  130  to select resveratrol to reduce cardiovascular disease. One or more receiving units  132  can receive one or more signals  130  to select numerous types of nutraceutical agents  118  to stimulate one or more metabolic pathways linked to the individual  108 .  
      At operation  2104 , the receiving operation  1810  may include receiving the one or more signals to select the one or more nutraceutical agents that inhibit one or more metabolic pathways linked to the individual. In some embodiments, one or more receiving units  132  receive one or more signals  130  to select one or more nutraceutical agents  118  that inhibit one or more metabolic pathways linked to the individual  108 .  
      In some embodiments, one or more receiving units  132  can receive one or more signals  130  to select one or more nutraceutical agents  118  that inhibit one or more enzymes that participate within a metabolic pathway. Such metabolic pathways may be involved with a specified goal  106  of an individual  108 . For example, angiotensin-converting enzyme has been linked to high blood pressure. Flavonoids have been shown to inhibit angiotensin-converting enzyme (Actis-Goretta et al., J. Agric. Food Chem., 54(1):229-234 (2006)). Accordingly, in some embodiments, one or more receiving units  132  can receive one or more signals  130  to select flavonoids to assist in the reduction of blood pressure (Li et al., Chin. J. Physiol., 48(2):101-106 (2005); Machha and Mustafa, J. Cardiovasc. Pharmacol., 46(1):36-40 (2005)). Genistein, one of the predominant soy isoflavones, has been shown to compete with 17beta-estradiol for estrogen receptor binding because of its structural similarity, resulting in agonistic or antagonistic activity. This has been shown to cause inhibition of cell growth in breast and prostate cancers in vivo and in vitro. Accordingly, in some embodiments, one or more receiving units  132  can receive one or more signals  130  to select soy isoflavones containing genistein as a nutraceutical agent  118  for cancer chemoprevention (Sarkar et al., Mini Rev. Med. Chem., 6(4):401-407 (2006)). The isoflavonoids, daidzin, daidzein, and puerarin have been shown to reduce alcohol consumption (Lin R C, Alcohol Clin. Exp. Res., 20(4):659-663 (1996)). A link between daidzin&#39;s capacity to reduce alcohol consumption and its ability to increase the liver mitochondrial monoamine oxidase: aldehyde dehydrogenase activity ratio has been established (Keung, Med. Res. Rev., 23(6):669-696 (2003)). This increase in ratio is thought to occur through inhibition of aldehyde dehydrogenase activity. Accordingly, in some embodiments, one or more receiving units  132  can receive one or more signals  130  to select isoflavonoid mixtures that include daidzin, daidzein, and/or puerarin to lower alcohol consumption. One or more receiving units  132  can receive one or more signals  130  to select numerous other types of nutraceutical agents  118  that inhibit one or more metabolic pathways linked to the individual  108 .  
      At operation  2106 , the receiving operation  1810  may include receiving the one or more signals to select at least one vitamin, mineral, enzyme, amino acid, homeopathic supplement, toxin, homeopathic substance, traditional remedy, herbal supplement, or glandular supplement. In some embodiments, one or more receiving units  132  receive one or more signals  130  to select at least one vitamin, mineral, enzyme, amino acid, homeopathic supplement, toxin, homeopathic substance, traditional remedy, herbal supplement, or glandular supplement.  
       FIG. 22  illustrates alternative embodiments of the example operational flow  1800  of  FIG. 18 .  FIG. 22  illustrates example embodiments where the selecting operation  1820  may include at least one additional operation. Additional operations may include an operation  2202 , an operation  2204 , an operation  2206 , an operation  2208 , and/or an operation  2210 .  
      At operation  2202 , the selecting operation  1820  may include selecting the one or more nutraceutical agents to increase one or more levels of one or more components associated with the one or more specified goals of the individual. In some embodiments, one or more receiving units  132  select one or more nutraceutical agents  118  to increase one or more levels of one or more components associated with the one or more specified goals  106  of the individual  108 .  
      In some embodiments, one or more nutraceutical agents  118  may be selected that may directly complement one or more levels of one or more components associated with one or more specified goals  106  of the individual  108 . For example, calcium in various forms (i.e., calcium citrate, calcium aspartate, calcium carbonate) may be selected by an individual  108  who wants to avoid or reduce the effects of osteoporosis. In another embodiment, chromium may be selected to lower blood sugar, increase insulin sensitivity, reduce body fat, control hunger, suppress appetite, increase lean body/muscle mass, or substantially any combination thereof. In some embodiments, one or more nutraceutical agents  118  associated with one or more specified goals  106  of an individual  108  may be selected that may be administered to an individual  108  to indirectly supplement a component associated with the one or more specified goals  106 . For example, 5-hydroxy-tryptophan may be selected for administration to an individual  108  if the individual  108  suffers from depression and is found to exhibit low levels of serotonin. The 5-hydroxy-tryptophan will be converted to serotonin following administration to the individual  108 . Numerous nutraceutical agents  118  may be selected to increase one or more levels of one or more components associated with one or more specified goals  106  of an individual  108 .  
      At operation  2204 , the selecting operation  1820  may include selecting the one or more nutraceutical agents to decrease one or more levels of one or more components associated with the one or more specified goals of the individual. In some embodiments, one or more receiving units  132  select one or more nutraceutical agents  118  to decrease one or more levels of one or more components associated with the one or more specified goals  106  of the individual  108 .  
      In some embodiments, one or more components may be associated with one or more specified goals  106  of an individual  108 . Low density lipoproteins are examples of components that are linked to vascular disease. Accordingly, in some embodiments, one or more nutraceutical agents  118  may be selected that will act to lower the low density lipoprotein concentration of an individual  108 . Examples of such nutraceutical agents  118  include, but are not limited to, plant stanols, dietary fiber, stanol esters, isoflavones, diallyl sulfides, niacin, soy protein, and substantially any combination thereof. Glucose is an example of a component that is linked to hyperglycemia. Accordingly, in some embodiments, buckwheat is an example of a nutraceutical agent  118  that may be selected to lower blood glucose levels of an individual  108 . Free radical oxygen species that include singlet oxygen, hydroxyl radicals, peroxides, and superoxide radicals are components that act to damage lipids and other cellular structures. Accordingly, one or more nutraceutical agents  118  may be selected to reduce levels of free radicals within an individual  108 . Examples of such nutraceutical agents  118  include, but are not limited to, terpenes, carotenoids, limonoids, phenols, flavonoids, isoprenoids, and the like. Numerous other nutraceutical agents  118  may be selected to decrease one or more levels of one or more components associated with the one or more specified goals  106  of the individual  108 .  
      At operation  2206 , the selecting operation  1820  may include selecting the one or more nutraceutical agents that stimulate one or more metabolic pathways linked to the individual. In some embodiments, one or more receiving units  132  select one or more nutraceutical agents  118  that stimulate one or more metabolic pathways linked to the individual  108 .  
      In some embodiments, stimulation of one or more metabolic pathways may be associated with one or more specified goals  106  of an individual  108 . For example, in some embodiments, decline in L-carnitine synthesis is thought to be linked to senile reduction in bone synthesis (Colucci et al., Calcified Tissue International, 76:458-465 (2005)). Dihydroepiandrosterone (DHEA) is thought to affect levels of L-carnitine through promoting the expression of carnitine-synthesizing enzymes (Chiu et al., Calcified Tissue International, 64:527-533 (1999)). Accordingly, DHEA may be selected to stimulate the L-carnitine synthetic pathway to reduce senile reduction in bone synthesis. In other embodiments, buckwheat extract may be selected to lower blood glucose due to the ability of buckwheat extract to activate mitogen activated protein kinase via phospholipase D (Appleton and Lockwood, The Pharmaceutical Journal, 277:78-83 (2006)). In another embodiment, resveratrol has been shown to stimulate endothelial nitric oxide synthase activity (Klinge et al., J. Biol. Chem., 280(9):7460-7468 (2005); Wallerath et al., Circulation, 106(13):1652-1658 (2002)). Endothelial nitric oxide synthase is an enzyme that catalyzes the formation of nitric oxide by vascular endothelial cells. Nitric oxide is needed to maintain arterial relaxation (vasodilation), and impaired nitric oxide-dependent vasodilation is associated with increased risk of cardiovascular disease (Duffy and Vita, Curr. Opin. Lipidol., 14(1):21-27 (2003)). Accordingly, in some embodiments, resveratrol may be selected to reduce cardiovascular disease. Numerous nutraceutical agents  118  may be selected to one or more metabolic pathways linked to the individual  108 .  
      At operation  2208 , the selecting operation  1820  may include selecting the one or more nutraceutical agents that inhibit one or more metabolic pathways linked to the individual. In some embodiments, one or more receiving units  132  select one or more nutraceutical agents  118  that inhibit one or more metabolic pathways linked to the individual  108 .  
      In some embodiments, one or more metabolic pathways may be inhibited through inhibition of one or more enzymes that participate within the metabolic pathway. Such metabolic pathways may be involved with a specified goal  106  of an individual  108 . For example, angiotensin-converting enzyme has been linked to high blood pressure. Flavonoids have been shown to inhibit angiotensin-converting enzyme (Actis-Goretta et al., J. Agric. Food Chem., 54(1):229-234 (2006)). Accordingly, flavonoids may be selected to assist in the reduction of blood pressure (Li et al., Chin. J. Physiol., 48(2):101-106 (2005); Machha and Mustafa, J. Cardiovasc. Pharmacol., 46(1):36-40 (2005)). Genistein, one of the predominant soy isoflavones, has been shown to compete with 17beta-estradiol for estrogen receptor binding because of its structural similarity, resulting in agonistic or antagonistic activity. This has been shown to cause inhibition of cell growth in breast and prostate cancers in vivo and in vitro. Accordingly, soy isoflavones containing genistein may be selected as a nutraceutical agent  118  for cancer chemoprevention (Sarkar et al., Mini Rev. Med. Chem., 6(4):401-407 (2006)). The isoflavonoids, daidzin, daidzein, and puerarin have been shown to reduce alcohol consumption (Lin RC, Alcohol Clin. Exp. Res., 20(4):659-663 (1996)). A link between daidzin&#39;s capacity to reduce alcohol consumption and its ability to increase the liver mitochondrial monoamine oxidase: aldehyde dehydrogenase activity ratio has been established (Keung, Med. Res. Rev., 23(6):669-696 (2003)). This increase in ratio is thought to occur through inhibition of aldehyde dehydrogenase activity. Accordingly, isoflavonoid mixtures that include daidzin, daidzein, and/or puerarin may be selected to lower alcohol consumption. Numerous other nutraceutical agents  118  may be selected that inhibit one or more metabolic pathways linked to the individual  108 .  
      At operation  2210 , the selecting operation  1820  may include selecting at least one vitamin, mineral, enzyme, amino acid, homeopathic supplement, toxin, homeopathic substance, traditional remedy, herbal supplement, or glandular supplement. In some embodiments, one or more receiving units  132  select at least one vitamin, mineral, enzyme, amino acid, homeopathic supplement, toxin, homeopathic substance, traditional remedy, herbal supplement, or glandular supplement.  
       FIG. 23  illustrates alternative embodiments of the example operational flow  1800  of  FIG. 18 .  FIG. 23  illustrates example embodiments where the indicating operation  1830  may include at least one additional operation. Additional operations may include an operation  2302 , an operation  2304 , an operation  2306 , an operation  2308 , an operation  2310 , and/or an operation  2312 .  
      At operation  2302 , the indicating operation  1830  may include indicating the one or more dosages of the one or more nutraceutical agents in human-readable format. In some embodiments, one or more indicating units  120  indicate the one or more dosages  122  of the one or more nutraceutical agents  118  in human-readable format In some embodiments, one or more indicating units  120  may indicate one or more dosages  122  of one or more nutraceutical agents  118  on a visual display, a touch display, an audible display, and the like. For example, in some embodiments, one or more indicating units  120  may display one or more dosages  122  on a light emitting diode display, a liquid crystal display, various monitors, and the like. Such visual displays may indicate one or more dosages  122  through display of colors, pictures, printed language, and the like. In some embodiments, one or more indicating units  120  may display one or more dosages  122  on a touch display (i.e., a touch pad display in Braille for use by blind or visually impaired persons). In some embodiments, one or more indicating units  120  may display one or more dosages  122  through use of an audible display that verbally speaks to an individual  108 .  
      In some embodiments, one or more indicating units  120  may display one or more dosages  122  of one or more nutraceutical agents  118  in typographical symbols in numerous languages that are in human-readable format. In some embodiments, one or more indicating units  120  may display one or more dosages  122  of one or more nutraceutical agents  118  and the formulation type of the one or more nutraceutical agents  118  in typographical symbols in numerous languages that are in human-readable format. In some embodiments, one or more indicating units  120  may display one or more dosages  122  of one or more nutraceutical agents  118  in pictographic form that is in human-readable format. In some embodiments, one or more indicating units  120  may display one or more dosages  122  of one or more nutraceutical agents  118  and the formulation type of the one or more nutraceutical agents  118  in pictographic form that is in human-readable format. In some embodiments, one or more indicating units  120  may display one or more dosages  122  of one or more nutraceutical agents  118  according to a color scheme that is in human-readable format. In some embodiments, one or more indicating units  120  may display one or more dosages  122  of one or more nutraceutical agents  118  and the formulation type of the one or more nutraceutical agents  118  according to a color scheme that is in human-readable format. In some embodiments, one or more indicating units  120  may display one or more dosages  122  of one or more nutraceutical agents  118 , one or more routes of administration for the one or more nutraceutical agents  118 , one or more times and/or periodicities for administration of the one or more nutraceutical agents  118 , one or more formulation types for the one or more nutraceutical agents  118 , whether to administer the one or more nutraceutical agents  118  with or without food, whether to administer the one or more nutraceutical agents  118  with or without other nutraceutical agents  118  and/or pharmaceutical agents, and substantially any combination thereof. Dosages  122  may be displayed according to numerous methods that are known and have been described (i.e., U.S. patent application Ser. No. 11/474,109, entitled CUSTOMIZED VISUAL MARKING FOR MEDICATION LABELING, filed 23 Jun. 2006, herein incorporated by reference to the extent such subject matter is not inconsistent herewith). In some embodiments, one or more indicating units  120  may indicate one or more dosages  122  in human-readable format and machine-readable format.  
      At operation  2304 , the indicating operation  1830  may include indicating the one or more dosages of the one or more nutraceutical agents in machine-readable format. In some embodiments, one or more indicating units  120  indicate the one or more dosages  122  of the one or more nutraceutical agents  118  in machine-readable format.  
      In some embodiments, one or more indicating units  120  may indicate one or more dosages  122  of one or more nutraceutical agents  118  in machine-readable format. Numerous methods may be used to indicate one or more dosages  122 . Examples of such methods include, but are not limited to, radio frequency identification, bar coding, typographical methods, symbol based methods (i.e., use of symbols that represent dosages  122  and nutraceutical agents  118 ), optical methods (i.e., pulsed light), and the like.  
      In some embodiments, one or more indicating units  120  may indicate one or more dosages  122  of one or more nutraceutical agents  118  and the formulation type of the one or more nutraceutical agents  118  in machine-readable form. In some embodiments, one or more indicating units  120  may indicate one or more dosages  122  of one or more nutraceutical agents  118  in a pictographic form that is in machine-readable format. In some embodiments, one or more indicating units  120  may indicate one or more dosages  122  of one or more nutraceutical agents  118  and the formulation type of the one or more nutraceutical agents  118  in a pictographic form that is in machine-readable format. In some embodiments, one or more indicating units  120  may indicate one or more dosages  122  of one or more nutraceutical agents  118  according to a color scheme that is in machine-readable format. In some embodiments, one or more indicating units  120  may indicate one or more dosages  122  of one or more nutraceutical agents  118  and the formulation type of the one or more nutraceutical agents  118  according to a color scheme that is in machine-readable format. In some embodiments, one or more indicating units  120  may indicate one or more dosages  122  of one or more nutraceutical agents  118 , one or more routes of administration for the one or more nutraceutical agents  118 , one or more times and/or periodicities for administration of the one or more nutraceutical agents  118 , one or more formulation types for the one or more nutraceutical agents  118 , whether to administer the one or more nutraceutical agents  118  with or without food, whether to administer the one or more nutraceutical agents  118  with or without other nutraceutical agents  118  and/or pharmaceutical agents, and substantially any combination thereof. Numerous labeling methods are known and have been described that may be adapted into a machine-readable format (i.e., U.S. patent application Ser. No. 11/474,109, entitled CUSTOMIZED VISUAL MARKING FOR MEDICATION LABELING, filed 23 Jun. 2006, herein incorporated by reference to the extent such subject matter is not inconsistent herewith). In some embodiments, one or more indicating units  120  may indicate one or more dosages  122  in human-readable and in a machine-readable format.  
      At operation  2306 , the indicating operation  1830  may include depositing the one or more dosages of the one or more nutraceutical agents on one or more labels. In some embodiments, one or more indicating units  120  deposit the one or more dosages  122  of the one or more nutraceutical agents  118  on one or more labels.  
      In some embodiments, one or more indicating units  120  may print one or more labels that include one or more dosages  122  of one or more nutraceutical agents  118  and the formulation type of the one or more nutraceutical agents  118 . In some embodiments, one or more indicating units  120  may print one or more labels that include one or more dosages  122  of one or more nutraceutical agents  118  in pictographic form. In some embodiments, one or more indicating units  120  may print one or more labels that include one or more dosages  122  of one or more nutraceutical agents  118  and the formulation type of the one or more nutraceutical agents  118  in pictographic form. In some embodiments, one or more indicating units  120  may print one or more labels that include one or more dosages  122  of one or more nutraceutical agents  118  according to a color scheme. In some embodiments, one or more indicating units  120  may print one or more labels that include one or more dosages  122  of one or more nutraceutical agents  118  and the formulation type of the one or more nutraceutical agents  118  according to a color scheme. In some embodiments, one or more indicating units  120  may indicate one or more dosages  122  of one or more nutraceutical agents  118 , one or more routes of administration for the one or more nutraceutical agents  118 , one or more times and/or periodicities for administration of the one or more nutraceutical agents  118 , one or more formulation types for the one or more nutraceutical agents  118 , whether to administer the one or more nutraceutical agents  118  with or without food, whether to administer the one or more nutraceutical agents  118  with or without other nutraceutical agents  118  and/or pharmaceutical agents, and substantially any combination thereof. Numerous labeling methods are known and have been described which may be adapted into machine-readable form (i.e., U.S. patent application Ser. No. 11/474,109, entitled CUSTOMIZED VISUAL MARKING FOR MEDICATION LABELING, filed 23 Jun. 2006, herein incorporated by reference to the extent such subject matter is not inconsistent herewith).  
      In some embodiments, one or more indicating units  120  may indicate one or more dosages  122  in human-readable and machine-readable form. Numerous types of depositing methods may be used by one or more indicating units  120 . Examples of such methods include, but are not limited to, printing methods (i.e., stamping, ink-jet printing, laser printing, and the like). In some embodiments, ink containing magnetic particles may be used.  
      At operation  2308 , the indicating operation  1830  may include dispensing the one or more nutraceutical agents. In some embodiments, one or more indicating units  120  dispense the one or more nutraceutical agents  118 .  
      One or more indicating units  120  may dispense one or more nutraceutical agents  118  in numerous dosage forms. In some embodiments, one or more indicating units  120  may dispense one or more nutraceutical agents  118  in powder form. In some embodiments, one or more indicating units  120  may dispense one or more nutraceutical agents  118  in liquid form. In some embodiments, one or more indicating units  120  may dispense one or more nutraceutical agents  118  in tablet form. In some embodiments, one or more indicating units  120  may dispense one or more nutraceutical agents  118  in capsule form.  
      At operation  2310 , the indicating operation  1830  may include dispensing the one or more nutraceutical agents in unit dosage form. In some embodiments, one or more indicating units  120  dispense the one or more nutraceutical agents  118  in unit dosage form.  
      In some embodiments, one or more indicating units  120  may dispense one or more nutraceutical agents  118  in a unit dosage form in which the entire dosage  122  is to be administered to an individual  108  as a single dosage  122 . In some embodiments, one or more indicating units  120  may dispense one or more nutraceutical agents  118  in a unit dosage form that may be administered such that the individual  108  will maintain a level of the one or more nutraceuticals for a given time period. For example, in some embodiments, a unit dosage form may be an amount of one or more nutraceutical agents  118  that will allow the one or more nutraceutical agents  118  to be maintained within an individual  108  for four hours. Numerous criteria may be used to determine a unit dosage form. Examples of such criteria include, but are not limited to, physical characteristics of the individual  108 , physiological characteristics of the individual  108 , activity of the individual  108 , and the like.  
      At operation  2312 , the indicating operation  1830  may include dispensing two or more of the one or more nutraceutical agents in a single administration form. In some embodiments, one or more indicating units  120  dispense two or more of the one or more nutraceutical agents  118  in a single administration form.  
      In some embodiments, one or more indicating units  120  may dispense two or more nutraceutical agents  118  in a single administration form to provide for administration of the two or more nutraceutical agents  118  to an individual  108 . Such methods have been described (i.e., U.S. patent application Ser. No. 11/453,571, filed 14 Jun. 2006; U.S. patent application Ser. No. 11/478,341, filed 28 Jun. 2006; U.S. patent application Ser. No. 11/478,296, filed 28 Jun. 2006; and U.S. patent application No. 11/486,998, filed 14 Jul. 2006, herein incorporated by reference to the extent such subject matter is not inconsistent herewith).  
       FIG. 24  illustrates an operational flow  2400  that includes a receiving operation  2410 , a selecting operation  2420 , and an indicating operation  2430  (which correspond to the receiving operation  1810 , the selecting operation  1820 , and the indicating operation  1830  illustrated in  FIG. 18 ) with an additional recording operation  2440 . In  FIG. 24 , discussion and explanation may be provided with respect to the above-described example of  FIG. 1 , and/or with respect to other examples and contexts. However, it should be understood that the operations may be executed in a number of other environments and contexts, and/or modified versions of  FIG. 1 . Also, although the various operations are presented in the sequence(s) illustrated, it should be understood that the various operations may be performed in other orders than those which are illustrated, or may be performed concurrently.  
      After a start operation, the operational flow  2400  includes the operations  2410 ,  2420 , and  2430  (which correspond to operations  1810 ,  1820 , and  1830  as described with regard to  FIG. 18 ) and an additional recording operation  2440  involving recording results of, the receiving one or more signals transmitted in response to intaking information linked to one or more parameters associated with one or more specified goals of an individual, the selecting one or more nutraceutical agents in response to the receiving the one or more signals transmitted in response to the intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual, or the indicating one or more dosages of the one or more nutraceutical agents in response to the selecting the one or more nutraceutical agents in response to the receiving the one or more signals transmitted in response to the intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual, on a recordable-medium.  
      In some embodiments, one or more recording units  124  may record results of, the receiving one or more signals  130  transmitted in response to intaking information  112  linked to one or more parameters  114  associated with one or more specified goals  106  of the individual  108 , the selecting one or more nutraceutical agents  118  in response to the receiving one or more signals  130  transmitted in response to intaking information  112  linked to one or more parameters  114  associated with one or more specified goals  106  of the individual  108 , or the indicating one or more dosages  122  of the one or more nutraceutical agents  118  in response to the selecting one or more nutraceutical agents  118  in response to the receiving one or more signals  130  transmitted in response to intaking information  112  linked to one or more parameters  114  associated with one or more specified goals  106  of the individual  108 , on a recordable-medium  126 .  
       FIG. 25  illustrates a system  2500  representing examples of circuitry that is related to systems for nutraceutical agent  118  and dosing. In  FIG. 25  discussion and explanation may be provided with respect to the above-described example of  FIG. 1 , and/or with respect to other examples and contexts. However, it should be understood that the circuitry may be assembled in a number of other environments and contexts, and/or modified versions of  FIG. 1 . Also, although various circuitry is presented in the sequence(s) illustrated, it should be understood that circuitry may be assembled in other configurations than those which are illustrated.  
      After a start operation, the system  2500  includes a circuitry block  2510  that includes circuitry for accepting data related to one or more specified goals of an individual. In some embodiments, the circuitry may be used for accepting data  104  related to one or more specified goals  106  of an individual  108 .  
      The one or more specified goals  106  may be virtually any goal to be achieved, or attempted by, an individual  108  that may be affected by administration of one or more nutraceutical agents  118  to the individual  108 . In some embodiments, administration of one or more nutraceutical agents  118  to an individual  108  may assist the individual  108  to achieve one or more specified goals  106 . In some embodiments, administration of one or more nutraceutical agents  118  to an individual  108  may stimulate the individual  108  to achieve one or more specified goals  106 . In some embodiments, administration of one or more nutraceutical agents  118  to an individual  108  may reduce an inhibition coupled to the individual  108  to promote achieving one or more specified goals  106  by the individual  108 . Numerous examples of specified goals  106  of an individual  108  exist. In some embodiments, specified goals  106  of an individual  108  may be related to attentiveness, alertness, test performance, relaxation, pain, fever, attractiveness, anxiety, fall, injury, accident, bite, bleeding, inflammation, infection, drowsiness, insomnia, discomfort, stress, grooming, appearance, capability, performance, improvement, enhancement, curtailment, wellbeing, vitality, vigor, disability, phobia, malady, psychosis, environmental extremes, environmental exposure, dysfunction, disease symptom, chronic condition, mental acuity, emotional behavior, physical prowess, addiction, obsession, therapy, remedy, behavior, nutrition, diet, exercise, immunization, prevention, diagnosis, subscription, regimen, social performance, social interaction, endurance, sexual attribute, sexual performance, age-related attribute, age-related condition, prophylaxis, treatment, and substantially any combination thereof. In some embodiments, data  104  may include identification of one or more of the specified goals  106  of an individual  108 . In some embodiments, data  104  may include characteristics of an individual  108 . Examples of such data  104  may include, but are not limited to, physical characteristics, metabolic characteristics, financial characteristics, and the like. In some embodiments, data  104  may include, an individual&#39;s  108  height, weight, gender, kidney function, liver function, level of physical fitness, age, allergic response, metabolic level (i.e., resting metabolic rate and/or activity-related metabolic rate), disease state, body fat percentage, body mass index, personal health habits (i.e., smoking, alcohol consumption, diet, illegal drug use, and the like), family health history, insurance coverage, food supplement usage, nutraceutical agent  118  usage, non-prescription drug use, prescription drug use, pregnancy status, and the like. In some embodiments, the one or more characteristics may be specifically associated with an individual  108 . As such, in some embodiments, the one or more characteristics may be unique to the individual  108  as opposed to being common to a group. For example, in some embodiments, an individual  108  may be a member of a group of persons who are diabetic while exhibiting one or more characteristics, such as metabolic characteristics, that are unique to the individual  108 . Accordingly, in some embodiments, data  104  may be input that provides for selection of nutraceutical agents  118  in accordance with one or more characteristics and specified goals  106  of an individual  108 .  
      After a start operation, the system  2500  includes a circuitry block  2520  that includes circuitry for intaking information linked to one or more parameters associated with the one or more specified goals of the individual. In some embodiments, the circuitry may be used for intaking information  112  linked to one or more parameters  114  associated with the one or more specified goals  106  of the individual  108 .  
      Numerous parameters  114  may be associated with one or more specified goals  106  of an individual  108 . Examples of such parameters  114  include, but are not limited to, blood sugar levels, blood insulin levels, blood iron levels, hormone levels (amine-derived hormones: such as catecholamines (adrenaline, dopamine, noradrenaline); tryptophan derivatives (melatonin, serotonin); tyrosine derivatives (thyroxine and triiodothyronine); peptide hormones such as antimullerian hormone, adiponectin, adrenocorticotropic hormone, angiotensinogen and angiotensin, antidiuretic hormone, atrial-natriuretic peptide, calcitonin, cholecystokinin, corticotropin-releasing hormone, erythropoietin, follicle-stimulating hormone, gastrin, ghrelin, glucagons, gonadotropin-releasing hormone, growth hormone-releasing hormone, human chorionic gonadotropin, growth hormone, inhibin, insulin, insulin-like growth factor, luteinizing hormone, melanocyte stimulating hormone, neuropeptide Y, oxytocin, parathyroid hormone, prolactin, relaxin, secretin, somatostatin, thrombopoietin, thyroid-stimulating hormone, thyrotropin-releasing hormone; steroid hormones: Glucocorticoids (cortisol); Mineralocorticoids (aldosterone); sex steroids: androgens (testosterone, dehydroepiandrosterone, dehydroepiandrosterone sulfate, androstenedione, dihydrotestosterone); estrogens (estradiol); progestagens (progesterone and progestins); sterol hormones: vitamin D derivatives (calcitriol); lipid hormones (prostaglandins, leukotrienes, prostacyclin, and thromboxane)), nutraceutical agent  118  levels, pharmaceutical agent levels, cytokine levels, and the like (i.e., Fitzgerald et al., The Cytokine Facts Book, Academic Press, San Francisco, Second Edition, (2001)). Methods to gain information  112  with regard to components of biological systems are known (i.e., Clinical Laboratory Medicine, Lippincott Williams and Wilkins, Philadelphia, Second Edition, 2002). In some embodiments, one or more intaking units  110  may include instrumentation that provides for analysis of a sample obtained from an individual  108 . For example, in some embodiments, an intaking unit  110  may be configured to intake a blood sample obtained from an individual  108  and analyze the blood sample to determine one or more parameters  114  associated with one or more specified goals  106  of an individual  108  (i.e., determine the level of free testosterone or the level of melatonin in a blood sample obtained from an individual  108 ). Numerous analytical technologies are known and may be included within one or more intaking units  110 . Examples of such technologies include, but are not limited to, gas chromatography, mass spectrometry, atomic absorption, immunoassay based methods, microfluidic based methods, spectrophotometry (i.e., infrared, ultraviolet, fluorescence, and the like), surface plasmon resonance, fluorescence resonance energy transfer, and the like. In some embodiments, one or more intaking units  110  may intake information  112  linked to one or more parameters  114  associated with the one or more specified goals  106  of an individual  108  from a source that is independent of the one or more intaking units  110 . In some embodiments, one or more intaking units  110  may intake information  112  linked to one or more parameters  114  associated with the one or more specified goals  106  of an individual  108  from a source that is coupled to the one or more intaking units  110 .  
      After a start operation, the system  2500  includes a circuitry block  2530  that includes circuitry for selecting one or more nutraceutical agents responsive to the circuitry for intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual. In some embodiments, the circuitry may be used for selecting one or more nutraceutical agents  118  responsive to the circuitry for intaking information  112  linked to one or more parameters  114  associated with the one or more specified goals  106  of the individual  108 .  
      In some embodiments, one or more selecting units  116  may select one or more nutraceutical agents  118  in response to one or more intaking units  110 . In some embodiments, one or more selecting units  116  may select one or more nutraceutical agents  118  in response to one or more accepting units  102 . In some embodiments, one or more selecting units  116  may select one or more nutraceutical agents  118  in response to one or more intaking units  110  and one or more accepting units  102 . Accordingly, in some embodiments, one or more selecting units  116  may select one or more nutraceutical agents  118  with regard to one or more characteristics of the individual  108  and one or more parameters  114  associated with one or more specified goals  106  of the individual  108 . For example, in some embodiments, one or more selecting units  116  may select one or more nutraceutical agents  118  based on the age of the individual  108  and the level of testosterone in the individual&#39;s  108  blood. In other embodiments, one or more selecting units  116  may select one or more nutraceutical agents  118  based on insurance coverage held by an individual  108  and a specified goal  106  of the individual  108 . Accordingly, numerous combinations of information  112  and data  104  may be used by one or more selecting units  116  to select one or more nutraceutical agents  118 .  
      After a start operation, the system  2500  includes a circuitry block  2540  that includes circuitry for indicating one or more dosages of the one or more nutraceutical agents responsive to the circuitry for selecting the one or more nutraceutical agents responsive to the circuitry for intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual. In some embodiments, the circuitry may be used for indicating one or more dosages  122  of the one or more nutraceutical agents  118  responsive to the circuitry for selecting one or more nutraceutical agents  118  responsive to the circuitry for intaking information  112  linked to one or more parameters  114  associated with the one or more specified goals  106  of the individual  108 .  
      In some embodiments, the circuitry may be used for indicating one or more dosages  122  of one or more nutraceutical agents  118  in human-readable format. In some embodiments, the circuitry may be used for indicating one or more dosages  122  of one or more nutraceutical agents  118  in machine-readable format. In some embodiments, the circuitry may be used for depositing one or more dosages  122  of one or more nutraceutical agents  118  on one or more labels. In some embodiments, the circuitry may be used for dispensing one or more nutraceutical agents  118 . In some embodiments, the circuitry may be used for dispensing one or more nutraceutical agents  118  in unit dosage form. In some embodiments, the circuitry may be used for dispensing two or more of one or more nutraceutical agents  118  in a single administration form.  
       FIG. 26  illustrates a system  2600  representing examples of circuitry that is related to systems for nutraceutical agent  118  and dosing. In  FIG. 26  discussion and explanation may be provided with respect to the above-described example of  FIG. 1 , and/or with respect to other examples and contexts. However, it should be understood that the circuitry may be assembled in a number of other environments and contexts, and/or modified versions of  FIG. 1 . Also, although various circuitry is presented in the sequence(s) illustrated, it should be understood that circuitry may be assembled in other configurations than those which are illustrated.  
      After a start operation, the operational flow  2600  includes circuitry blocks  2610 ,  2620 ,  2630 , and  2640  (which correspond to circuitry blocks  2510 ,  2520 ,  2530 , and  2540  as described with regard to  FIG. 25 ) and an additional circuitry block  2650  involving circuitry for recording, responsive to the circuitry for accepting the data related to the one or more specified goals of the individual, responsive to the circuitry for intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual, responsive to the circuitry for selecting the one or more nutraceutical agents responsive to the circuitry for intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual, or responsive to the circuitry for indicating the one or more dosages of the one or more nutraceutical agents responsive to the circuitry for selecting the one or more nutraceutical agents responsive to the circuitry for intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual, on a recordable-medium. In some embodiments, the circuitry may be used for recording, responsive to the circuitry for accepting data  104  related to one or more specified goals  106  of an individual  108 , responsive to the circuitry for intaking information  112  linked to one or more parameters  114  associated with the one or more specified goals  106  of the individual  108 , responsive to the circuitry for selecting one or more nutraceutical agents  118  responsive to the circuitry for intaking information  112  linked to one or more parameters  114  associated with the one or more specified goals  106  of the individual  108 , or responsive to the circuitry for indicating one or more dosages  122  of the one or more nutraceutical agents  118  responsive to the circuitry for selecting one or more nutraceutical agents  118  responsive to the circuitry for intaking information  112  linked to one or more parameters  114  associated with the one or more specified goals  106  of the individual  108 , on a recordable-medium  126 .  
       FIG. 27  illustrates a system  2700  representing examples of circuitry that is related to systems for nutraceutical agent  118  and dosing. In  FIG. 27  discussion and explanation may be provided with respect to the above-described example of  FIG. 1 , and/or with respect to other examples and contexts. However, it should be understood that the circuitry may be assembled in a number of other environments and contexts, and/or modified versions of  FIG. 1 . Also, although various circuitry is presented in the sequence(s) illustrated, it should be understood that circuitry may be assembled in other configurations than those which are illustrated.  
      After a start operation, the system  2700  includes a circuitry block  2710  that includes circuitry for accepting data related to one or more specified goals of an individual. In some embodiments, the circuitry may be used for accepting data  104  related to one or more specified goals  106  of an individual  108 .  
      The one or more specified goals  106  may be virtually any goal to be achieved, or attempted by, an individual  108  that may be affected by administration of one or more nutraceutical agents  118  to the individual  108 . In some embodiments, administration of one or more nutraceutical agents  118  to an individual  108  may assist the individual  108  to achieve one or more specified goals  106 . In some embodiments, administration of one or more nutraceutical agents  118  to an individual  108  may stimulate the individual  108  to achieve one or more specified goals  106 . In some embodiments, administration of one or more nutraceutical agents  118  to an individual  108  may reduce an inhibition coupled to the individual  108  to promote achieving one or more specified goals  106  by the individual  108 . Numerous examples of specified goals  106  of an individual  108  exist. In some embodiments, specified goals  106  of an individual  108  may be related to attentiveness, alertness, test performance, relaxation, pain, fever, attractiveness, anxiety, fall, injury, accident, bite, bleeding, inflammation, infection, drowsiness, insomnia, discomfort, stress, grooming, appearance, capability, performance, improvement, enhancement, curtailment, wellbeing, vitality, vigor, disability, phobia, malady, psychosis, environmental extremes, environmental exposure, dysfunction, disease symptom, chronic condition, mental acuity, emotional behavior, physical prowess, addiction, obsession, therapy, remedy, behavior, nutrition, diet, exercise, immunization, prevention, diagnosis, subscription, regimen, social performance, social interaction, endurance, sexual attribute, sexual performance, age-related attribute, age-related condition, prophylaxis, treatment, and substantially any combination thereof. In some embodiments, data  104  may include identification of one or more of the specified goals  106  of an individual  108 . In some embodiments, data  104  may include characteristics of an individual  108 . Examples of such data  104  may include, but are not limited to, physical characteristics, metabolic characteristics, financial characteristics, and the like. In some embodiments, data  104  may include, an individual&#39;s  108  height, weight, gender, kidney function, liver function, level of physical fitness, age, allergic response, metabolic level (i.e., resting metabolic rate and/or activity-related metabolic rate), disease state, body fat percentage, body mass index, personal health habits (i.e., smoking, alcohol consumption, diet, illegal drug use, and the like), family health history, insurance coverage, food supplement usage, nutraceutical agent  118  usage, non-prescription drug use, prescription drug use, pregnancy status, and the like. In some embodiments, the one or more characteristics may be specifically associated with an individual  108 . As such, in some embodiments, the one or more characteristics may be unique to the individual  108  as opposed to being common to a group. For example, in some embodiments, an individual  108  may be a member of a group of persons who are diabetic while exhibiting one or more characteristics, such as metabolic characteristics, that are unique to the individual  108 . Accordingly, in some embodiments, data  104  may be input that provides for selection of nutraceutical agents  118  in accordance with one or more characteristics and specified goals  106  of an individual  108 .  
      After a start operation, the system  2700  includes a circuitry block  2720  that includes circuitry for intaking information linked to one or more parameters associated with the one or more specified goals of the individual. In some embodiments, the circuitry may be used for intaking information  112  linked to one or more parameters  114  associated with the one or more specified goals  106  of the individual  108 .  
      Numerous parameters  114  may be associated with one or more specified goals  106  of an individual  108 . Examples of such parameters  114  include, but are not limited to, blood sugar levels, blood insulin levels, blood iron levels, hormone levels, nutraceutical agent  118  levels, pharmaceutical agent levels, cytokine levels, and the like (i.e., Fitzgerald et al., The Cytokine Facts Book, Academic Press, San Francisco, Second Edition, (2001)). Methods to gain information  112  with regard to components of biological systems are known (i.e., Clinical Laboratory Medicine, Lippincott Williams and Wilkins, Philadelphia. Second Edition, 2002). In some embodiments, one or more intaking units  110  may include circuitry for analysis of a sample obtained from an individual  108 . For example, in some embodiments, an intaking unit  110  may include circuitry that is configured for analysis of a blood sample obtained from an individual  108  to determine one or more parameters  114  associated with one or more specified goals  106  of an individual  108  (i.e., determine the level of free testosterone or the level of melatonin in a blood sample obtained from an individual  108 ). Numerous analytical technologies are known and may be included within one or more intaking units  110 . Examples of such technologies include, but are not limited to, gas chromatography, mass spectrometry, atomic absorption, immunoassay based methods, microfluidic based methods, spectrophotometry (i.e., infrared, ultraviolet, fluorescence, and the like), surface plasmon resonance, fluorescence resonance energy transfer, and the like. In some embodiments, the circuitry may be used to intake information  112  linked to one or more parameters  114  associated with the one or more specified goals  106  of an individual  108  from a source that is independent of the one or more intaking units  110 . In some embodiments, the circuitry may intake information  112  linked to one or more parameters  114  associated with the one or more specified goals  106  of an individual  108  from a source that is coupled to the one or more intaking units  110 .  
      After a start operation, the system  2700  includes a circuitry block  2730  that includes circuitry for transmitting one or more signals responsive to the circuitry for intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual. In some embodiments, the circuitry may be used for transmitting one or more signals  130  responsive to the circuitry for intaking information  112  linked to one or more parameters  114  associated with the one or more specified goals  106  of the individual  108 .  
      In some embodiments, the circuitry may be used for transmitting one or more levels of one or more metabolic indicators linked to the individual  108 . In some embodiments, the circuitry may be used for transmitting one or more levels of one or more metabolic activities linked to the individual  108 . In some embodiments, the circuitry may be used for transmitting one or more levels of one or more nutraceutical agents  118  linked to the individual  108 . In some embodiments, the circuitry may be used for transmitting one or more levels of one or more pharmaceutical agents linked to the individual  108 . In some embodiments, the circuitry may be used for transmitting one or more parameters  114  associated with the one or more specified goals  106  of the individual  108 . In some embodiments, the circuitry may be used for transmitting one or more instructions to select one or more nutraceutical agents  118  in response to the intaking information  112  linked to one or more parameters  114  associated with the one or more specified goals  106  of the individual  108 . In some embodiments, the circuitry may be used for transmitting one or more signals  130  to select one or more nutraceutical agents  118  to increase one or more levels of one or more components associated with the one or more specified goals  106  of the individual  108 . In some embodiments, the circuitry may be used for transmitting one or more signals  130  to select one or more nutraceutical agents  118  to decrease one or more levels of one or more components associated with the one or more specified goals  106  of the individual  108 . In some embodiments, the circuitry may be used for transmitting one or more signals  130  to select one or more nutraceutical agents  118  that stimulate one or more metabolic pathways linked to the individual  108 . In some embodiments, the circuitry may be used for transmitting one or more signals  130  to select one or more nutraceutical agents  118  that inhibit one or more metabolic pathways linked to the individual  108 . In some embodiments, the circuitry may be used for transmitting one or more signals  130  to select at least one vitamin, mineral, enzyme, amino acid, homeopathic supplement, toxin, homeopathic substance, traditional remedy, herbal supplement, glandular supplement, or substantially any combination thereof.  
      In some embodiments, the circuitry may be used for transmitting one or more signals  130  that include data  104  related to one or more specified goals  106  of an individual  108 . The circuitry used for transmitting one or more signals  130  may use numerous technologies. Examples of such technologies include, but are not limited to, wireless circuitry, telephone circuitry, internet circuitry, digital circuitry, analog circuitry, optical circuitry, and the like.  
       FIG. 28  illustrates a system  2800  representing examples of circuitry that is related to systems for nutraceutical agent  118  and dosing. In  FIG. 28  discussion and explanation may be provided with respect to the above-described example of  FIG. 1 , and/or with respect to other examples and contexts. However, it should be understood that the circuitry may be assembled in a number of other environments and contexts, and/or modified versions of  FIG. 1 . Also, although various circuitry is presented in the sequence(s) illustrated, it should be understood that circuitry may be assembled in other configurations than those which are illustrated.  
      After a start operation, the operational flow  2800  includes circuitry blocks  2810 ,  2820 , and  2830  (which correspond to circuitry blocks  2710 ,  2720 , and  2730  as described with regard to  FIG. 27 ) and an additional circuitry block  2840  involving circuitry for recording, responsive to the circuitry for accepting the data related to the one or more specified goals of the individual, responsive to the circuitry for intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual, or responsive to the circuitry for transmitting the one or more signals responsive to the circuitry for intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual, on a recordable-medium. In some embodiments, the circuitry may be used for recording, responsive to circuitry for accepting data  104  related to one or more specified goals  106  of an individual  108 , responsive to circuitry for intaking information  112  linked to one or more parameters  114  associated with the one or more specified goals  106  of the individual  108 , or responsive to circuitry for transmitting one or more signals  130  responsive to the circuitry for intaking information  112  linked to one or more parameters  114  associated with the one or more specified goals  106  of the individual  108 , on a recordable-medium  126 .  
       FIG. 29  illustrates a system  2900  representing examples of circuitry that is related to systems for nutraceutical agent  118  and dosing. In  FIG. 29  discussion and explanation may be provided with respect to the above-described example of  FIG. 1 , and/or with respect to other examples and contexts. However, it should be understood that the circuitry may be assembled in a number of other environments and contexts, and/or modified versions of  FIG. 1 . Also, although various circuitry is presented in the sequence(s) illustrated, it should be understood that circuitry may be assembled in other configurations than those which are illustrated.  
      After a start operation, the system  2900  includes a circuitry block  2910  that includes circuitry for receiving one or more signals transmitted in response to intaking information linked to one or more parameters associated with one or more specified goals of an individual. In some embodiments, the circuitry may be used for receiving one or more signals  130  transmitted in response to intaking information  112  linked to one or more parameters  114  associated with one or more specified goals  106  of the individual  108 .  
      In some embodiments, the circuitry may be used for receiving one or more signals  130  that include data  104  related to one or more specified goals  106  of an individual  108 . In some embodiments, the circuitry may be used for receiving one or more signals  130  indicating one or more levels of one or more metabolic indicators linked to the individual  108 . In some embodiments, the circuitry may be used for receiving one or more signals  130  indicating one or more metabolic activities linked to the individual  108 . In some embodiments, the circuitry may be used for receiving one or more signals  130  indicating one or more levels of one or more nutraceutical agents  118  linked to the individual  108 . In some embodiments, the circuitry may be used for receiving one or more signals  130  indicating one or more levels of one or more pharmaceutical agents linked to the individual  108 . In some embodiments, the circuitry may be used for receiving one or more parameters  114  associated with the one or more specified goals  106  of the individual  108 . In some embodiments, the circuitry may be used for receiving one or more instructions to select one or more nutraceutical agents  118  in response to the intaking information  112  linked to one or more parameters  114  associated with the one or more specified goals  106  of the individual  108 . In some embodiments, the circuitry may be used for receiving one or more signals  130  to select one or more nutraceutical agents  118  to increase one or more levels of one or more components associated with the one or more specified goals  106  of the individual  108 . In some embodiments, the circuitry may be used for receiving one or more signals  130  to select one or more nutraceutical agents  118  to decrease one or more levels of one or more components associated with the one or more specified goals  106  of the individual  108 . In some embodiments, the circuitry may be used for receiving one or more signals  130  to select one or more nutraceutical agents  118  that stimulate one or more metabolic pathways linked to the individual  108 . In some embodiments, the circuitry may be used for receiving one or more signals  130  to select one or more nutraceutical agents  118  that inhibit one or more metabolic pathways linked to the individual  108 . In some embodiments, the circuitry may be used for receiving one or more signals  130  to select at least one vitamin, mineral, enzyme, amino acid, homeopathic supplement, toxin, homeopathic substance, traditional remedy, herbal supplement, glandular supplement, or substantially any combination thereof.  
      In some embodiments, the circuitry may be used for receiving one or more signals  130  that include data  104  related to one or more specified goals  106  of an individual  108 . The circuitry used for receiving may receive one or more signals  130  through use of numerous technologies. Examples of such technologies include, but are not limited to, wireless circuitry, telephone circuitry, internet circuitry, digital circuitry, analog circuitry, optical circuitry, and the like.  
      After a start operation, the system  2900  includes a circuitry block  2920  that includes circuitry for selecting one or more nutraceutical agents responsive to the circuitry for receiving the one or more signals transmitted in response to intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual. In some embodiments, the circuitry may be used for selecting one or more nutraceutical agents  118  responsive to the circuitry for receiving one or more signals  130  transmitted in response to intaking information  112  linked to one or more parameters  114  associated with one or more specified goals  106  of the individual  108 .  
      In some embodiments, the circuitry may be used for selecting one or more nutraceutical agents  118  in response to circuitry for receiving one or more signals  130  transmitted in response to intaking information  112  linked to one or more parameters  114  associated with one or more specified goals  106  of the individual  108 . In some embodiments, circuitry may be used for selecting one or more nutraceutical agents  118  in response to circuitry for accepting. In some embodiments, the circuitry may be used for selecting one or more nutraceutical agents  118  in response to circuitry for intaking units  110  and circuitry for accepting. Accordingly, in some embodiments, circuitry may be used for selecting one or more nutraceutical agents  118  with regard to one or more characteristics of the individual  108  and one or more parameters  114  associated with one or more specified goals  106  of the individual  108 . For example, in some embodiments, circuitry may be used for selecting one or more nutraceutical agents  118  based on the age of the individual  108  and the level of testosterone in the individual&#39;s  108  blood. In other embodiments, circuitry may be used for selecting one or more nutraceutical agents  118  based on insurance coverage held by an individual  108  and a specified goal  106  of the individual  108 .  
      After a start operation, the system  2900  includes a circuitry block  2930  that includes circuitry for indicating one or more dosages of the one or more nutraceutical agents responsive to the circuitry for selecting the one or more nutraceutical agents responsive to the circuitry for receiving the one or more signals transmitted in response to intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual. In some embodiments, the circuitry may be used for indicating one or more dosages  122  of the one or more nutraceutical agents  118  responsive to the circuitry for selecting one or more nutraceutical agents  118  responsive to the circuitry for receiving one or more signals  130  transmitted in response to intaking information  112  linked to one or more parameters  114  associated with one or more specified goals  106  of the individual  108 .  
      In some embodiments, the circuitry may be used for indicating one or more dosages  122  of one or more nutraceutical agents  118  in human-readable format. In some embodiments, the circuitry may be used for indicating one or more dosages  122  of one or more nutraceutical agents  118  in machine-readable format. In some embodiments, the circuitry may be used for indicating one or more dosages  122  of one or more nutraceutical agents  118  on one or more labels. In some embodiments, the circuitry may be used for dispensing one or more nutraceutical agents  118 . In some embodiments, the circuitry may be used for dispensing one or more nutraceutical agents  118  in unit dosage form. In some embodiments, the circuitry may be used for dispensing two or more of one or more nutraceutical agents  118  in a single administration form.  
       FIG. 30  illustrates a system  3000  representing examples of circuitry that is related to systems for nutraceutical agent  118  and dosing. In  FIG. 30  discussion and explanation may be provided with respect to the above-described example of  FIG. 1 , and/or with respect to other examples and contexts. However, it should be understood that the circuitry may be assembled in a number of other environments and contexts, and/or modified versions of  FIG. 1 . Also, although various circuitry is presented in the sequence(s) illustrated, it should be understood that circuitry may be assembled in other configurations than those which are illustrated.  
      After a start operation, the operational flow  3000  includes circuitry blocks  3010 ,  3020 , and  3030  (which correspond to circuitry blocks  2910 ,  2920 , and  2930  as described with regard to  FIG. 29 ) and an additional circuitry block  3040  involving circuitry for recording, responsive to the circuitry for receiving the one or more signals transmitted in response to intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual, responsive to the circuitry for selecting the one or more nutraceutical agents responsive to the circuitry for receiving the one or more signals transmitted in response to intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual, or responsive to the circuitry for indicating the one or more dosages of the one or more nutraceutical agents responsive to the circuitry for selecting the one or more nutraceutical agents responsive to the circuitry for receiving the one or more signals transmitted in response to intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual, on a recordable-medium. In some embodiments, the circuitry may be used for recording, responsive to circuitry for receiving one or more signals  130  transmitted in response to intaking information  112  linked to one or more parameters  114  associated with one or more specified goals  106  of the individual  108 , responsive to the circuitry for selecting one or more nutraceutical agents  118  responsive to the circuitry for receiving one or more signals  130  transmitted in response to intaking information  112  linked to one or more parameters  114  associated with one or more specified goals  106  of the individual  108 , or responsive to the circuitry for indicating one or more dosages  122  of the one or more nutraceutical agents  118  responsive to the circuitry for selecting one or more nutraceutical agents  118  responsive to the circuitry for receiving one or more signals  130  transmitted in response to intaking information  112  linked to one or more parameters  114  associated with one or more specified goals  106  of the individual  108 , on a recordable-medium  126 .  
       FIG. 31  illustrates a partial view of a system  3100  that includes a computer program  3104  for executing a computer process on a computing device. An embodiment of the system  3100  is provided using a signal-bearing medium bearing, one or more instructions for accepting data related to one or more specified goals of an individual, one or more instructions for intaking information linked to one or more parameters associated with the one or more specified goals of the individual, one or more instructions for selecting one or more nutraceutical agents in response to the intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual, and one or more instructions for indicating one or more dosages of the one or more nutraceutical agents in response to the selecting the one or more nutraceutical agents in response to the intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual.  
      The one or more instructions may be, for example, computer executable and/or logic-implemented instructions. In some embodiments, the signal-bearing medium  3102  may include a computer-readable medium  3106 . In some embodiments, the signal-bearing medium  3102  may include a recordable medium  3208 . In some embodiments, the signal-bearing medium  3102  may include a communications medium  3110 .  
       FIG. 32  illustrates a partial view of a system  3100  that includes a computer program  3204  for executing a computer process on a computing device. An embodiment of the system  3200  is provided using a signal-bearing medium bearing, one or more instructions for accepting data related to one or more specified goals of an individual, one or more instructions for intaking information linked to one or more parameters associated with the one or more specified goals of the individual, one or more instructions for selecting one or more nutraceutical agents in response to the intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual, one or more instructions for indicating one or more dosages of the one or more nutraceutical agents in response to the selecting the one or more nutraceutical agents in response to the intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual, and one or more instructions for recording, the accepting data related to one or more specified goals of an individual, the intaking information linked to one or more parameters associated with the one or more specified goals of the individual, the selecting one or more nutraceutical agents in response to the intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual, or the indicating one or more dosages of the one or more nutraceutical agents in response to the selecting the one or more nutraceutical agents in response to the intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual, on a recordable-medium.  
      The one or more instructions may be, for example, computer executable and/or logic-implemented instructions. In some embodiments, the signal-bearing medium  3202  may include a computer-readable medium  3206 . In some embodiments, the signal-bearing medium  3202  may include a recordable medium  3208 . In some embodiments, the signal-bearing medium  3202  may include a communications medium  3210 .  
       FIG. 33  illustrates a partial view of a system  3300  that includes a computer program  3304  for executing a computer process on a computing device. An embodiment of the system  3300  is provided using a signal-bearing medium bearing, one or more instructions for accepting data related to one or more specified goals of an individual, one or more instructions for intaking information linked to one or more parameters associated with the one or more specified goals of the individual, and one or more instructions for transmitting one or more signals in response to the intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual.  
      The one or more instructions may be, for example, computer executable and/or logic-implemented instructions. In some embodiments, the signal-bearing medium  3302  may include a computer-readable medium  3306 . In some embodiments, the signal-bearing medium  3302  may include a recordable medium  3308 . In some embodiments, the signal-bearing medium  3302  may include a communications medium  3310 .  
       FIG. 34  illustrates a partial view of a system  3400  that includes a computer program  3404  for executing a computer process on a computing device. An embodiment of the system  3400  is provided using a signal-bearing medium bearing, one or more instructions for accepting data related to one or more specified goals of an individual, one or more instructions for intaking information linked to one or more parameters associated with the one or more specified goals of the individual, one or more instructions for transmitting one or more signals in response to the intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual, and one or more instructions for recording, the accepting data related to one or more specified goals of an individual, the intaking information linked to one or more parameters associated with the one or more specified goals of the individual, or the transmitting one or more signals in response to the intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual, on a recordable-medium.  
      The one or more instructions may be, for example, computer executable and/or logic-implemented instructions. In some embodiments, the signal-bearing medium  3402  may include a computer-readable medium  3406 . In some embodiments, the signal-bearing medium  3402  may include a recordable medium  3408 . In some embodiments, the signal-bearing medium  3402  may include a communications medium  3410 .  
       FIG. 35  illustrates a partial view of a system  3500  that includes a computer program  3504  for executing a computer process on a computing device. An embodiment of the system  3500  is provided using a signal-bearing medium bearing, one or more instructions for receiving one or more signals transmitted in response to intaking information linked to one or more parameters associated with one or more specified goals of an individual, one or more instructions for selecting one or more nutraceutical agents in response to the receiving the one or more signals transmitted in response to the intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual, and one or more instructions for indicating one or more dosages of the one or more nutraceutical agents in response to the selecting the one or more nutraceutical agents in response to the receiving the one or more signals transmitted in response to the intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual.  
      The one or more instructions may be, for example, computer executable and/or logic-implemented instructions. In some embodiments, the signal-bearing medium  3502  may include a computer-readable medium  3506 . In some embodiments, the signal-bearing medium  3502  may include a recordable medium  3508 . In some embodiments, the signal-bearing medium  3502  may include a communications medium  3510 .  
       FIG. 36  illustrates a partial view of a system  3600  that includes a computer program  3604  for executing a computer process on a computing device. An embodiment of the system  3600  is provided using a signal-bearing medium bearing, one or more instructions for receiving one or more signals transmitted in response to intaking information linked to one or more parameters associated with one or more specified goals of an individual, one or more instructions for selecting one or more nutraceutical agents in response to the receiving the one or more signals transmitted in response to the intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual, one or more instructions for indicating one or more dosages of the one or more nutraceutical agents in response to the selecting the one or more nutraceutical agents in response to the receiving the one or more signals transmitted in response to the intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual, and one or more instructions for recording, the receiving one or more signals transmitted in response to intaking information linked to one or more parameters associated with one or more specified goals of an individual, the selecting one or more nutraceutical agents in response to the receiving the one or more signals transmitted in response to the intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual, or the indicating one or more dosages of the one or more nutraceutical agents in response to the selecting the one or more nutraceutical agents in response to the receiving the one or more signals transmitted in response to the intaking the information linked to the one or more parameters associated with the one or more specified goals of the individual, on a recordable-medium.  
      The one or more instructions may be, for example, computer executable and/or logic-implemented instructions. In some embodiments, the signal-bearing medium  3602  may include a computer-readable medium  3606 . In some embodiments, the signal-bearing medium  3602  may include a recordable medium  3608 . In some embodiments, the signal-bearing medium  3602  may include a communications medium  3610 .  
      With respect to the use of substantially any plural and/or singular terms herein, those having skill in the art can translate from the plural to the singular and/or from the singular to the plural as is appropriate to the context and/or application. The various singular/plural permutations are not expressly set forth herein for sake of clarity.  
      While particular aspects of the present subject matter described herein have been shown and described, it will be apparent to those skilled in the art that, based upon the teachings herein, changes and modifications may be made without departing from the subject matter described herein and its broader aspects and, therefore, the appended claims are to encompass within their scope all such changes and modifications as are within the true spirit and scope of the subject matter described herein. Furthermore, it is to be understood that the invention is defined by the appended claims. It will be understood by those within the art that, in general, terms used herein, and especially in the appended claims (e.g., bodies of the appended claims) are generally intended as “open” terms (e.g., the term “including” should be interpreted as “including but not limited to,” the term “having” should be interpreted as “having at least,” the term “includes” should be interpreted as “includes but is not limited to,” etc.). It will be further understood by those within the art that if a specific number of an introduced claim recitation is intended, such an intent will be explicitly recited in the claim, and in the absence of such recitation no such intent is present. For example, as an aid to understanding, the following appended claims may contain usage of the introductory phrases “at least one” and “one or more” to introduce claim recitations. However, the use of such phrases should not be construed to imply that the introduction of a claim recitation by the indefinite articles “a” or “an” limits any particular claim containing such introduced claim recitation to inventions containing only one such recitation, even when the same claim includes the introductory phrases “one or more” or “at least one” and indefinite articles such as “a” or “an” (e.g., “a” and/or “an” should typically be interpreted to mean “at least one” or “one or more”); the same holds true for the use of definite articles used to introduce claim recitations. In addition, even if a specific number of an introduced claim recitation is explicitly recited, those skilled in the art will recognize that such recitation should typically be interpreted to mean at least the recited number (e.g., the bare recitation of “two recitations,” without other modifiers, typically means at least two recitations, or two or more recitations). Furthermore, in those instances where a convention analogous to “at least one of A, B, and C, etc.” is used, in general such a construction is intended in the sense one having skill in the art would understand the convention (e.g., “a system having at least one of A, B, and C” would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and/or A, B, and C together, etc.). In those instances where a convention analogous to “at least one of A, B, or C, etc.” is used, in general such a construction is intended in the sense one having skill in the art would understand the convention (e.g., “a system having at least one of A, B, or C” would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and/or A, B, and C together, etc.). It will be further understood by those within the art that virtually any disjunctive word and/or phrase presenting two or more alternative terms, whether in the description, claims, or drawings, should be understood to contemplate the possibilities of including one of the terms, either of the terms, or both terms. For example, the phrase “A or B” will be understood to include the possibilities of “A” or “B” or “A and B.” 
      Those having skill in the art will recognize that the state of the art has progressed to the point where there is little distinction left between hardware and software implementations of aspects of systems; the use of hardware or software is generally (but not always, in that in certain contexts the choice between hardware and software can become significant) a design choice representing cost vs. efficiency tradeoffs. Those having skill in the art will appreciate that there are various vehicles by which processes and/or systems and/or other technologies described herein can be effected (e.g., hardware, software, and/or firmware), and that the preferred vehicle will vary with the context in which the processes and/or systems and/or other technologies are deployed. For example, if an implementer determines that speed and accuracy are paramount, the implementer may opt for a mainly hardware and/or firmware vehicle; alternatively, if flexibility is paramount, the implementer may opt for a mainly software implementation; or, yet again alternatively, the implementer may opt for some combination of hardware, software, and/or firmware. Hence, there are several possible vehicles by which the processes and/or devices and/or other technologies described herein may be effected, none of which is inherently superior to the other in that any vehicle to be utilized is a choice dependent upon the context in which the vehicle will be deployed and the specific concerns (e.g., speed, flexibility, or predictability) of the implementer, any of which may vary. Those skilled in the art will recognize that optical aspects of implementations will typically employ optically-oriented hardware, software, and/or firmware.  
      The foregoing detailed description has set forth various embodiments of the devices and/or processes via the use of block diagrams, flowcharts, and/or examples. Insofar as such block diagrams, flowcharts, and/or examples contain one or more functions and/or operations, it will be understood by those within the art that each function and/or operation within such block diagrams, flowcharts, or examples can be implemented, individually and/or collectively, by a wide range of hardware, software, firmware, or virtually any combination thereof. In one embodiment, several portions of the subject matter described herein may be implemented via Application Specific Integrated Circuits (ASICs), Field Programmable Gate Arrays (FPGAs), digital signal processors (DSPs), or other integrated formats. However, those skilled in the art will recognize that some aspects of the embodiments disclosed herein, in whole or in part, can be equivalently implemented in integrated circuits, as one or more computer programs running on one or more computers (e.g., as one or more programs running on one or more computer systems), as one or more programs running on one or more processors (e.g., as one or more programs running on one or more microprocessors), as firmware, or as virtually any combination thereof, and that designing the circuitry and/or writing the code for the software and or firmware would be well within the skill of one of skill in the art in light of this disclosure. In addition, those skilled in the art will appreciate that the mechanisms of the subject matter described herein are capable of being distributed as a program product in a variety of forms, and that an illustrative embodiment of the subject matter described herein applies regardless of the particular type of signal-bearing medium used to actually carry out the distribution. Examples of a signal-bearing medium include, but are not limited to, the following: a recordable type medium such as a floppy disk, a hard disk drive, a Compact Disc (CD), a Digital Video Disk (DVD), a digital tape, a computer memory, etc.; and a transmission type medium such as a digital and/or an analog communication medium (e.g., a fiber optic cable, a waveguide, a wired communications link, a wireless communication link, etc.).  
      In a general sense, those skilled in the art will recognize that the various embodiments described herein can be implemented, individually and/or collectively, by various types of electromechanical systems having a wide range of electrical components such as hardware, software, firmware, or virtually any combination thereof; and a wide range of components that may impart mechanical force or motion such as rigid bodies, spring or torsional bodies, hydraulics, and electro-magnetically actuated devices, or virtually any combination thereof. Consequently, as used herein “electro-mechanical system” includes, but is not limited to, electrical circuitry operably coupled with a transducer (e.g., an actuator, a motor, a piezoelectric crystal, etc.), electrical circuitry having at least one discrete electrical circuit, electrical circuitry having at least one integrated circuit, electrical circuitry having at least one application specific integrated circuit, electrical circuitry forming a general purpose computing device configured by a computer program (e.g., a general purpose computer configured by a computer program which at least partially carries out processes and/or devices described herein, or a microprocessor configured by a computer program which at least partially carries out processes and/or devices described herein), electrical circuitry forming a memory device (e.g., forms of random access memory), electrical circuitry forming a communications device (e.g., a modem, communications switch, or optical-electrical equipment), and any non-electrical analog thereto, such as optical or other analogs. Those skilled in the art will also appreciate that examples of electro-mechanical systems include but are not limited to a variety of consumer electronics systems, as well as other systems such as motorized transport systems, factory automation systems, security systems, and communication/computing systems. Those skilled in the art will recognize that electromechanical as used herein is not necessarily limited to a system that has both electrical and mechanical actuation except as context may dictate otherwise.  
      In a general sense, those skilled in the art will recognize that the various aspects described herein which can be implemented, individually and/or collectively, by a wide range of hardware, software, firmware, or any combination thereof can be viewed as being composed of various types of “electrical circuitry” Consequently, as used herein “electrical circuitry” includes, but is not limited to, electrical circuitry having at least one discrete electrical circuit, electrical circuitry having at least one integrated circuit, electrical circuitry having at least one application specific integrated circuit, electrical circuitry forming a general purpose computing device configured by a computer program (e.g., a general purpose computer configured by a computer program which at least partially carries out processes and/or devices described herein, or a microprocessor configured by a computer program which at least partially carries out processes and/or devices described herein), electrical circuitry forming a memory device (e.g., forms of random access memory), and/or electrical circuitry forming a communications device (e.g., a modem, communications switch, or optical-electrical equipment). Those having skill in the art will recognize that the subject matter described herein may be implemented in an analog or digital fashion or some combination thereof.  
      Those skilled in the art will recognize that it is common within the art to implement devices and/or processes and/or systems in the fashion(s) set forth herein, and thereafter use engineering and/or business practices to integrate such implemented devices and/or processes and/or systems into more comprehensive devices and/or processes and/or systems. That is, at least a portion of the devices and/or processes and/or systems described herein can be integrated into other devices and/or processes and/or systems via a reasonable amount of experimentation. Those having skill in the art will recognize that examples of such other devices and/or processes and/or systems might include—as appropriate to context and application—all or part of devices and/or processes and/or systems of (a) an air conveyance (e.g., an airplane, rocket, hovercraft, helicopter, etc.), (b) a ground conveyance (e.g., a car, truck, locomotive, tank, armored personnel carrier, etc.), (c) a building (e.g., a home, warehouse, office, etc.), (d) an appliance (e.g., a refrigerator, a washing machine, a dryer, etc.), (e) a communications system (e.g., a networked system, a telephone system, a voice-over IP system, etc.), (f) a business entity (e.g., an Internet Service Provider (ISP) entity such as Comcast Cable, Quest, Southwestern Bell, etc), or (g) a wired/wireless services entity (e.g., such as Sprint, Cingular, Nextel, etc.), etc.  
      Although user  136  is shown/described herein as a single illustrated figure, those skilled in the art will appreciate that a user  136  may be representative of a human user  136 , a robotic user  136  (e.g., computational entity), and/or substantially any combination thereof (e.g., a user  136  may be assisted by one or more robotic agents). In addition, a user  136  as set forth herein, although shown as a single entity may in fact be composed of two or more entities. Those skilled in the art will appreciate that, in general, the same may be said of “sender” and/or other entity-oriented terms as such terms are used herein.  
      The herein described subject matter sometimes illustrates different components contained within, or connected with, different other components. It is to be understood that such depicted architectures are merely exemplary, and that in fact many other architectures can be implemented which achieve the same functionality. In a conceptual sense, any arrangement of components to achieve the same functionality is effectively “associated” such that the desired functionality is achieved. Hence, any two components herein combined to achieve a particular functionality can be seen as “associated with” each other such that the desired functionality is achieved, irrespective of architectures or intermedial components. Likewise, any two components so associated can also be viewed as being “operably connected”, or “operably coupled”, to each other to achieve the desired functionality, and any two components capable of being so associated can also be viewed as being “operably couplable”, to each other to achieve the desired functionality. Specific examples of operably couplable include but are not limited to physically mateable and/or physically interacting components and/or wirelessly interactable and/or wirelessly interacting components and/or logically interacting and/or logically interactable components.  
      All publications, patents and patent applications cited herein are incorporated herein by reference. The foregoing specification has been described in relation to certain embodiments thereof, and many details have been set forth for purposes of illustration, however, it will be apparent to those skilled in the art that the invention is susceptible to additional embodiments and that certain of the details described herein may be varied considerably without departing from the basic principles of the invention.